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Abstract 
 
It is well recognised that most proteins are subject to post translational modifications 
and that these modifications can have specific effects on the biological properties 
and functions of these proteins. The majority of proteins secreted by cells are 
modified by the attachment of oligosaccharide chains. This glycosylation event has 
been shown to impact correct protein folding, protein stability, solubility, to aid in 
cell recognition and to help regulate cell processes. In order to gain a deeper 
understanding into the impact of altered glycosylation patterns on cellular processes 
and cell recognition it is necessary to develop new technologies to profile the glycan 
species displayed on the surface of protein molecules.  
 
The present study was dedicated to the development of prokaryotic chitin-binding 
proteins as novel carbohydrate-binding molecules. Prokaryotic chitin-binding 
proteins from Serratia marcescens, Pseudomonas aeruginosa, Photorhabdus 
asymbiotica and Photorhabdus luminescens were cloned, over-expressed in E. coli 
and purified to homogeneity via (His)6 affinity tags. The activity and specificity of 
these proteins was tested using a number of insoluble substrates; chitin, chitosan and 
crystalline cellulose. The ability of these proteins to bind to protein linked glycans 
was tested using Enzyme linked lectin assays (ELLAs). None of the proteins 
exhibited any ability to bind glycoproteins in this assay format. A novel N-
acetylglucosamine binding assay was developed using CBP21 and the ability to 
immobilise active CBP21 on a sepharose surface was also demonstrated. Sugar 
inhibition studies indicated that CBP21 may be capable of binding to mannan and 
galactan polymers. A site-directed mutagenesis of CBP21 was carried out on the 
putative binding domain residues to alter the affinity of CBP21. Residues Y54, E55, 
P56, Q57, S58, E60, T111, H114 and D182 were mutated to alanine, expressed, 
purified and characterised. The mutation H114A was shown to negatively impact on 
β-chitin affinity, the Q57A mutant had an increased affinity for chitosan with the 
proteins Y54A, T111A and D182A displaying an increased affinity for Cellulose. 
Furthermore it was shown that the putative C-terminal binding domain of CbpD is a 
chitin-binding domain and that the putative chitin-binding proteins CbpA and CbpL 
are capable of binding to both α- and β-chitin. 
  
 
 
 
 
 
 
 
 
 
 
1.0 Introduction 
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1.1 Glycobiology 
The term glycobiology was coined in 1988 to recognize the coming together of the 
traditional disciplines of carbohydrate chemistry and biochemistry  (Rademacher et 
al., 1988). Glycobiology is defined in the broadest sense as the study of the 
structure, biosynthesis, and biology of saccharides (sugar chains or glycans) that are 
widely distributed in nature. Glycobiology has come to the forefront of the 
community in the past number of years with the discovery that many proteins, 
especially those destined for secretion or insertion into cell membranes are modified 
by the attachment of carbohydrates in a process known as glycosylation.  
 
1.2 Glycosylation 
Glycosylation is most often classified as a form of post translational modification, 
where proteins are adapted by addition of carbohydrate chains. Among the different 
types of covalent modifications that proteins can undergo, none are as diverse as 
glycosylation. Unlike proteins glycans are not encoded on a DNA or RNA-like 
sequence and monosaccharides have the capacity to combine with each other in a 
variety of ways that differ not only in the sequence and chain length but also in 
anomery, the position of linkages and branching points (i.e. not template driven). 
Further structural diversity can arise from the attachment of sulphate, phosphate, 
acetyl or methyl groups to the sugars. In the words of Winterburn and Phelps (1972) 
„carbohydrates are  ideal for generating compact units with explicit informational 
properties, since the permutations on linkages are larger than can be achieved by 
amino acids, and, uniquely in biological polymers, branching is possible‟. A 
staggering possible number of isomer permutations for a hexamer with an alphabet 
of just 20 letters have been calculated as 1.44x10
15
 (Laine, 1997). 
 
The glycosylation process takes place in the endoplasmic reticulum of eukaryotic 
cells, giving rise to protein-carbohydrate conjugates, or glycoproteins.  The most 
common forms of glycosylation take place through N- or O-linkages on the 
polypeptide chain (see section 1.2.1 and 1.2.3). From analysis of the SWISS-PROT 
database Apweiler et al., (1999) have predicted that more than half of all eukaryotic 
proteins are glycosylated, up to 90% being N-linked with the remainder decorated 
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with O-linkages. The nature of the glycan attached to an individual glycoprotein is 
dependent on the protein and the cell in which it is expressed. The structure of the 
glycoprotein can also influence the glycosylation pattern, the position of certain 
glycosylation sites within some proteins favouring highly branched structures while 
other sites remain decorated with low complexity structures. An important challenge 
in the field of glycobiology is to understand why eukaryotes are endowed with such 
extensive glycosylation mechanisms and the effects these glycosylation patterns 
exert. 
  
1.2.1 Eukaryotic N-linked glycosylation 
The biosynthesis of N-linked glycans in eukaryotes is a task shared by the 
endoplasmic reticulum (ER) and the Golgi apparatus. N-linked Glycans are formed 
by a series of complex pathways, beginning with the en bloc attachment of a pre-
synthesised core oligomer (see Fig 1.2) to the nitrogen of an asparagine residue 
within a tripeptide consensus sequence, Asn-X-Ser/Thr, where X can be any amino 
acid except proline. The 14-unit core glycan structure is first assembled on a lipid 
molecule, dolichol phosphate (see Fig 1.1), at the membrane of the ER (see Fig 1.3), 
for review see Burda and Aebi (1999). An enzyme known as oligosaccharyl 
transferase (OT) transfers the lipid linked oligosaccharide to the amide nitrogen of 
an Asn within the consensus sequence of a growing peptide chain. This co-
translational event takes place within the lumen of the ER. The attached 
oligosaccharide subsequently undergoes a number of enzymatic modifications as the 
protein moves through the ER. Beginning with the removal of the 3 glucose 
residues, by glycosidases, the mannose structure is trimmed with the removal of 
some or all of the four mannose residues in α1-2 linkages until the core GlcNAc unit 
with attached mannose residues remain (see Fig 1.4).  
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Fig 1.1: Structure of the lipid dolichol molecule. The precursor oligosaccharide is 
linked by a phosphoryl group to dolichol. It is a highly hydrophic molecule, long 
enough (75-95 carbon atoms) to span the ER membrane 3-4 times. Image produced 
using Chemsketch.  
 
 
             
Fig 1.2: Pre cursor oligosaccharide for N-linked glycosylation. Schematic of the 
dolichol lipid linked oligosaccharide common to all N-linked glycans. Image 
produced using Chemsketch. 
          
 
This assembly of the oligosaccharide precursor and the initial processing of the 
oligosaccharide in the ER are similar in almost all eukaryotes but the later stages of 
glycosylation may differ. Once the glycoproteins have folded and oligomerized 
properly they move into the golgi apparatus, where some glycans remain in the 
mannosidase treated state while others are processed into more complex forms (see 
Fig 1.4). In mammals the branched structures may be re-elongated with the 
attachment of a GlcNAc residue to the 1-3 arm of the core, with further extensions 
including the addition of galactose, either as a single residue at the end of a branch 
or as a longer polylactosamine chain. A variety of terminal elaborations can then be 
added to this chain, which acts as a scaffold. These elaborations can include the 
simple addition of sialic acid through a number of linkages or additionally the 
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attachment of sulphate groups. Bi-antennary glycans are most common but rarer 
glycans containing up to 5 or more have been documented. Complex-type plant N-
linked glycans can be characterised by the absence of sialic acid and the presence of 
fucose and/or xylose residues linked respectively to the proximal N-
acetylglucosamine and to the β-mannose residues of the core (Lerouge, et al., 1998). 
Yeast N-glycan maturation invariably involves the addition of further mannose 
residues directly to the core, termed core maturation, or in some instances outer 
chains of variable sizes may also be added. The majority of these glycoproteins in 
yeasts are incorporated into the rigid cell wall structure as mannans (Herscovics and 
Orlean, 1993).  
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Fig 1.3: Biosynthesis of the precursor oligosaccharide molecule for N-linked 
glycan synthesis. N-glycan synthesis is initiated at the cystolic face of the ER with 
the sequential addition of GlcNAc and mannose residues to a dolichol phosphate 
molecule. Membrane flippase proteins facilitate the transfer of the oligosaccharide 
as well as the subsequently required free mannose and glucose residues across the 
ER membrane. The oligosaccharide is finally transferred co-translationally to an Asn 
residue on the polypeptide by the action of an oligosaccharide transferase.  Image 
produced using ChemBioDraw 12.0. 
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Fig 1.4: Processing of the precursor oligosaccharide for N-linked glycosylation 
to a complex glycan. Following transfer to the polypeptide, the N-linked glycan is 
processed, first by removal of the three glucose residues by glucosidases 1 and 2 in 
the ER. Some or all of the four α1-2 linked mannose residues are then trimmed by 
the action of mannosidases, as the peptide moves into the cis portion of the Golgi 
apparatus. Re-elongation is initiated by the attachment of GlcNAc with 
galactosyltransferase and sialytransferase responsible for attachment of galactose 
and sialic acid residues in the trans portion of the golgi apparatus. Image produced 
using ChemBioDraw 12.0. 
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1.2.2 N-linked glycosylation quality control 
Akin to the proof reading abilities of DNA polymerases, mammalian glycosylation 
systems also have a stringent regulatory pathway or „quality control‟ system to 
ensure that transport is limited to properly folded and assembled proteins. Beginning 
with the en bloc attachment of the core oligosaccharide to the growing peptide 
chain, the first and second glucose units are removed by glucosidases I and II 
respectively (see Fig 1.4). The remaining monoglucosylated ligand binds the 
glycoprotein transiently to resident ER proteins calnexin or calreticulin (Hammond 
et al., 1994). Calnexin (transmembrane protein) and calreticulin (soluble luminal 
protein) are molecular chaperones responsible for preventing aggregation or 
premature departure of immature oligomers until correct folding has taken place. 
Both also promote correct disulphide bond formation through interaction with 
ERp57. To release the bound chains from calnexin and calreticulin glucosidase II 
removes the remaining glucose residue. Correctly folded glycoproteins can now 
move from the ER to the golgi apparatus for further processing, whereas 
incompletely folded glycoproteins are bound by a folding sensor, a soluble enzyme 
known as UDP-glucose glycoprotein glycosyltransferase (GT). GT reglucosylates 
incompletely folded glycoproteins with the transfer of glucose residues from UDP-
glucose to protein-bound high mannose glycans. Once complete, the proteins are re-
bound by calnexin or calreticulin and stay in this cycle until they are either properly 
folded and oligomerized or degraded. Degradation takes place through the 
endpoplasmic reticulum-associated protein degradation pathway or ERAD, which 
involves the translocation of the misfolded peptides to the cytoplasm where, 
digestion by proteasomes occurs (Helenius and Aebi, 2004).  
 
1.2.3 Eukaryotic O-linked glycosylation 
O-linked glycans represent the second most common form of glycosylation in 
eukaryotes. O-glycans are extremely diverse in both structure and function, with the 
full extent of this diversity not yet well established. While N-linked glycans share a 
common core structure, O-linked glycans are built on a different set of protein-
glycan linkages. Attachment of O-linked glycans to the peptide backbone can take 
place via the hydroxyl group of serine, threonine, tyrosine, hydroxyproline, 
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hydroxylysine or other hydroxylated amino acids in a stepwise series of reactions. 
Unlike N-linked glycosylation, no consensus sequence has been identified for O- 
glycosylation, although proline residues are often close to O-glycosylated Ser/Thr 
residues (Christlet and Veluraja, 2001).  Sugar transfer to the protein occurs post-
translationally in the Golgi apparatus, with the most common types of O-linked 
glycans containing an initial GalNAc residue. Other initial sugars include galactose, 
mannose, fucose, GlcNAc, xylose or glucosamine. Due to the heterogeneity of O-
linked glycans they are generally classified by their core structure.  
  
The structure of O-glycans is most often reflected by the levels of enzymes in the 
cell. For example, the differences between A, B and O blood groups is brought 
about by the variation in glycan motifs of the A, B and H antigens expressed on the 
surface of erythrocytes. These antigens differ only in the sugar residues at the non-
reducing ends of the glycans (see Fig 1.5). The H antigen occurring in type O 
individuals is a precursor oligosaccharide of the A and B antigens. Type A 
individuals express a transferase that specifically adds an N-acetylgalactosamine 
(GalNAc) residue to the terminal position of the H antigen, whereas type B 
individuals add a galactose to the terminal position. 
          
Fig 1.5: H, A and B antigens that form the O, A and B blood group 
determinants. The H antigen forms the O blood group, the A antigen the A blood 
group and the B antigen the B blood group.  Image created using ChemBioDraw 
12.0 
 
The most abundant and widely characterised type of O-glycans in eukaryotes are the 
mucins (Gum, 1992). The primary purpose of many mucins is to retain water at 
surfaces that are exposed to the environment but are not sealed by moisture 
permeable layers, such as the surfaces of the digestive and respiratory tracts (Perez-
10 
 
Vilar and Hill, 1999). Mucins contain extended stretches of peptide sequence with 
repeating serine, threonine and proline residues, O-glycan decoration of these 
proteins can account for up to 80% of the overall mass. Mucin glycosylation, 
containing initial GalNAc residues, is based on a relatively simple set of core 
structures with step-by-step addition of further glycans (see Fig 1.6).  The overall 
pathway of mucin glycosylation is regulated by the branchpoint enzyme T-synthase 
(Ju et al., 2008). T-synthase is a resident golgi protein, a β3-galactosyltransferase 
that adds galactose to the Tn antigen, generating mucin core structure 1.  T-synthase 
requires a unique, client specific-chaperone, core 1 β3-Gal-T specific molecular 
chaperone or Cosmc, which is required for the formation of active enzyme When 
Cosmc, a resident ER protein, is absent, T-synthase is retained in the lumen of the 
ER as an enzymatically inactive complex. Thus Cosmc serves a unique function in 
the ER as the key post-translational regulator for expression of T-synthase and 
consequently regulates mucin O-glycosylation. Cosmc orthologues have been 
identified in all vertebrates and are highly conserved across species. T-synthase 
function has been found to be developmentally important in mice (Wu et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.6: Mucin synthesis. N-acetylgalactosamine is linked to the side chain of 
serine or threonine residue. A single β1-3 linked galactose is attached forming Core 
structure 1. This core structure can be disialyated or further processed by elongation 
with the addition of N-acetyllactosamine and sialic acid. Image produced using 
ChemBioDraw 12.0. 
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Although the method of formation differs, terminal structures on some O-linked 
glycans have been found to be identical to structures on N-linked glycans, 
suggesting that there may be a functional overlap between the two types of 
glycosylation. It is also known that glycoproteins can be glycosylated with both N-
linked and O-linked glycan structures. 
 
1.2.4 Bacterial glycosylation 
Until the 1970s, protein glycosylation was thought to be a task limited to eukaryotes. 
With evidence to the contrary growing every year it is now a widely accepted that 
glycoproteins are a common feature in all domains of life. The first examples of 
non-mammalian glycosylation came with the discovery of sugar structures on 
surface layer (S-layer) proteins belonging to archaeal and bacterial species, the 
halophile Halobacterium halobium (salinarum) and the thermophilic Clostridium 
thermosaccharolyticum (Mescher and Strominger, 1976, Sleytr and Thorne, 1976). 
It is now know that S-layer proteins can undergo glycosylation to an overall degree 
of up to 15% (Schaffer and Messner 2001). In the case of Halobacterium halobium 
S-layer N-and O-linked glycoproteins account for up to 50% of the total cell 
envelope protein (Mescher et al., 1974). From the information available on the 
possible structures of the prokaryotic glycoproteins, it is obvious that while they 
share some characteristics, they are far more diverse than the structures found in 
eukaryotes (Moens and Vanderleyden, 1997). This diversity constitutes differences 
in consensus sequences, sugar constituents and linkage units, as reviewed Schaffer 
et al. (2001). 
 
Since the initial discovery of S-layer protein glycosylation, it has become more 
apparent that bacterial glycosylation is not limited in this regard. Non S-layer 
glycoproteins have been found increasingly in insect and mammalian bacterial 
pathogens. The flagellin of a number of bacterial species are known to be 
extensively glycosylated, including Halobacter subspecies (Serganova et al., 1995), 
Campylobacter jejuni (Doig et al.,  1996), Clostridium subsp. (Arnold et al., 1998, 
Lyristis et al., 2000), Helicobacter pylori (Schirm et al., 2003)  and Listeria 
monocytogenes (Schirm et al.,  2004). Pili are also known to be decorated with sugar 
moieties that constitute major virulence factors such as those of Pseudomonas 
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aeruginosa (Castric et al., 2001) and Neisseria meningitides (Virji et al., 1993). P. 
aeruginosa pili are known to be composed of pilin subunits that are glycosylated 
with a sugar similar in structure to sialic acid, pseudaminic acid, while both N- and 
O-linked glycan structures have been identified on N. meningitides pili that 
incorporate galactose residues (Virji, 1997). 
 
Speculations as to the possible role of protein glycosylation in prokaryotic systems 
vary widely and are reviewed by Upreti et al., (2003). Their prominent location on 
the cell surface or surface associated organelles suggests a role in host interaction. 
Carbohydrate modification has also been shown to affect protein stability and 
function, including secretion and subunit interactions and assembly (Schirm et al., 
2003, Guerry 2007). Decoration with typical mammalian glycans and mammalian-
like sugar units points towards a role in the evasion of the immune response, while 
expression of sugar moieties is also known to be a requirement for effective host 
colonisation (Lyristis et al., 2000, Duck et al., 2007).  
 
1.3 Lectins 
In vivo recognition of glycan structures occurs via specific molecules termed 
„lectins‟ (Boyd and Shapleigh, 1954). The word lectin stems from the latin word 
legere meaning to select or to choose and has been defined as a carbohydrate 
binding protein other than an enzyme or antibody. Knowledge of the presence of 
lectins in nature began in 1888 with Peter Hermann Stillmark‟s discovery that 
certain plant proteins had the ability to agglutinate erythrocytes. It wasn‟t until 1936, 
when Concanavalin A (Con A), the first pure lectin was isolated from the Jack Bean 
(Canavalia ensiformis), that the sugar specificity was demonstrated (James and 
Stacey, 1936). With much foresight they suggested that the hemaglutination induced 
by Con A might be a consequence of a reaction from the plant protein with 
carbohydrates on the surface of the red cells. In the subsequent decades lectins were 
isolated not only from plants but from mammals, viruses and bacteria, encompassing 
proteins from a wide range of protein families holding diverse functionalities. There 
are numerous comprehensive reviews delineating lectin structures, functions and 
incidences in nature (Van Damme et al., 1998, Kasai and Hirabayashi, 1996, 
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Rapoport et al., 2008, Sharon and Lis, 2004, Leffler et al., 2002, Loris, 2002, Singh 
et al.,  Imberty et al., 2004).  
 
The most striking feature of lectin-sugar interactions is that the binding affinities for 
monosaccharides are relatively quite low. Many lectins are made up of multiple 
subunits that increase the capability of binding to disaccharides and more complex 
oligosaccharide structures with significantly higher affinities and exquisite 
specificity. This ability is a prerequisite for their ability to function as recognition 
molecules in biological processes (Ambrosi et al., 2005). In some cases the 
oligosaccharide-binding specificity is dependent not only on the composition of an 
oligosaccharide chain or on the presence or absence of specific terminal residues but 
on the overall structure of the glycan. This may include the positions and anomeric 
(α or β) configurations of the linkages between the constituent monosaccharide 
subunits (Weis and Drickamer, 1996, Ambrosi et al., 2005, Geyer and Geyer, 2006). 
Table 1.1 summarises a number of lectin-carbohydrate complexes. 
Table 1.1: Lectin-carbohydrate complexes 
Lectin Family Lectin Abbreviation Sugar specificity 
Plant Lectins    
Legume lectins Concanavalin A ConA Man/α1-Me 
 Griffonia simplicifolia lectin 1 GSLI  α-gal 
 Griffonia simplicifolia lectin II GSLII β1-4 GlcNAc 
Cereal lectins Wheat germ agglutinin 
WGA 
NeuNAc, 
GlcNAc 
Plant toxins Ricin 
RCA 
β-gal/ 
lactosamine 
Bulb lectins Snowdrop lectin GNL  Man 
Animal lectins    
Galectins Galectin 1 Gal-1 Lactose 
 Galectin 2 Gal-2 Fucose 
 Galectin 3 Gal-3 Fucose 
P-type lectin Mannose-6 phosphate receptor 
M6P 
Man-6 
phosphate 
Bacterial lectins    
 P. aeruginosa Lectin 1 PA-IL β-gal 
 P. aeruginosa Lectin 1 PA-IIL Fucose/Man 
Viral lectins    
Influenza Hemagglutinin HA NeuNAc 
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1.4 Significance of glycoforms in eukaryotic systems 
Glycoproteins are known to be of fundamental importance to many biological 
processes as reviewed by Paulson (1989) and Varki (1993). Glycan roles include 
immune defence, cell growth, cell-cell adhesion, inflammation and fertilisation. 
Attachment of glycoforms to proteins also functions to stabilise proteins against 
denaturation and proteolysis, confer structural rigidity, enhance solubility, increase 
blood retention time and reduce immunogenicity. Unfortunately, our greatest 
understanding of the significance of glycans to biological processes arises from the 
study and genetic engineering of abnormal glycosylation and disease states.  
 
1.4.1 Significance of terminal residues 
 
The multistep process of glycan formation, whether N- or O-linked, involves several 
enzymes that are competing with one another for a single substrate and/or acceptor 
molecule. As a result glycoproteins contain a micro heterogeneous array of 
oligosaccharides (Kobata, 1992). Hence glycoproteins are often truncated containing 
terminal sialic acids (Sias), galactose and GlcNAc residues. Mammalian 
glycoproteins generally terminate in galactose or sialic acid. Sialic acid, the more 
abundant of the two, is found on vertebrate cell surface glycoproteins and 
glycolipids. Mannose and GlcNAc are not commonly found as terminal residues on 
mammalian glycoproteins, though they are frequently found on the glycoproteins 
that decorate the surface of yeasts and many microorganisms.  
 
Most mammalian cell surfaces display two major sialic acids (Sias), N-
acetylneuramic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc). Humans 
however lack Neu5Gc due to a hydroxylase mutation that occurred after the 
divergence from great apes (Muchmore et al., 1998). The presence of sialic acid as a 
terminal moiety is known to greatly increase the blood retention time of many 
glyoproteins and glycosylated therapeutics (Sorensen et al., 2009, Darlinget al., 
2002). Bisecting fucose is present in a wide variety of organisms. In mammals 
fucose containing glycans play many important roles, most notably in blood 
transfusion reactions, host-microbe interactions (Cambi et al., 2005), cell signalling 
and development, for review see Becker and Lowe (2003).  
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Although the terminal residues expressed on glycoprotein surfaces are deemed 
optimal for each biological process, they can also facilitate host pathogen 
interactions, e.g. mammalian-expressed Sias are known to facilitate cell recognition 
by organism-extrinsic receptors, such as the viral haemagglutinin influenza via 
specific viral lectins (Janakiraman et al., 1994). Similarly fucosylation of blood 
group antigens facilitates Helicobacter pylori cell-lectin interaction, leading to 
H.pylori mediated peptic ulcer disease (Mahdavi et al., 2002).  
 
Human and animal studies of glycoprotein clearance have shown that alterations in 
the glycan structure can significantly affect its pharmacokinetic properties (Jones et 
al., 2007). This metabolic clearance of glycoproteins is caused by specific receptors 
which recognise certain structural features of the sugar moiety.  
 
1.4.2 Carbohydrate-specific receptors 
The revelation that some de-sialylated serum glycoproteins had drastically reduced 
survival times in circulation compared to native forms of the same proteins (terminal 
sialic acid) led to the discovery of the asialoglycoprotein receptor.  A specific 
receptor on hepatocytes, this receptor was found to mediate their clearance by 
recognition of terminal galactose residues (Morell et al., 1971, Dini et al., 1992). 
Similarly, the mannose receptor was identified in the late 1970s as a receptor 
involved in the clearance of certain internal glycoproteins (Stahl P., 1979). It was 
observed that the exposure of terminal GlcNAc on glycans was accompanied by 
rapid clearance from circulation. Subsequently it was discovered that this receptor 
recognised both high mannose N-linked glycans, terminal GlcNAc and fucose 
residues (Taylor et al., 2005, Jones et al., 2007).  
 
The most extensively studied glycoprotein receptors are the asialoglycoprotein and 
mannose receptors and are reviewed by Ashwell (1982). Other carbohydrate specific 
receptors have also been described, including those specific for fucose and 6-
phosphomannose (Shepherd et al., 1982, Dahms et al., 2008). The carbohydrate-
specific receptors vary in structure and cellular location but all contain multi-subunit 
lectin-like carbohydrate recognition domains, which can in themselves be 
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glycosylated. These lectin-like receptors bind preferentially to different branches of 
target glycans (see Fig 1.7 and 1.8). 
 
Since their initial discovery the carbohydrate-specific receptors have furthermore 
been implicated not only in the clearance of intracellular glycoproteins but in the 
recognition of exposed glycan residues on the surface of selected pathogens and the 
internalisation of glycosylated antigens (Taylor et al., 2005, Schwartz, 1984). 
Although built from the same building blocks, glycans on bacteria, yeast and fungi 
can differ widely but many share a few key characteristics. As the glycans usually 
serve structural roles they tend to have repetitive structures and these structures 
often present terminal glucose, GlcNAc and mannose residues. Recognition of these 
features allows the carbohydrate receptors to distinguish between self and non-self 
glycoproteins.  
 
 
Fig 1.7: Structure of the mannose receptor. Domain structure of the mannose 
receptor showing the proposed extended conformation and predicted N-linked 
glycosylation. The cysteine domain (CR) is shown in red, the fibronectin type II 
domain (FNII) in orange, and the lectin like carbohydrate recognition domains 
(CTLD) in green. (Taylor et al., 2005) 
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Fig 1.8: Structure of the asialoglycoprotein recptor.  The interaction of the lectin-
like carbohydrate recognition domains (CTLDs) of the asialoglycoprotein receptor 
with the terminal galactose residues (yellow) of an asialo N-linked glycan. Image 
produced using ChemBioDraw 12.0. 
 
1.4.3 Aberrant glycoglycosylation 
Firstly, it is important to note that eukaryotic cells require N- and O-linked 
carbohydrates for survival. At least thirteen congenital disorders of glycosylation 
have been identified to date and they almost invariably affect N-glycan assembly or 
processing. These disorders are characterized most prominently by neurological and 
developmental deficiencies, (Freeze, 1998, Jaeken and Matthijs, 2001, Spiro 2002). 
Mice lacking N-acetylglucosaminyltransferase 1 activity die at mid-gestation, 
showing a pronounced lack of development in neural tissues (Ioffe and Stanley, 
1994). Transgenic mice, born devoid of calreticulin or calnexin, responsible for N-
glycan quality control, have embryonic lethal phenotypes, or are born with strong 
debilitation phenotypes including myelinopathy (Kraus et al., 2010).  
 
Post-translational modifications not only play a crucial role in normal nervous 
system development but also in brain injury and neurodegeneration, specifically 
Alzheimers disease. More than 30% of all detectable proteins in the human frontal 
cortex appear to be glycosylated, with decreased O-GlcNAc addition of tau proteins 
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mediating the progression of the neurodegeneration that leads to Alzheimers 
(Kanninen et al., 2004). Muscular dystrophies, including muscle-eye brain disease, 
Duchenn, Becker and Fukuyama congenital muscular dystrophy have also been 
shown to be facilitated by an altered glycosylation pattern on α-dystroglycan 
(Muntoni et al., 2002).   
 
More recently it has been shown that an altered glycosylation phenotype is present 
on mucins of the cystic fibrosis airway epithelial cells. This altered phenotype, 
decreased sialylation and/or increasd fucosylation, facilitates the colonisation of the 
lung by bacteria such as Haemophilus influenza and Pseudomonas aeruginosa by 
means of asialo-substrate and fucose-binding lectins, (Scanlin and Glick, 2000, 
Rhim et al., 2001, Stoykova and Scanlin, 2008). There are multiple other instances 
in which altered glycoforms have been implicated, such as cardiac conditions, 
diabetes, stress, nephropathy (Smith et al., 2006), some auto-immune diseases 
(Hirschberg, 2001), and arthritis (Rudd et al., 2001). Of the diseases caused or 
signified by a difference in glycosylation patterns, however, none are more studied 
than cancer. 
 
1.4.4 Aberrant glycosylation in cancer 
Aberrant glycosylation occurs in essentially all types of experimental and human 
cancers, with many glycosyl epitopes constituting tumor-associated antigens. What 
is not presently understood is whether aberrant glycosylation is a result or cause of 
initial oncogenic transformation (Hakomori, 2002). Aberrant glycosylation has been 
implicated as an essential mechanism in defining stage, direction and fate of tumor 
progression. Studies have shown that there are clear correlations between altered 
glycan patterns, status of primary tumors, invasive/metastatic potentials of the 
cancer and ultimately, patient survival rates (Ludwig and Weinstein, 2005, 
Moiseeva et al., 2005). Altered carbohydrate structures in tumor cells can influence 
cell recognition, signalling and adhesion allowing tumor cell growth in addition to 
altering tumor cell motility, promoting or inhibiting invasion and metastasis 
(Hakomori, 1996). 
 
19 
 
Changes in glycosylation and cancer include both the under and over expression of 
naturally occurring glycans, as well as neoexpression of glycans normally restricted 
to embroyonic tissues (Hakomori, S., 1985) . These structures most often arise from 
changes in the expression levels of glycosyltransferases in the golgi compartment of 
cancerous cells. One of the most common changes is an increase in size and 
branching of N-linked glycans, the increased branching facilitates additional sites for 
terminal sugar residues, that in conjunction with an up-regulation of sialyltransferase 
leads to an increase in overall sialyation (Brockhausen et al., 1995). In addition 
altered terminal structures can also be associated with malignancy, again most 
notably with the addition of terminal sialic acid structures e.g. Neu5Gc and Lewis 
structures (sialylated fucosylated structures). These are reviewed by Kim and Varki 
(1997) and Dube and Bertozzi (2005).  
 
A deeper understanding of the glycosylation processes and disease states has 
allowed for the development of a number of glycosylated tumor marker candidates 
(Reis et al., 2010). Miyoshi et al. (2006) have identified an increase in α1-3, α1-4, 
and α1-6 fucosylation in the haptoglobin purified from the sera of patients with 
pancreatic cancer. Subsequent assay development led to the development of a novel 
method for the prediction of pancreatic cancer, using the increase in fucosylation as 
a tumor marker (Matsumoto et al., 2010). Similarly Fukushimo et al., (2010) have 
revealed that there is elevated expression of α1-2 fucosylated and β-N-
acetylgalactosaminylated prostate-specific antigen (PSA) in cases of prostate cancer. 
They have proposed that this increase in glycosylation may be exploited as a 
potential marker of prostate cancer in the future.   
 
1.5 Glycoprotein analysis and separation  
The total glycome of a cell is characteristic of a particular cell type at a specific state 
of development. Glycosylation patterns are known to vary between individuals, with 
some variation associated with disease conditions as previously discussed. Thus, 
analysis of glycomes provides a basis for understanding the functions of glycans in 
cell differentiation, disease and as targets for receptor binding. Although it has been 
estimated that only 36 sugar building blocks are required to construct 75% of the 
3299 mammalian oligosaccharides identified to date (Werz, et al., 2007), the 
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characterisation of glycans attached to proteins still presents a more daunting task 
than the sequencing of proteins and nucleic acids. Difficulties lie not only in the 
branched nature of the structures but also in extensive heterogeneity of the glycans 
(Taylor and Drickamer, 2006). Projects to catalogue the structures of all glycans 
associated with particular cells are underway with databases containing published 
glycan sequences, providing a clue as to the scale of glycomes. Allowing for 
structures missing from these databases and for others that have not yet been 
examined, it seems reasonable to estimate that there may be around 500 endogenous 
mammalian glycan structures in glycoproteins and glycolipids (Drickamer and 
Taylor, 2002). In order to crack the glycocode, a diverse range of technologies are 
coming into play (see Fig 1.9). Primary current analysis methods include the use of 
2D gel electrophoresis, Mass spec, NMR, HPLC, lectin chromatography and 
oligosaccharide arrays with an extensive review of all strategies available by Geyer 
and Geyer (2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.9: Cracking the glycocode: emerging technologies underpinning 
glycomics. A range of technologies are now being exploited to undertake large-scale 
analyses of the structure–function relationships of the glycome. These approaches 
hold the potential to decode the glycome, leading to new insights and biomedical 
applications, adapted from Mislovicova et al, (2009) 
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1.5.1 Two dimensional (2D) gel electrophoresis  
As one of the most efficient protein separation/analytical techniques, gel 
electrophoresis is often the first step employed for glycan analysis. 2D gel 
electrophoresis can be used to separate proteins, reflecting both size and/or 
isoelectric points. Once separated the glycosylation of electroblotted proteins can be 
characterised by probing with carbohydrate-specific lectins or antibodies. A 
significant drawback to this technique is the frequent under-representation of 
membrane proteins, due to the high degree of insolubility in the solubilisation 
detergents (Geyer and Geyer, 2006). Another is that this technique merely gives an 
indication of whether glycans are present or not, it does not allow the elucidation of 
definitive carbohydrate structures or bonds beyond the terminal elaborations. 
 
1.5.2 Mass Spectrometry (MS) 
Mass spectrometry is an analytical technique that detects samples that can be 
successfully converted to gas-phase ions. The resulting ions are accelerated out of 
the ionisation source into a mass analyser, where they are separated according to 
their mass to charge ratio and detected to produce a mass spectrum (Hitchen and 
Dell, 2006). Mass spectrometric identification of glycopeptides has proven to be an 
important tool. Due to its high degree of sensitivity, it can be used to resolve the 
components of a glycan mixture and derive information about the structures of 
individual glycans. There are several ways in which mass spectrometry can be used 
to analyse individual structures; accurate mass determinations of intact glycans can 
be used to derive their compositions, as only a limited number of combinations will 
be consistent with observed masses. Alternatively, glycans can be fragmented, with 
the differences between the masses of the glycans providing information about the 
composition (Taylor and Drickamer, 2006).  
 
For mass determination, glycans must first be separated from the protein backbone. 
Separation is typically carried out using enzymatic or chemical techniques. Enzymes 
such as trypsin and PNGaseF, a glycosidase that cleaves between the innermost 
GlcNAc and asparagine residues of N-linked glycans, are most often used to 
separate glycans prior to analysis. Drawbacks exist with both release techniques in 
22 
 
that the enzymatic release of glycans is dependent on the protein-glycan linkage and 
that not all glycans may be released, while chemical release may lead to the 
destruction of the non-carbohydrate constituents of the protein backbone. Where 
there are multiple glycosylation sites in a single protein the information as to the 
specific site and the exact protein-glycan linkage will be lost. For the analysis of a 
heterogenous glycan mixture, an initial separation step is necessary. This can be 
achieved by using MS/MS or sample enrichment using lectin-specific matrices 
(Dalpathado and Desaire, 2008, Budnik et al., 2006).  
 
1.5.3 Nuclear Magnetic Resonance (NMR) 
NMR analysis of glycoproteins is based on the extent that a glycan distorts in a 
magnetic field. It is a non-destructive technique and can provide full structural 
information and so serves as the ultimate source of definitive information on glycan 
structures. There are some major limitations associated with this technique, 
including not only the high cost of equipment and trained personnel but also the 
amount of glycan required, concentrations of 3-4 orders of magnitude (10-100 ng) of 
the purified glycan (Budnik et al., 2006). NMR is also less well adapted to work on 
mixtures. Although NMR can provide information that cannot be obtained from 
other approaches and is well suited to the analysis of small sugars, interpretation of 
the spectra can be made difficult by the similar environments of many of the protons 
(Taylor and Drickamer, 2006).   
 
1.5.4 High Pressure Liquid Chromatography (HPLC) 
Due to their structural heterogeneity, glycoprotein glycans represent often complex 
mixtures of closely related isomeric compounds. HPLC has proven to be of great 
value in the separation and profiling of glycans due to the wide range of adsorbents 
and solvent systems available, in addition to the speed and reproducibility of 
separation. Anion exchange chromatography can be used to separate glycans 
predominantly on the basis of the number of charged groups present. Similar 
systems can be used to separate glycans on the basis of hydrophilicity (NP-HPLC) 
and hydrophobicity (RP-HPLC). One of the major advantages of this technique is 
the ability to predict possible glycan structures through the comparison of elution 
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times with standard glucose oligomers using only pico moles of sample. A HPLC 
database for sugar maps has been constructed based on a large number of well-
defined standard oligosaccharides 
http://www.gak.co.jp/ECD/Hpg_eng/hpg_eng.htm  (Geyer and Geyer, 2006).  
 
1.5.5 Lectin analysis 
Lectins are emerging at the forefront of new methods in glycoprotein analysis. As 
discussed in section 1.3 lectins have been identified and characterised from a broad 
range of sources and have been shown to have wide ranging sugar binding 
specificities. Numerous techniques that employ glycan specific lectins have been 
developed over a number of years (Mislovicova and Danica, 2009) such as the 
ability of lectins to distinguish between subtle variations of oligosaccharide 
structure, making them perfectly suitable as decoders for carbohydrate information. 
  
Lectin affinity techniques so far seem to potentially offer the most comprehensive 
approach to glycan analysis. Lectin affinity chromatography is especially useful 
where a heterogeneous mixture of oligosaccharides is passed over a lectin column. 
Based on the relative affinity of the lectin for sugars, the glycans may be tightly 
bound to the column, requiring haptenic sugars for elution, thus separating them 
from the unbound material (Geyer and Geyer, 2006). This technique can be 
expanded indefinitely using multiple columns with several specificities represented, 
and also in conjunction with other analysis methods such as MS and NMR, where 
separation or sample enrichment/preparation is usually necessary to achieve the 
required result. 
 
The enzyme-linked lectin assay (ELLA) is a potentially useful technique for the 
generation of glycan profiles. The ELLA, analogous to an ELISA in the 
immunology field, has been reported numerous times over the past 3 decades as a 
useful tool for both glycan and lectin profiling (Matsumoto et al., 2010, McCoy et 
al., 1983, Andrade et al., 1988, Lambre et al., 1991). The ELLA involves the 
immobilisation of a protein-glycan conjugate on a plate surface. Subsequent to 
blocking, the carbohydrate can be probed by specific labelled lectins; binding is then 
detected using colourmetric techniques (see Fig 1.10). This method may also be 
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used in conjunction with the traditional ELISA. Used in combination an 
immobilised antibody can be used to capture an antigen before the carbohydrate 
structure is probed with labelled lectins (Matsumoto et al., 2010).  
 
 
 
 
 
 
Fig 1.10: Enzyme linked lectin assay (ELLA). A protein carbohydrate conjugate is 
immobilised on the bottom of a 96 well plate. The plate is blocked with appropriate 
blocking solution. The glycan complex is probed with labelled lectin(s). The lectins 
are detected using specific, peroxidase labelled antibodies. The antibody-peroxidase 
conjugate can be detected using colormetric techniques. 
 
The main advantage of ELLA analysis of glycoconjugates compared with some of 
the aforementioned techniques, is the lack of a need for protein denaturation or 
peptide cleavage. Exposure of underlying residues and specific linkages can be 
achieved by the glycosidase-mediated trimming of terminal glycans and the use of 
sugar and linkage specific lectins. Due to the highly specific nature of lectin-glycan 
interactions, high concentrations of glycan are not a prerequisite. In addition to the 
uses already mentioned lectins can also be applied to in vitro and in vivo studies. 
With the greater understanding of lectin glycan interactions commercial lectins can 
be used to localise specific glycans in cells by conjugating them to probes such as 
fluorescent tags e.g. GFP (Fitches et al., 2001, Krist et al., 2004, Wanchoo et al., 
2009), and radiolabelling (Smart et al., 2002). The biggest drawback to the use of 
lectins is the cost and limited availability of fully characterised lectins.  
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1.5.6 Carbohydrate arrays 
The biggest drawback to the aforementioned analysis techniques is not just the cost 
and high degree of personnel expertise required but the lack of large-scale 
applicability and automation. The call for increased time and cost-efficient methods 
has been answered with the development of oligosaccharide arrays. The first high 
throughput sugar array assemblies were described in 2002 (Bryan et al., 2002, Fukui 
et al., 2002, Houseman and Mrksich, 2002), with much effort invested in the 
development of these glycan arrays in the latter half of the last decade. A paradigm 
of DNA and protein arrays carbohydrate microarrays primarily consist of sugars that 
are attached to a surface in a spatially defined and miniaturised fashion. A spacer 
between the sugar and the surface ensures that the binding partner, usually a lectin, 
can gain access to the immobilised carbohydrate (see Fig1.11). The microarray 
format minimises the amount of carbohydrate needed for each binding experiment 
and makes the most of the expensive materials. The dense presentation of the sugars 
on the surface mimics the situation encountered on cell surfaces that allows for 
multivalent interactions of relatively weak binding sugars (Horlacher and Seeberger, 
2008). 
 
Researchers have developed a number of carbohydrate array formats to 
accommodate multipurpose applications in carbohydrate research. Oligosaccharide 
array technologies can be classified into monosaccharide chips, oligosaccharide 
chips and microarrays of carbohydrate-containing macromolecules, including 
polysaccharides and various glycoconjugates. The mono- and disaccharide arrays 
are suitable for screening and characterising novel carbohydrate-binding proteins 
(CBPs) or carbohydrate catalysing/binding enzymes and for the identification of 
novel inhibitors of carbohydrate protein interactions. Arrays containing more 
complex carbohydrate ligands are suited for the screening of lectins with intricate 
binding specificities and antibodies with anticarbohydrate binding (Wang, 2003). 
Glycan arrays have been exploited not just for the characterisation of novel 
carbohydrate structures or carbohydrate binders but for investigating biological 
systems. A microarray system was used to analyse the glycan dependent interactions 
of two HIV-1 envelope proteins which are responsible for initiating the uptake of the 
virus into the host cell. Blocking these proteins allows for the prevention of virus 
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internalisation and replication (Adams et al., 2004). Glycan array technologies also 
have applications in sport; in 2010, Hardy et al.,  developed a glycoprotein 
microarray assay to detect antibodies produced in response to recombinant human 
EPO (rHuEPO) use/abuse in animal based sports. These anti-rHuEPO antibodies 
remained in circulation for considerably longer than EPO itself, thus prolonging the 
window in which dopers can be caught. 
 
Carbohydrate or oligosaccharide standards for array immobilisation are either 
isolated from natural sources or chemically synthesised, with access to these 
structures the major bottle-neck for the production of carbohydrate arrays (Horlacher 
and Seeberger, 2008). For glycan array fabrication a number of different 
immobilisation technologies have been developed, which can be divided into three 
classes: on-chip synthesis, covalent conjugation and physical adsorption (Lepenies 
and Seeberger, 2010, Wang, 2003). Recent advances in glycan array fabrication and 
glycoprofiling have most recently been reviewed by Liang and Wu (2009).  
 
 
 
Fig 1.11: Conduct of microarray experiments exemplified for protein binding. 
Binding of a protein to arrayed sugars, binding of the fluorescently labelled 
detection protein, read out by a fluorescence scanner and analysis (Horlacher and 
Seeberger, 2008) 
 
1.5.6.1 Problems associated with carbohydrate arrays 
 
A key outstanding issue in the glycan-screening field is the importance of the 
context in which glycans are normally seen by lectins. In contrast to cDNA arrays, 
where on-chip denaturation is a prerequisite, carbohydrate arrays require 
preservation of the molecular structures, particularly the 3D conformations. 
Oligosaccharides are usually present on the surfaces of glycoproteins and lipid 
bilayers rather than free in solution or on synthetic chemical surfaces. 
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Immobilisation of glycans to array surfaces can have at least three different effects 
on their interactions with lectins. Firstly, lectins are usually oligomeric and bind 
with highest avidity when making multiple interactions with appropriately spaced 
oligosaccharides. The tightest binding may be achieved when multiple glycans are 
present on the surface of a specific glycoprotein at appropriate spacings. Secondly, 
some lectins actually bind to protein-carbohydrate co-determinants rather than to 
glycans alone. Finally, the proximity to protein or polysaccharide surfaces can 
increase the affinity of lectin- binding to glycoproteins or to terminal structures on 
large oligosaccharides, without the need for extended, highly specific binding sites 
(Drickamer and Taylor, 2002). A number of additional technical difficulties will 
also have to be overcome in order to establish this carbohydrate microarray 
technology. Difficulties include considering whether carbohydrate macromolecules 
of hydrophilic character can be immobilised on a chip surface by methods that are 
suitable for high-throughput production of microarrays. Whether immobilised 
carbohydrate-containing macromolecules preserve their immunological properties, 
(such as expression of carbohydrate-epitopes or antigenic determinants and their 
solvent accessibility) or whether the carbohydrate microarray system can reach the 
sensitivity and capacity to detect a broad range of antibody specificities in clinical 
specimens. Finally whether this technology can be applied to investigate the 
carbohydrate-mediated molecular recognition on a scale that was previously 
impossible is another consideration (Wang, 2003).  
 
To circumvent the problems associated with the synthesis of carbohydrate polymers 
and the immobilisation of oligosaccharides in appropriate orientations, methods 
based on the reverse methodology, lectin arrays, have recently been developed. Of 
those described none are more successful than GlycoScope
TM
 and 
Qproteome
TM
Glycoarray kits marketed by the registered company Procognia. These 
rapid kit-based assays consist of an array of multiple immobilised plant lectins with 
overlapping specificities that can be used to profile intact glycoproteins. The binding 
of a glycoprotein to the array results in a characteristic fingerprint that is highly 
sensitive to changes in the proteins glycan composition (Rosenfeld et al., 2007).  
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The biggest advantage of lectin arrays is that no pre-treatment of the samples are 
necessary, contrary to what is the case for oligosaccharide arrays and the other 
profiling techniques discussed. However, it is likely that not all glycan substructures 
are readily accessible for lectin recognition without appropriate treatment of the 
underlying glycoproteins. Sometimes glycans may be shielded by other glycan 
structures but, by contrast, it can be advantageous for some research questions to 
only screen the accessible glycans on the surface. Certain other issues arise when 
working with lectin microarrays. For example, washing steps are necessary to 
remove, e.g., unbound sample, which can be detrimental for the relatively low 
affinity binding of lectins with their ligand. Also, absolute amount of glycans cannot 
be directly derived from the obtained signals and relative quantification can 
sometimes be complex since a fraction of the applied lectins have overlapping 
substrate specificities thus making it difficult to normalise. The presence of 
interfering free sugars could also leade to false positive results. Finally, some lectins 
are glycosylated and could potentially be bound by proteins present in the sample 
(Vanderschaeghe et al., 2010). 
  
 
1.6 Glycosylation – Implications for the biopharmaceutical industry 
Commercial interest in new high-throughput methods for automated, quantitative 
analysis of glycosylation patterns are indicative of a growing biotech industry wide 
focus on glycan importance and analysis (Sheridan, 2007). The focus of this industry 
has dramatically shifted in the past number of years with the majority of new drugs 
entering the market today recombinant glycoprotein molecules. As of 2006 70% of 
the therapeutic proteins approved by the European and US regulatory authorities 
were glycosylated with some 500 candidates at the clinical development stage 
(Sethuraman and Stadheim, 2006). Due to the nature of glycosylation, the specific 
glycan moieties on the surface of these therapeutic molecules can vary dramatically. 
Thus variation can have a large impact on the efficacy of the drug by affecting 
plasma half life, and can affect tissue targeting and impact a drug‟s biological 
activity. In order to meet the demands of the regulatory authorities, 
biopharmaceutical companies require rapid throughput techniques to enable detailed 
glycoprotein analysis, not only for initial product characterisation and process 
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validation but for continuous process monitoring, to ensure product consistency 
from batch-to-batch (Paul Clarke et al., 2011 manuscript in preparation). 
 
With the emergence of genetic engineering techniques and a proficiency in 
recombinant protein production, therapeutic product production from mammalian 
cell lines, yeast, bacteria and insect cells has become the norm. These expression 
systems vary widely with regard to the ability and proficiency of the cells to 
incorporate glycans. The choice of particular cell expression systems and the 
influence of the manufacturing process are important considerations when producing 
any recombinant products (Jenkins et al., 1996). Adequate control of the 
microheterogeneity of glycoprotein pharmaceuticals is critical for the production of 
batches possessing reproducible pharmacokinetic properties. Studies analysing 
glycoproteins from batch samples demonstrate that the culture environment can 
influence both the macroheterogeneity and microheterogeneity of oligosaccharides 
in recombinant glycoproteins (Jenkins et al., 1996). From the known properties of 
glycoprotein clearance, the main focus of batch assessment is often the sialic acid 
content. While many non-mammalian cell based expression systems offer clear 
advantages over mammalian cell lines for recombinant protein expression, cell line 
choices are limited by the glycosylation machinery. For example, yeast-based 
expression systems carry significant advantages over mammalian cell lines, such as 
higher protein titers, shorter fermentation times and the ability to grow in 
chemically-defined media. Yeast has been used for the production of several 
approved therapeutics including recombinant insulin, the ability of yeast to carry out 
N- glycosylation offering a major advantage. The presence of yeast-specific high 
mannose sugars has, however, limited the use of recombinant proteins produced in 
yeast to those that do not require N-glycosylation for therapeutic efficacy e.g. insulin 
(Sethuraman and Stadheim, 2006).   
 
Advances in attempts to humanise cell lines are providing major advantages to this 
industry, with the possibility that the availability of such cell lines may eliminate the 
need for mammalian cell culture in the future. The biggest success story in this 
regard is the humanisation of yeast by GlycoFi. By altering the N-linked 
glycosylation pathway, Gerngross and colleagues at Darthmoth and GlycoFi 
30 
 
succeeded in generating a yeast cell line capable of secreting terminally-sialylated, 
complex, bi-antenary glycoproteins (Hamilton et al., 2006, Beck et al., 2010).  
Merck parted with $400 million in 2006 to acquire GloyoFi, giving an indication of 
the importance of such technologies to this industry (Sheridan, 2007).  
 
Although great strides have been made in altering cellular machineries for increased 
sialylation for some glycoprotein therapeutics, it is not always sialic acid that is the 
key player for the improvement of drug efficiencies. As lectins of the immune 
system play an essential role in the recognition of glycan structure on the surface of 
pathogens and autoantigens, they represent valuable targets for cell-specific delivery 
of immunomodulatory drugs (Lepenies and Seeberger, 2010). For example, 
glucocerebrosidase (GBA) is a therapeutic molecule approved for the treatment of 
Gaucher‟s disease. GBA requires GlcNAc2Man3 (paucimannose) for targeting 
through the mannose-binding receptor to macrophages in the liver, where the 
recombinant enzyme metabolises accumulated glucocerebroside (Friedman et al., 
1999). GBA is currently produced in CHO cells, resulting in terminal sialylation; 
thus, it requires a series of enzymatic digests to produce paucimannose through the 
sequential removal of sialic acid, galactose and GlcNAc (Sethuraman and Stadheim, 
2006).  
 
An increased awareness of the importance of product glycosylation in the 
biotechnology industry has not only led to more detailed carbohydrate analysis at 
earlier stages of product development and the glycoengineering of cell expression 
systems but has also led to an increase in the requirement to provide evidence of 
glycan elaborations to both regulatory agencies and legal departments. These bodies 
will use the resulting information to assess product safety and in patent applications 
to substantiate claims and to distinguish their organisations material from that of 
their competitors (Jenkins et al., 1996). 
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1.7 Novel carbohydrate binding molecules 
It is now more than evident that progress in the understanding of cell glycosylation 
machinery, cell-glycan interactions, host-microbe interactions and, aberrant 
glycosylation etc., is limited primarily by the analytical techniques accessible for 
glycan profiling. While major strides have been made over the past 40 years it 
appears the biggest limiting factor in years to come may be the availability of glycan 
binding molecules. Lectins that bind glycoforms are employed in almost all analysis 
techniques whether for glycan enrichment, separation or detection. The cost and 
availability of these molecules are the major limiting factors for use and 
development. Traditionally, lectins have been isolated whole from plant seeds, fruit, 
stems and bark. Lectins, from these sources, are typically multi-subunit proteins in 
which the subunits themselves may vary. This makes it difficult to produce large 
quantities of plant lectins recombinantly and also gives rise to a wide degree of 
variation depending on the method of isolation. An explosion in advances of 
genome sequencing and bioinformatics has meant that prokaryotes have emerged 
over the past number of years as an almost limitless source of novel carbohydrate-
binding molecules (Imberty et al., 2004, Loris et al., 2003). Unlike plant lectins, by 
their very nature, bacterial lectins are more likely to be amenable to overproduction 
in simple bacterial expression systems. DNA methods can be used to further 
enhance carbohydrate-binding molecules and facilitate their implementation in 
glycoanalytical platforms. A number of protein sequence affinity tags, such as His-, 
Strep- and poly-lysine could be engineered to enhance not only downstream 
purification of recombinant binding proteins but to simplify their incorporation onto 
chromatography or array based methodologies. These tags could also facilitate a 
more efficient orientation specific immobilisation. Recombinant carbohydrate-
binding molecules could also be subjected to mutagenesis in order to enhance or 
change their binding specificities. In addition to the aforementioned benefits, the 
ability to scale production of these molecules and simplified downstream 
purification methodologies could enable the use of these lectins for wide reaching 
applications at low costs. Potential useful directions for the development and 
expansion of novel carbohydrate-binding molecules include those which target 
terminal elaborations that when present on circulatory molecules, are cleared by the 
mannose receptor - terminal GlcNAc and terminal mannose.  
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New carbohyrate-binding molecules with novel sugar-binding properties would have 
a number of applications in all industries, whether for glycan array methodologies or 
for use in therapeutic molecule enrichment or removal to enhance product 
efficiencies. 
 
 
1.8 Chitin 
Chitin is a naturally occurring glucose derivative, a homopolymer consisting of 
variable length linear chains of β1-4 linked GlcNAc (see Fig 1.12). It is structurally 
identical to cellulose apart from the hydroxyl (-OH) group in cellulose at C2 which is 
replaced by an acetamide group (NH.CO.CH3). Chitin is a common constituent of 
arthropod exoskeletons, shells of crustaceans and the cell walls of fungi and yeast. 
The derivative is one of the most abundant naturally occurring materials in nature, 
second to only cellulose (Gooday 1990). In the aquatic atmosphere alone >10
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metric tons of chitin are produced annually (Meibom et al., 2004). It is a possibility 
that proteins that are capable of interacting with chitin may be capable of binding to 
the GlcNAc elaborations present on glycan structures.  
 
 
Fig 1.12: Chemical structure of chitin. Image generated using ChemDraw 
 
Chitin occurs in nature as ordered insoluble crystalline microfibrils, occurring in two 
polymorphs, α- and β-chitin. In both structures the chitin chains are organised in 
sheets where they are held by a number of intra-sheet hydrogen bonds, but differ in 
the packing and polarities of adjacent polymer chains (Sikorski et al., 2009).  In α-
chitin the piles of chains are arranged alternately antiparallel (see Fig 1.13), whereas 
they are all parallel in β-chitin (see Fig 1.14). A second member of the α family, γ-
33 
 
chitin, has also been identified, when two chains run in one direction and another 
chain in the opposite direction. α-chitin is the most abundant of the chitin 
polymoprhs and is found in fungal and yeast cell walls, lobster and crab tendons, 
and also shrimp shells. It is also the most thermodynamically stable, with strong 
inter-sheet and intra-sheet hydrogen bonding. In contrast the rarer β-chitin, derived 
from squid pen, exhibits no inter-sheet hydrogen bonding with weak hydrogen 
bonding by intra-sheets, (Jang et al., 2004). Conversion from the β-form to the α-
form is possible, but not in the reverse (Khoushab and Yamabhai, 2010).  
 
 
Fig 1.13: Structure of α-chitin. The structure of α-chitin in the (a) ac projection; 
(b) bc projection; (c) ab projection (Rinaudo, M., 2006). 
 
 
Fig 1.14: Structure of β-Chitin. The structure of β-chitin in the (a) ac projection; 
(b) bc projection; (c) ab projection (Rinaudo, M. 2006). 
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Chitin naturally occurs partially deacetylated, depending on the source. When the 
degree of deacetylation reaches about 50% it becomes soluble in aqueous acidic 
media and is called chitosan (see Fig 1.15). Commercially chitosan is obtained by 
deacetylation of chitin in its solid state under alkaline conditions (concentrated 
NaOH) or by enzymatic hydrolysis in the presence of a chitin hydrolase (Rinaudo 
2006). Despite the abundant production and inherent insolubility, chitin does not 
accumulate in most ecosystems due to the presence of chitinolytic organisms.  
 
 
Fig 1.15: Chemical structure of chitosan. Image produced using ChemDraw 
 
1.9 Chitin active/binding enzymes  
Chitin active enzymes and nonhydrolytic proteins serve a wide variety of purposes, 
depending on the host organism. In bacteria they play a role in nutrition, infection 
and parasitism (Keyhani and Roseman, 1999, Oh et al., 2007, Yu et al., 1991,  Joshi 
et al., 2008, Manos et al., 2009, Meibom et al., 2004, Shen and Jacobs-Lorena, 
1998). In fungi, protozoa and invertebrates they are also involved in morphogenesis 
(Merzendorfer and Zimoch, 2003, Wessels, 1993,  Sahai and Manocha, 1993) , and 
are used as defence mechanisms in plants, invertebrates and mammals (Hejgaard et 
al., 1992, Millaret al., 1992, Kawabata et al., 1996, Brameld and Goddard, 1998, 
Okawa et al.,  2003, Sanders et al.,  2007). 
 
Carbohydrate-active enzymes can exhibit modular structures, when a module is 
defined as a functional and structural unit. In the classification of Carbohydrate-
Active enZYmes (CAZy) (http://www.cazy.org/), each family in the CAZy database 
is classified depending on a common segment within the gene that ultimately 
contains the catalytic or binding module (Cantarel et al., 2009). At present CAZy 
provides details of four classes of enzyme activities, Glycoside Hydrolases, 
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Glycosyltransferases, Polysaccharide lyases and Carbohydrate esterases. CAzy also 
provides family classification of carbohydrate-binding modules, classified as a 
contiguous amino acid sequence within a carbohydrate-active enzyme with a 
discrete fold having carbohydrate-binding activity. Chitin synthases are classified as 
belonging to family 2 of the glycosyltransferases. Proteins and protein domains with 
chitin-binding properties are classified by CAZy into several sub-families e.g. 
families 18, 19 and 48 of the glycoside hydrolases and families 1, 2, 3, 5, 12, 14, 18, 
19, 33, and 37 of the carbohydrate-binding modules.  
 
1.10 Chitin Synthases 
Chitin synthases (E.C 2.4.1.16) catalyse the formation of chitin through the transfer 
of N-acetyl-D-glucosamine residues to the chitin polymer, using uridine diphosphate 
N-acetyl-D-glucosamine (UDPGlcNAc) and chitin as substrates. This produces a 
longer chitin chain and UDP as the reaction products (reviewed by Cohen, E. 2001). 
Chitin synthesis is a necessary event in the life cycle of many organisms. As 
previously mentioned, chitin serves as the major cell wall/exoskeleton scaffolding in 
many species of crustaceans, arthropods, yeasts and fungi (Mellado et al., 1996). 
Chitin synthases have also been described in nematodes (Veronico et al., 2001) and 
amoebae (Campos-Gongora et al., 2004), where chitin synthesis is necessary for 
cyst development. Most organisms contain two or more chitin synthase genes which 
fall into one of two categories; the first is a zymogen that is activated in vitro by 
trypsin treatment, while the second type does not require proteolytic activation. The 
zymogen form can be further subdivided into five categories based on sequence 
similarity (Bowen et al., 1992, Ruiz-Herrera et al., 2002, Ruiz-Herrera and Ortiz-
Castellanos, 2010). Although chitin is not present in vertebrates, chitin metabolism 
by glycosyl hydrolases is important as a control strategy against chitinous 
organisms.  
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1.11 Glycoside Hydrolases 
Chitinases (E.C. 3.2.1.14) that catalyse the hydrolysis of chitin may be divided into 
three categories, classified as endo-, exochitinases or β-N-acetylglucosaminidase. 
Endochitinases act to catalyse the hydrolysis of chitin at random, internal sites along 
the polymer, where as exochitinases remove single N-acetyl-D-glucosamine residues 
from the non-reducing ends of chitin chains. β-N-acetylglucosaminidases cleave 
GlcNAc units sequentially from the non reducing end of the substrate. Chitinases are 
classified as belonging to families 18, 19 and 48 of the glycoside hydrolases. They 
do not share amino acid similarity between families and have completely different 
3D structures. Chitinases characteristically contain both chitin binding and catalytic 
domains, where the chitin binding domain helps anchor the catalytic unit near the 
substrate, thus enhancing its activity (Ubhayasekera et al., 2007). The presence of 
separate carbohydrate binding and catalytic domains is a generally observed feature 
in enzymes that hydrolyse solid carbohydrate substrates and is also observed in 
cellulases and amylases (Beintema, 1994). 
 
1.11.1 Glycosyl Hydrolases – family 18 
Family 18 glycosyl hydrolases encompass chitinases from most living organisms 
and according to a recent study by Karlsson and Magnus (2009) may be further 
characterised into three separate clusters, namely, A, B and C.  Clusters A and B 
both contain representatives from bacteria, fungi and plants. Cluster C consists of 
hydrolytic domains with bacterial origin, with the exception of the carboxy-terminal 
domain of an archean ChiA protein. No obvious domain patterns separate the three 
main clusters but subgroups corresponding to taxonomic groupings within the 
clusters display similar length and analogous domain patterns in addition to the 
chitinolytic domain (Karlsson and Stenlid, 2009). This suggests functional 
differentiation of family 18 glycosyl hydrolases and that proteins with similar 
domain structure have adapted to a specific substrate and possibly to a specific 
biological function. Typical family 18 glycosyl hydrolases can comprise up to five 
distinct domains: an N-terminal signal peptide region, a catalytic domain, a 
serine/threonine-rich region, a chitin binding domain and a C-terminal extension 
region (Perrakis, et al., 1994). The signal peptide preceding the N-terminal domain 
37 
 
of the mature protein presumably mediates secretion of the enzyme and is cleaved 
off by signal peptidases after the protein has been transported across the membrane. 
The catalytic domain of family 18 chitinases consists of an (α/β)8-barrel with a deep 
substrate-binding cleft formed by loops positioned between the carboxy-terminal 
end of β-strands and the amino terminal end of the helices (Davies and Henrissat, 
1995, Henrissat et al., 1995, Perrakis et al., 1994). The active site of GH18s contain 
a conserved consensus of amino acids residues, (LIVMFY)-(DN)-G-(LIVMF)-
(DN)-(LIVMF)-(DN)-X-E, which are essential for catalytic activity (Watanabe, et 
al.,  1993). The chitin-binding domain is not always present and is not necessary for 
chitinase activity but it is thought to enhance the efficiency of the enzymes by acting 
as an anchor thus keeping the chitinase in contact with the substrate (Suzuki et al., 
1999, Kuranda and Robbins, 1991).  
 
Fig 1.16: The crystal structure Chtinase A (ChiA) from Serratia marcescens in 
complex with tetra-N-acetylchitotriose.  An image of the crystal structure of ChiA 
from S. marcescens, a member family 18 of the glycosyl hydrolases, in complex 
with tetra-N-acetylchitotriose (PDB Code: 1K9T). ChiA comprises three domains: 
an all β-strand amino-terminal domain, a catalytic α/β-barrel domain, and a small α- 
and β-fold domain. Image generated using Pymol. 
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1.11.2 Glycosyl Hydrolases – family 19 
Family 19 chitinases had until recently only been isolated from higher plants but 
have since been reported in a number of bacterial species, (Brameld and Goddard, 
1998, Watanabe et al., 1999, Sasaki et al., 2006). A variety of putative family 19 
chitinases from eukaryotes, bacteria and viruses are also reported in the CAzY 
database.  With few exceptions family 19 chitinases are synthesised with an N-
terminal signal sequence. After removal of the signal the mature protein consists of 
two domains, a chitin-binding domain and the catalytic module. In contrast to the 
family 18 chitinases, the catalytic domain of family 19 chitinases comprise of two 
lobes, each of which is rich in α-helical structure. A conserved motif to characterise 
the substrate binding site of family 19 chitinases has been proposed by Huet et al.,  
(2008), defined between Tyr111 and Tyr125 as 
111
Y-(FHY)-G-R-G-(AP)-x-Q-(IL)-
(ST)-(FHYW)-(HN)-(FY)-N-Y
125
. Only one member of family 48 has been 
described as having chitinase activity.  
 
 
Fig 1.17: Crystal structure of wheat germ agglutinin (WGA) in complex with 
GlcNAc. An image of the crystal structure of WGA, a member of family 19 of the 
glycosyl hydrolases, in complex with GlcNAc. GlcNAc residues are highlighted in 
orange (PDB Code: 2UVO). Image generated using Pymol. 
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In addition to a lack of homology, family 18 and 19 endo- and exo- acting chitinases 
also differ in their mechanisms of action. The family 18 chitinases reported to date 
yield a β-anomer hydrolysis product, whereas family 19 chitinases give rise to α-
anomer configuration. This dissimilarity is explained by a proposed difference in the 
mechanism of hydrolysis employed by the two distinct families. Family 18 
chitinases are thought to utilise a double displacement mechanism, where 
protonation of a GlcNAc residue in a boat configuration leads to an oxazoline 
intermediate, which may be hydrolised to form a product with retention of the 
anomeric configuration (see Fig 1.18a). A single displacement mechanism has been 
proposed for family 19 chitinases where two acidic residues are required in the 
active site and the hydrolysis product has inversion of the anomeric configuration 
(see Fig 1.18b) (Brameld and Goddard, 1998).  
 
 
 
 
Fig 1.18: Proposed hydrolysis mechanism for family 18 and 19 chitinases from 
the glycoside hydrolase family. (a) The double-displacement hydrolysis 
mechanism proposed for family 18 chitinases. Protonation of a GlcNAc residue in a 
boat conformation leads to an oxazoline intermediate, which may be hydrolyzed to 
form a product with retention of the anomeric configuration. (b) The single 
displacement hydrolysismechanismproposed for family 19 chitinases. Two acidic 
residues are required in the active site and the hydrolysis product has inversion of 
the anomeric configuration (Brameld and Goddard, 1998).  
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1.11.3 Carbohydrate-binding modules 
The families of carbohydrate binding modules that display chitin binding activity 
(families 1, 2, 3, 5, 12, 14, 18, 19, 33 and 37) as described by CAZy, are simple 
units, approx 40-150 residues long, that appear as discrete domains within larger 
carbohydrate active proteins. The one exception to this is the family 33 CBMs. 
Some members of this family are distinct i.e. they also exist as independent, non-
catalytic chitin-binding proteins, mainly found in bacteria and viruses. Genome 
analysis indicates that secreted family 33 CBPs are produced by most chitin-
degrading organisms (Vaaje-Kolstad et al.,n2005b), though only a few have been 
characterised to date. Independent family 33 CBMs have been reported and isolated 
from Streptomycetes (Saito et al., 2001, Schnellmann et al., 1994, Kolbe et al., 
1998, Svergun et al., 2000, Schrempf.H, 2001), Pseudoalteromonas sp. 
(Techkarnjanaruk and Goodman, 1999), Pseudomonas aeruginosa (Folders et al., 
2000), Bacillus amyloliquefaciens (Chu et al., 2001), Serratia sp. (Fuchs et al., 
1986, Watanabe et al., 1997), Thermobifida fusco (Moser et al., 2008) and 
Lactococcus lactis spp (Vaaje-Kolstad et al., 2009). These nonhydrolytic chitin-
binding proteins (CBPs) are thought to act synergistically with chitinases by 
increasing substrate accessibility thus increasing chitinase activity (Moser et al., 
2008, Vaaje-Kolstad et al., 2009, Vaaje-Kolstad et al., 2005a). As is a common 
feature of the chitinases discussed previously, the family 33 CBPs have N-terminal 
signal sequences, which are cleaved from the protein during secretion of the proteins 
to the extracellular medium, suggesting a requirement for export and localisation 
outside the cell. The combination of sequence and structural information from site-
directed mutagenesis studies have shown that the surface of family 33 CBPs contain 
a patch of highly conserved mostly polar residues which are important for binding to 
chitin and for the positive effect on chitinase efficiency (Vaaje-Kolstad et al.,  
2005b, Vaaje-Kolstad et al., 2005a). The exact mechanism of interaction, however, 
remains unknown.  
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1.12 Fungal chitin active enzymes 
Fungal chitin synthases and chitinases are involved in fungal growth and 
development, spore formation, pathogenicity and parasitism. The rigid chitinous cell 
wall of fungi provides both protective and aggressive functions. In this way, it acts 
as an initial barrier to the outside environment while harbouring many hydrolytic 
and toxic molecules. With the exception of unicellular yeasts, fungi typically grow 
by means of hyphae that extend only at their apices and ramify into a mycelium. 
Analysis of the chemistry of the fungal wall and its biosynthesis by Joseph Wessels 
(1993) has disclosed a simple mechanism explaining the transition from a newly 
formed expandable wall at the apex to a more rigid wall at the base of the hyphal 
extension zone. Two individual wall polymers, chitin and β-glucan, are extruded at 
the apex and modified within the domain of the wall. Among the modifications 
observed are the formation of covalent crosslinks between these two polymers and 
hydrogen bonds between the homologous polymer chains, leading to the formation 
of chitin microfibrils crosslinked to a glucan matrix (see Fig 1.19). By extending at 
their hyphae in this way, fungi can penetrate solid substrata such as wood, allowing 
for the excretion of lytic enzymes, including chitinases to digest the substrate 
polymers and convert them to nutrients.   
 
In yeast cells, chitin produced by synthase genes accounts for 1% of the cell wall 
(Orlean, 1987). Located in the septum chitin is important for the mechanical stability 
of the temporary junction between mother and daughter cells during budding. 
Separation of the progeny is dependent on expression of a chitinase to break down 
the chitin in the primary septum (Kuranda and Robbins, 1991). Most fungal 
chitinases belong to family 18 of the glycosyl hydrolases (reviewed by Duo-Chuan, 
2006) and therefore are typically composed of up to five domains, an N-terminal 
signal peptide region, a catalytic domain, a serine/threonine-rich region, a chitin 
binding domain and a C-terminal extension region. Generally fungal chitinases lack 
the last three domains but are still catalytically active. Fungal chitinases lacking an 
N-terminal signal peptide have been shown to be located intracellularly and may 
function during morphogenesis (Takaya et al., 1998, Seidl et al., 2005). The 
serine/threonine-rich region of fungal chitinases is usually glycosylated with sugar 
chains, thought to be necessary for secretion and stability of the protein.  
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Fig 1.19: The steady-state model of apical wall growth. For the extending apex 
the schematic drawing shows the stretching of the wall and the addition of new wall 
material from the cytoplasmic side, maximally at the extreme tip. Newly added wall 
consists of chitin chains (straight lines) and (1→3)-β-glucan chains (wavy lines). 
With time, these two polymers interact to form chitin microfibrils and β-glucan 
triple helices while covalent linkages occur between chitin and β-glucan chains, 
which also become branched. At the very tip (a) the wall is minimally crosslinked 
and supposed to be most plastic. Subapically (b) a wall volume added at the very tip 
is stretched and partially crosslinked (increased shading) while new wall material is 
being added from the inside to maintain wall thickness. At (c) the average 
crosslinking has proceeded to the point that the wall hardly yields to turgor pressure 
but it has not yet maximal strength. Crosslinking continues in the tubular part of the 
wall till completion far behind the apex (d). (Wessels, 1993). 
 
1.13 Plant chitin active enzymes 
The β1-4 GlcNAc linkages of chitin do not occur in plants, whereas multi-domain 
enzymes consisting of several chitinase and chitin-binding domains occur 
frequently. The chitinous components of the cell wall of fungal pathogens have been 
regarded as the target of plant chitinases for defence purposes (Werner et al., 2002). 
Present knowledge also suggests that they are differentially expressed in response to 
different forms of environmental stress such as mechanical wounding, drought, 
salinity and frost (Hejgaard et al., 1992, Millar et al., 1992, Sasaki et al., 2006). 
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Plant chitinases are synthesised at ribosomes attached to the ER, before entering the 
lumen of the ER where they are transported further through the golgi apparatus to a 
vacuole. Some plant chitinases are modified during the synthesis pathway, 
undergoing cleavage of their N-terminal signal sequences and the addition of N-
linked glycan chains. Others may undergo rearrangements, deletions and 
reglucosylation to ensure proper folding. Prior to the development of the CAzY 
database, plant chitinases had been categorized as either b-type or h-type with 
further subdivision into five classes based on the amino acid sequence and domain 
features. According to the classification of glycoside hydrolases by Henrissat and 
Davies (1995), b-type enzymes of classes I, II, and IV are included in family 19, 
whereas h-type classes III , and V are included in family 18. Class I chitinases have 
an N-terminal cysteine-rich chitin binding domain and a C-terminal catalytic domain 
which are connected by a short linker peptide of about 10–20 amino acid residues. 
On the other hand, class II chitinases consist only of a catalytic domain homologous 
to that of class I chitinases. Class IV chitinases share homology with class I 
chitinases. Class III and V chitinases show no homology with classes I, II, and IV 
but have distinct sequence similarity to bacterial and fungal chitinases (Beintema, 
1994, Graham and Sticklen, 1994).  
 
 
1.14 Invertebrate chitin active enzymes 
Arthropod growth and development is strictly dependent on the capability to 
remodel chitinous structures. For example, insect cuticles form an exoskeleton that 
is limited in its capacity to keep pace with body growth due to the rigidity of the 
structure caused by the presence of chitin and other sclerotised proteins. In order for 
insects to develop, they are periodically forced to replace their old cuticle with a 
new, looser one during ecdysis (molting) (Merzendorfer and Zimoch, 2003). Ecdysis 
is initiated by apolysis, where the epidermal cells are separated from the old cuticle 
by molting fluid secretion and ecdysial membrane formation. The molting fluid 
contains multiple chitinases to aid in the digestion of the old endocuticle. Once 
degraded, the fluid is then re-absorbed, recycling the old cuticle components. 
Secretion of cuticle proteins and chitin fibers from epidermal cells initiates 
formation of the new cuticle. Chitin synthesis is also necessary for formation of the 
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Peritrophic Matrix (PM). The PM is an extracellular chitin-containing envelope that 
completely surrounds the food bolus in the guts of most arthropods. It is thought to 
be crucial for protection of the digestive cells from bacterial damage and parasitic 
invasion, in addition to facilitating the digestive processes. All PMs are composed of 
chitin, proteins and proteoglycans (Elvin et al., 1996). Arthropod chitinases belong 
to family 18 of the glycosyl hydrolases and contain the typical modular stucture, an 
N-terminal signal peptide region, the mature catalytic amino-terminal domain, a 
serine/threonine-rich domain and a chitin binding domain. Like some fungal 
chitinases insect chitinases can also be extensively glycosylated, with a size range of 
40-85 kDa. 
 
While chitin-containing organisms use chitin synthases and chitinases to remodel 
their own structures, the same classes of enzymes are exploited for colonisation by 
viruses and parasitic organisms. For instance insect viruses produce chitinases to
 
disintegrate the PM of their target organism,
 
thereby increasing viral infectiousness. 
The malaria parasite Plasmodium falciparum however, uses chitinases to cross the 
chitinous PM of the
 
mosquito host (Shen and Jacobs-Lorena, 1998, Mitsuhashi et 
al.,  2007, Vaaje-Kolstad Horn et al., 2005). Anopheline mosquitoes are the sole 
vectors for human malaria, causing about 2 million deaths annually. Upon ingestion 
of an infected blood meal, the mosquito forms a PM around it. Inside the PM 
Plasmodium gametes mate, develop into ookinetes, and about one day later, the 
ookinetes penetrate the PM and the gut epithelial cells through the secretion of 
chitinases. After traversing the gut epithelium and reaching the gut basal lamina, the 
ookinetes develop into oocysts. Each oocyst eventually releases thousands of 
sporozoites that invade the salivary glands and infect the next person when the 
mosquito bites again.  
 
 
1.15 Mammalian chitin active enzymes 
To date, chitin has not been found in mammals. However several proteins showing 
homology to chitinases (all members of family 18 of the glycosyl hydrolases) have 
been reported in a number of species. The first mammalian chitinase to demonstrate 
chitinolytic activity was a tetra-N-acetylchitotetraoside isolated from man (Boot et 
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al., 1995). Chitotriosidase was found to be synthesised by activated macrophages 
and its activity was found to be markedly increased in plasma and tissue of patients 
with Gauchers disease (Hollak et al., 1994). This marked increase was due to the 
massive production and secretion by the lipid laden macrophages which accumulate 
as a consequence of this disease.  The presence of a chitotriosidase gene in humans 
suggests an anti-microbial function, however people showing a mutation in the gene 
encoding chitotriosidase produce no functional protein and yet have no greater 
susceptibility to infection (Boot et al., 1998).  
 
A second catalytically active human chitinase, namely, acidic mammalian chitinase 
(AMCase), with a homologue in cynomolgus monkeys, was also recently identified 
(Boot et al., 2001, Krykbaev et al., 2010). Like chitotriosidase, AMCase contains an 
N-terminal catalytic core domain and C-terminal chitin binding domain, separated 
by a hinge region. Unlike chitotriosidase, AMCase is expressed in the stomach and 
lung tissue, where it is thought that it may play a dual role in food assimilation and 
defence respectively (Boot, 2001).  
 
A third GlcNac active enzyme, Di-N-Acetyl-Chitobiase has also been identified in 
humans (Fisher and Aronson, 1992). It is a reducing end glycosidase that functions 
along with a number of other acid hydrolases to split the GlcNAcβ-D-(1-4)GlcNAc 
chitobiose core of asparagine-linked glycoproteins, completely degrading these 
glycoproteins and related glycoconjugates.  
 
A number of chitinase-like proteins, termed chi-lectins, Oviductin (Buhi 2002), 
human cartilage protein gp-39 (YKL40) (Hakala et al., 1993), human condrocyte 
protein 39 (YKL39) (Hu et al., 1996) , and stablin-1 interacting chitinase-like 
protein (SI-CLP) (Kzhyshkowska et al., 2006) , have also been identified as capable 
of binding chitin. These chi-lectins lack enzymatic activity due to substitution of 
active-site catalytic residues (Bussink et al., 2007). While the precise functions of 
these chi-lectins and mammalian chitinases are not yet precisely understood, most of 
the human family 18 chitinases have been linked to a variety of diseases and could 
potentially be used as diagnostic and prognostic markers for those diseases (see 
Table 1.2) (Guan et al.,  2009). 
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Table 1.2: Chitin active proteins and associated human diseases. (Guan et al., 
2009) 
Chitinase Character of Disease Disease 
AMCase Th2-mediated inflammation 
Asthma 
Rhinosinusitis with nasal polyps 
Vernal keratoconjunctivitis and season 
allergic conjunctivitis 
Chitotriosidase 
Inherited lysosomal storage 
disorders/Sphingolipids 
Gaucher‟s disease or β-glucocerebrosidase 
deficiency 
Niemann Pick 
GMI-gangliosidosis 
Krabbe‟s disease 
YLK-40 
Infection 
Human endotaxemia 
Streptococcus pneumoniase pneumonia 
S.pneumonia bacteraemia 
Purulent meningitis and encephalitis 
Joint Disease 
Rheumatoid arthritis 
Osteoarthritis 
Ankylosing spondylitis 
Chronic inflammation 
Giant cell arthritis 
Inflammatory bowel disease 
Sarcoidosis 
Systemic sclerosis 
Liver fibrosis 
Alcoholic liver disease 
Chronic hepatitis C virus infection 
Advanced cancer 
Adencarcinoma 
Small cell lung cancer 
Glioblastoma 
Myxoid chondrosarcoma 
Papillary thyroid carcinoma 
Melanoma 
Arthersclerosis 
YLK-39 Joint disease 
Rheumatoid arthritis 
Osteoarthritis 
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1.16  Bacterial chitin active enzymes 
Chitin turnover is an essential process for recycling carbon and nitrogen, with 
bacteria the primary degraders of chitin in the biosphere. Bacteria capable of 
degrading chitin usually produce an array of chitinases; Serratia marcescens 
produces three chitinases, a hexosaminidase and a non-catalytic chitin-binding 
protein, when grown on chitin (Suzuki et al., 2002, Fuchs et al., 1986). Similarily,   
Streptomyces olivaceoviridis produces five chitin active proteins (Romaguera et al., 
1992). This multi-protein approach allows microorganisms to launch a synergistic 
attack on insoluble chitin matrices, with endochitinases attacking the chitin chain at 
random intervals, exochitinases attacking at either the reducing or non-reducing ends 
and the hexosaminidases converting the chitobiose products to GlcNAc. These 
compounds may then enter the periplasm where chitodextrinases (EC 3.2.1.14) and 
N-acetylglucosaminidases (E.C. 3.2.1.52) act to form a pool of GlcNAc and 
chitobiose (Howard et al., 2003). Following transport to the cytoplasm, the GlcNAc 
and chitobiose are metabolised or modified for use in cell wall biogenesis (see Fig 
1.20). 
 
 
 
 
Fig 1.20: Chitin recycling system employed by microbial organisms. Multiple 
enzymes are required for the degradation of chitin. Shaded ovals Transporters, OM 
outer membrane, IM inner membrane, (Howard et al., 2003). 
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In bacteria an alternative strategy for chitin degradation is also sometimes employed, 
involving nonhydrolitic chitin binding proteins (family 33 of the carbohydrate 
binding modules) that act synergistically with chitinases, as mentioned in section 
1.11.3. Genome analyses indicate that these proteins are secreted by most chitin-
degrading microorganisms but few have been characterised biochemically. 
Biochemical studies have revealed a large diversity in binding preferences (see table 
1.3). 
 
Table 1.3: Binding preferences of family 33 non-hydrolytic bacterial chitin binding 
proteins 
Organism Name Binding preference Reference 
Serratia marcescens CBP21 β-chitin cellulose (Watanabe et al., 1997) 
Streptomyces coelicolor Chb3 
α-chitin, β-chitin, 
chitosan 
(Saito et al.  2001) 
Streptomyces 
olivaceoviridis CBH1 α-chitin 
(Schnellmann et al.   
1994) 
Sterptomyces reticuli CHB2 α-chitin (Kolbe et al., 1998) 
Streptomyces tendae 
AF1 
α-chitin, chitosan, 
fungal cell walls 
(Bormann et al.  1999) 
Pseudomonas aeruginosa CbpD α-chitin (Folders, et al., 2000) 
Pseudoalteromonas 
piscicida Cbp1 
α-chitin, cellulose, 
β-chitin 
(Tsujibo, et al., 2002) 
Bacillus amyloliquefaciens ChbB 
β-chitin, cellulose, 
α-chitin, β-glucans 
(Chu et al., 2001) 
Thermobifidia fusca 
E7 
β-chitin, α-chitin, 
cellulose 
 
(Moser et al., 2008) 
E8 
β-chitin, α-chitin, 
cellulose 
Lactocossus lactis  LICBP33A 
β-chitin, α-chitin, 
cellulose 
(Vaaje-Kolstad et al., 
2009) 
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1.16.1 Chitin-binding proteins utilized in this project 
 
In the search for novel carbohydrate-binding proteins, particularly those with 
preference for GlcNAc, four family 33 chitin-binding proteins were chosen; CBP21 
from S. marcescens, CbpD from P. aeruginosa and two previously uncharacterised 
proteins that show homology to CBP21. They have been named CbpA and CbpL 
from Photorhabdus asymbiotica and Photorhabdus luminescens respectively, for the 
purposes of this project. The chitinolytic system of S. marcescens is one of the most 
extensively studied. The previously characterised CBP21 is a good candidate on 
which to model expression and binding studies of the three other molecules. 
 
1.16.2 The chitinolytic system of Serratia marcescens 
 
Serratia marcescens is a species of gram-negative bacteria that belongs to the family 
Enterobacteriacae. A human pathogen, it is involved in nosocomial infections, 
particularly urinary tract infections and wound infections, and as discussed 
previously, is one of the most efficient and well studied chitinolytic organisms. S. 
marcescens is capable of producing 3 chitinases, ChiA, ChiB and ChiC, a β-N-
acetylglucosaminidase, and a non catalytic chitin binding protein CBP21 (belonging 
to family 33 of the carbohydrate binding modules) when grown in the presence of 
chitin.  
 
CBP21 was first described by Fuchs, R.L et al., in 1986 as a 21 kDa catalytically 
active chitinase. It was later shown by Watanabe et al., (1997) that this 21kDa 
protein, found in the culture supernatant of Serratia marcescens 2170, cultivated in 
the presence of 0.5% colloidal chitin, did not have any chitinase activity but did 
adsorb chitin. Chitin-binding activity and the fact that only 5 proteins are produced 
by this strain in medium containing colloidal chitin suggested that CBP21 
participated in the chitin degradation system of this bacterium. The nucleotide 
sequence of CBP21 was later elucidated by Suzuki et al., (1998), who also 
demonstrated that the production of chitinases and CBP21 from S. marcscens 2170 
are regulated in parallel, but only in the sense that the substrates that induce 
production of chitinases also induce production of CBP21. In addition, they 
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examined the binding of CBP21 to various insoluble substrates. It was demonstrated 
that the highest binding activity of CBP21 was observed when β-chitin was used as a 
substrate, followed by regenerated chitin and colloidal chitin. Binding of CBP21 to 
cellulose was less significant and binding to chitosan was almost negligible (Suzuki 
et al., 1998). Although the function of chitin-binding proteins like CBP21 are 
relatively not well understood, Vajee-Kolstad et al., (2005a) have shown that the 
binding of CBP21 to chitin leads to the disruption of the crystalline substrate 
structure and to a dramatic increase in chitinase efficiency. This is thought to be 
achieved through a number of specific polar interactions which alter the substrate 
structure.  
 
The crystal structure of CBP21 was solved using rhenium single-wavelength 
anomalous dispersion in 2005. The structure consists of a three-stranded and a four-
stranded β-sheet that form a β-sandwich. There is a bud like 65-residue pseudo 
domain between β-strands one and two which consist of loops, one short α-helix, 
and two short 310 helices. The four cysteine residues appear as two disulfide bridges, 
one in the loop/helical region and one joining β-strands 4 and 5 (see Fig 1.21) 
(Vaaje-Kolstad et al., 2005b).  
 
Fig 1.21: Crystal structure of CBP21. The structure of CBP21 (PDB code: 
2EBM). The FnIII-like fold of CBP21 consists of two β-sheets, the first β-strands 1, 
2, and 5, and the second β-strands 3, 4, 6, and 7. The loop/helical domain consists of 
one α-helix and two 310 helices. Image generated using PyMol. 
1 
2 
5 
3 
4 
6 
7 
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Attempts to solve the crystal structure of CBP21 in complex with GlcNAc by Vaaje-
Kolstad et al., (2005b) have so far proved fruitless, in part perhaps because CBP21 
is not capable of binding to a single GlcNAc unit. A number of studies have 
demonstrated the importance of particular residues for chitin binding, although, none 
have definitively characterised the residues involved in chitin interaction. Zeltins 
and Schrempf generated a number of mutant chb1 genes and concluded that a Trp 
residue in position 57 was essential for binding of CHB1 to α-chitin, (Zeltins and 
Schrempf, 1997). Tryptophan, although present in a number of species in this 
position, is not ubiquitously conserved among all chitin binding proteins thus far 
characterised (see Fig 1.23). Vaaje-Kolstad et al., (2005b) have shown that a 
conserved aromatic residue in this position (Tyr-54) does not contribute to the chitin 
affinity of CBP21 but they have identified a number of other potentially important 
residues through site directed mutagenesis studies (see Table 1.4).  
 
 
Table 1.4: Binding of CBP21 mutants to β-chitin. (Vaaje-Kolstad et al., 2005b) 
 
CBP21 Kd (µM) βmax (µmol of CBP21/g) 
Wild type 1.4 ± 0.4 5.9 ± 0.4 
Y54A 11.0 ± 3.1 4.0 ± 0.6 
E55A 5.1 ± 1.4 2.1 ± 0.2 
E60A 8.2 ± 2.6 7.9 ± 1.4 
H114A 6.9 ± 1.7 3.0 ± 0.4 
D182A 7.4 ± 1.8 5.3 ± 0.6 
N185A 6.6 ± 2.0 7.3 ± 1.1 
 
 
In nature chitin is often found as a composite where layers/sheets of chitin are 
interwoven with proteins and/or minerals in a recalcitrant heteropolymer (Vaaje-
Kolstad et al., 2009). The crystalline chitin used in most experiments has been 
treated by strong acids and bases in order to remove the protein and/or mineral 
fraction. It is conceivable that the real natural substrates of the CBP proteins differ 
from chitin/cellulose and chitosan. There may exist composite natural chitinous 
substrates that are more susceptible to the action of CBPs. Through the mutagenesis 
of highly conserved residues it is possible that those necessary for binding can 
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finally be elucidated, and give direction to possible substitutions that may alter the 
proteins binding preference (see Fig 1.23). 
 
 
 
Fig 1.22: Location of surface patch residues of CBP21 thought to be involved in 
chitin binding. A surface representation of CBP21 illustrating the patch of 
conserved residues. (Vaaje-Kolstad et al., 2005b) 
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Figure 1.23: Multiple sequence alignment of the N-terminal region of family 33 bacterial CBPs. The blue arrow indicates the first 
residue after the signal sequence, the red arrows indicate conserved surface patch residues thought to be involved in chitin binding 
through hydrophobic interactions. CHB3; Streptomyces coelicolor, CHB1; Streptomyces olivaceoviridis, CHB2; Streptomyces reticuli, 
ChbB; Bacillus amyloquefaciens, LICBP33A; Lactococcus lactis, CBP21; Serratia marcescens, CbpL; Photorhabdus luminescens, 
CbpA; Photorhabdus asymbiotica, CbpD; Pseudomonas aeruginosa, E7; Thermobifidia fusca, E8; Thermobifidia fusca and Cbp1; 
Pseudoalteromonas piscicida. Alignment generated using ClustalW and Gendoc 2.6 (section 2.13). 
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1.16.3 CbpD from Pseudomonas aeruginosa 
 
Pseudomonas aeruginosa is a pathogenic gram-negative bacterium. It is a 
ubiquitous and opportunistic organism capable of inhabiting a large range of 
environments. It poses significant problems as a human pathogen, particularly in 
hospitals, where it accounts for more than 10% of hospital-acquired infections 
(Thompson et al., 2001). P. aeruginosa is able to secrete many proteins, including 
exoenzymes, S and T, exotoxin A, proteases and elastases into the extracellular 
medium. Most of these proteins contribute to the virulence of the bacteria, as they 
are associated with epithelial cell and tissue damage or dys-functioning of infected 
host cells (Folders et al., 2000).  
 
In 2000 Folders et al., identified a chitin-binding protein, with homology to Chb1 
and CBP21 of S. olivacerviridis and S. marcescens respectively, in the culture 
supernatant of P. aeruginosa. It was shown that like Chb1 the 43 kDa protein CbpD 
consists of two domains and that the CbpD is a chitin-binding protein (Folders et al., 
2000). As with all family 33 chitin-binding proteins the physiological function of 
CbpD remains unclear. It is known that CbpD is produced by a type II secretion 
system that is under control of the quorum-sensing system (Folders, et al., 2000), 
indicating that CbpD is only needed under high-density conditions, such as in 
biofilms and during pathogenesis. In this study Folders and co-workers carried out a 
search for homologues of CbpD in different Pseudomonas spp. , and discovered that 
while present in many clinical isolates it was not in the soil pseudomonads tested. 
They surmised that this suggested a role for CbpD in pathogenicity, speculatively 
that a glycosylated epithelial cell surface molecule might exist as a receptor for 
CbpD. While both domains of CbpD cluster with proven and putative N-
acetylglucosamine binding proteins (see Fig 1.24) it is still not known if both are 
capable of binding to chitin or whether both have diverse binding preferences. 
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Fig 1.24: Multiple sequence alignment of CbpD homologous proteins. Multiple sequence alignment of proteins that show homology with CbpD when 
residues 211-389 are submitted to a BLAST search. The blue arrow indicates the first residue after the signal sequence. YP_631148.1; Myxococcus 
Xanthus, ZP_01467014; Stigmatella aurantiaca, Ipp0257; Legionella pneumophila, CbpD from P. aeruginosa, NP_902262; Chromobacterium 
violaceum, YP_002030259; Stenotrophomonas maltophilia, ZP_01865556; Vibrio shilonii, ZP_0441177; Vibrio cholerae, YP_001140518; 
Aeromonassalmonicida  YP_43511776; Vibrio cholera. *Putative GlcNAc binding proteins, *Putative chitinase. Alignment generated using ClustalW 
and Gendoc 2.6 (section 2.13). 
* 
* 
* 
 
* 
* 
* 
* 
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* 
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1.16.4 Chitin-binding proteins of Photorhabdus 
 
Photorhabdus organisms are γ-proteobacteria that display the curious property of 
bioluminescence. Three species are currently recognized: P. asymbiotica, P. 
luminescens, and P. temperata (Fischer-Le Saux et al., 1999). The latter 2 species 
have been intensively studied by entomologists because they are virulent insect 
pathogens. They form a symbiotic relationship with nematodes (Heterorhabditis 
sp.) that invade the larvae of insects. The nematodes regurgitate the bacteria, 
which kill the insects and provide a food source for the nematodes. Insect-
pathogenic nematodes are thought to be harmless to vertebrates and are used in 
horticulture for biologic control of insects (Duchaud et al., 2003, Gerrard et al., 
2006). Gerrard et al., (2006) have shown that P. asymbiotica is also found in a 
symbiotic association with an insect-pathogenic soil nematode of the genus 
Heterorhabditis.  
 
Metabolites of the species Photorhabdus are known to lyse fungal mycelia that 
contain chitin in the cell wall, implying the existence of chitinases (Chen et al., 
1994). This observation led to an investigation of exoenzymatic activity of strains 
of Photorhabdus species by Chen et al., 1996. They demonstrated the chitinase 
activity of various Photorhabdus strains by the fact that the proteinaceous 
preparations of the culture broth hydrolyzed glycol chitin after gel 
electrophoresis (Chen et al., 1996). In 2003 Duchand et al., published the 
genome sequence of Photorhabdus luminescens and predicted a chitin-binding-
like protein Plu2352, (CbpL) and chitinase-like proteins Plu2235, Plu2458 and 
plu2461. As chitin and its oligomers appear to be predominant surface molecules 
in invertebrates they may be specifically recognized by microbial symbionts, 
much as hosts recognize microorganisms through patterned surface molecules 
such as the peptidoglycans (Chaston and Goodrich-Blair, 2010). While the 
genome of P. asymbiotica has been sequenced, no chitin-binding molecules have 
thus far been identified. 
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1.17 Uses of chitin active proteins 
 
As reviewed by Rinuado (2006) and Khoushab and Montarop (2010), chitin and 
its derivatives have a number of high value added applications in industrial and 
applied fields due in part to the biodegradability and biocompatibility of these 
compounds. 
The biggest emerging industry use for chitin-based products is in the medical 
field, where uses for chitin-derived products include drug and vaccine delivery 
systems, wound and burn treatments (Dai et al., 2009), blood cholesterol 
lowering agents (Maezaki et al.,  1993), anti-clotting agents, and enhanced 
dissolution of certain drugs such as ibuprofen (Okawa et al., 2003). The key 
property of chitin-derived products for application in biomedical fields is the 
immuno-modulating effect. Chitin and its polymers have the ability to enhance 
macrophage production, activate complement, and have been shown to be 
effective agents for hemostasis of blood coagulation, thus promoting wound 
healing (Muzzarelli, 2009, Muzzarelli, 2010, Muzzarelli, 1997, Khoushab and 
Yamabhai, 2010). Chitin derivates furthermore have antibacterial activity, 
thought due in part to the positive charge of C2 amino group in glucosamine, a 
monomer of chitosan. This positive charge interacts with negatively charged 
microbial cell membrane and lead to leakage of the intracellular constituents of 
the microorganisms (Dutta et al., 2009). This property has promoted the use of 
chitosan based films in the medical field, as wound dressings (Dai et al., 2009) 
and in the food preservation industry where it can delay the growth of 
microorganisms (Dutta et al., 2009). 
 
Due to their rigid nature chitin and chitosan are widely used to immobilise 
enzymes and whole cells, allowing for improvements in heterogeneity of the 
immobilised enzymes. This facilitates easier recovery of both enzyme and 
product, in addition to increasing enzyme robustness and reusability of supports. 
This technology has applications in the food industry, such as organic 
contaminant removal from wastewaters to sophisticated biosensor design (for 
review see Krajewska, 2004). Rigid chitinous structures in addition, have 
applications as scaffolds for bone and other natural tissue regeneration, as well as 
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structures by which three-dimensional formation of tissues are supported 
(Tsioptsias et al.,  2009). 
 
Chitin and chitosan are often used in applications such as bioremediation of 
heavy metal contamination due to their ability to form specific complexes with a 
number of ions or dyes and with small organic molecules (Mazeau et al., 1994). 
Both have also been exploited in the field of paper and textile production, as 
additives in animal feed and as components of cosmetics. Chitin and chitosan 
derivatives have wide applications in the field of cosmetics due to their high 
water-holding capacity and positive anti-microbial characteristics (Jayakumar et 
al., 2010). The patents for the use of chitin and chitosan derivatives in skin care 
cosmetics cover strong moisturizing activity, photo-protection from UV and 
sunlight, anti-aging, skin elasticity-increasing activity, antibacterial and anti-
inflammatory effects. 
 
Since chitin metabolism is crucial for fungal and arthropod development, 
inhibition or de-regulation of the key enzymes are important objectives for the 
development of fungicides and insecticides, including anti-malaria agents, not 
least because chitin polymers are absent in vertebrates. Chitinases have been 
shown to act as biocontrol and anti-fungal agents in addition to having anti-
biofouling applications (Bormann et al., 1999, Chang et al., 2010, Dehestani et 
al., 2010). Recombinant bacterial chitinases can also be used to produce 
transgenic plants with enhanced resistance against pathogenic fungi (Dehestani et 
al., 2010, Chang et al., 2010 and Andersen et al., 2005). Chitin-binding modules 
have furthermore been incorporated into protein expression vectors to facilitate 
the purification of recombinant proteins (Chong et al., 1997). Chitin has been 
used to prepare affinity chromatography columns to isolate lectins with GlcNAc 
affinities and to determine their structure (Vaaje-Kolstad et al., 2005b, Vaaje-
Kolstad et al., 2005a) . 
 
Extraction of chitin from crustacean shells is routinely carried out using a 
chemical demineralisation and deproteinisation process (Goycoolea et al., 2000). 
The build up of waste chemicals from this process creates an expensive disposal 
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problem, not least caused by enforced environmental controls and disposal 
measures. An alternative and inexpensive, environmentally-friendly process for 
the demineralisation of crab shell has been proposed using the chitin degrading 
organisms Pseudomonas aeruginosa F722 by Oh et al. (2007). It has also been 
proposed that the enzymatic conversion of structural polysaccharides, namely 
cellulose to biofuel could be improved by exploiting chitin-binding-like proteins 
to improve substrate accessibility, thus reducing the need for processive enzymes 
(Eijsink, et al., 2008) . 
 
 
 
 
1.18 Project aims and objectives 
 
The aim of this project was to identify, clone, express, purify and characterise 
prokaryotic carbohydrate-binding proteins for potential use in GlcNAc detection 
in important therapeutic glycoproteins. Chitin-binding proteins from four 
different organisms; S. marcescens, P. aeruginosa, P. luminescens and P. 
asymbiotica were selected for this study. Recombinant proteins would be 
produced in Escherichia coli based expression systems, with particular focus on 
the selection of an appropriate vector system for each, capable of producing 
soluble, active protein. Following successful expression of these molecules, 
protocols would be developed to yield relatively large quantities of highly 
purified protein, for sugar/oligosaccharide binding characterisation studies. 
CBP21 would be mutated within the proposed sugar-binding site to confirm if the 
sugar specificity of these proteins could be manipulated and ultimately altered. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
2.0 Materials and Methods 
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2.1 Bacterial strains, primers and plasmids 
 
Table 2.1:  Bacterial Strains 
Strain Genotype Features/Uses Source 
Escherichia Coli    
XL10 Gold ∆(mcrA)183 ∆(mcrCB- 
hsdSMR-mrr)173 endA1 
recA1 relA1 gyrA96 supE44 
thi-1 lac [F∆ proAB 
lacIqZ∆M15 ::Tn10(tetR) 
Amy (CmR)]  
 
All purpose cloning 
strain. Produces stable 
plasmid DNA. 
Stratagene 
JM109 F∆traD36, proAB+ lacIq, 
∆lacZ M15 endA1 recA1 
hsdR17(rk-, mk+) mcrA 
supE44 - gyrA96 relA1 ∆ 
(lacproAB)  
thi-1  
 
All purpose cloning 
strain. Produces stable 
plasmid DNA. 
Sigma 
KRX [F´, traD36, ΔompP, 
proA+B+, lacIq, 
Δ(lacZ)M15] ΔompT, 
endA1, recA1, gyrA96 
(Nalr), thi-1, hsdR17 (rk–, 
mk+), relA1, supE44, Δ(lac-
proAB), Δ(rhaBAD)::T7 
RNA polymerase  
 
Expression strain Promega 
BL21 (DE3) F∆ dcm ompT hsdSB(rB-
,mB-) gal  
 
Expression strain Novagen 
Serratia marcescens    
Klon Wild Type  NCIMB no 2302  
Pseudomonas aeruginosa    
PAO1 Wild type Dr Keith Poole  
Photorhabdus luminescens   
TT01 Wild type Rif
R
 Dr David Clarke  
Photorhabdus asymbiotica   
ATCC43949 Wild type Dr David Clarke 
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Table 2.2: Plasmids 
Plasmid Description Source 
Vectors   
pQE30 Amp
R
 Expression vector for N-terminally-tagged (His)6 
proteins, T5 promoter/lac operon 
Qiagen 
pQE60 Amp
R
 Expression vector for C-terminally tagged (His)6 
proteins, T5 promoter/lac operon 
Qiagen 
pQE_DsbA pQE60 (Qiagen) derived plasmid with DsbA signal 
sequence for periplasmic expression of C-terminally 
(His)6 tagged proteins. Amp
R
, T5 promoter/lac operon 
Ryan, 2006  
(Ph.D Thesis) 
pQE_PelB pQE60 (Qiagen) derived plasmid with pelB signal 
sequence for periplasmic expression of C-terminally 
(His)6 tagged proteins. Amp
R
, T5 promoter/lac operon 
Ryan, 2006  
(Ph.D Thesis) 
Constructs   
pCBP21_30 pQE30 containing cbp21 ORF This Work 
pCBP21_60 pQE60 containing cbp21 ORF This Work 
pCBP2130_N pQE30 containing cbp21 ORF without N-terminal leader 
sequence 
This Work 
pCBP2160_N pQE60 containing cbp21 ORF without N-terminal leader 
sequence 
This Work 
pCBP21wt pQE60 containing cbp21 with a stop codon encoded 
before the (His)6 tag 
This Work 
pCBP21Y54A pQE60 containing cbp21 with Y54A mutation This Work 
pCBP21E55A pQE60 containing cbp21 with E55A mutation This Work 
pCBP21P56A pQE60 containing cbp21 with P56A mutation This Work 
pCBP21Q57A pQE60 containing cbp21 with Q57A mutation This Work 
pCBP21S58A pQE60 containing cbp21 with S58A mutation This Work 
pCBP21E60A pQE60 containing cbp21 with E60 mutation This Work 
pCBP21T111A pQE60 containing cbp21 with T111A mutation This Work 
pCBP21H114A pQE60 containing cbp21 with H114A mutation This Work 
pCBP21D182A pQE60 containing cbp21 with D182A mutation This Work 
   
pCbpD_60 pQE60 vector containing cbpD ORF This Work 
pCbpD_UN pQE60 containing cbpD with a stop codon encoded 
before the (His)6 tag 
This Work 
pPelBCbpD pQE60 containing cbpD ORF with PelB periplasmic 
leader sequence 
This Work 
 
pDsbACbpD pQE60 containing cbpD ORF with DsbA periplasmic 
leader sequence 
This Work 
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Table 2.2 continued…….. 
Plasmid Description Source 
pCbpda pQE60 containing cbpD ORF residues 1-212  This Work 
pCbpDc pQE60 containing cbpD ORF residues 117-389  This Work 
pCbpDb pQE60 containing cbpD ORF residues 212-389 This Work 
pCbpL_60 pQE60 vector containing  ORF P.luminescens This Work 
pCbpA_60 pQE60 vector containing  ORF P.asymbiotica This Work 
 
 
Table 2.3: Primer sequences (Synthesised by Sigma-Aldrich, U.K.) 
 
Name Primer Sequence (5’-3’)      TM (°C) 
Pseudo-R2 GTCAGTAGATCTCAGCAGGGTCCAGGCGTCC 72.6 
Pseudo-R4 P-TTACAGCAGGGTCCAGGCGTCCTG 69.8 
Pseudo-R5 GTCAGTAGATCTGGCGCCGCTGAAGCTCACGTC  72.1 
Pseudo-R6 P-CAGCAGGGTCCAGGCGTCCTGCCA 75.1 
pQE60_F1    P-TAAAGATCTCATCACCATCACCATCACTAAGCTTAATTA 61.5 
Pseudo-F3 GTCAGTCCATGGGAAAACACTACTCAGCCACCC 78.7 
Pseudo-F4 P-CACGGCTCGATGGAAACGCC 65.5 
Pseudo-F7     GTCAGTGCGGCCGCCCACGGCTCGATG 76.8 
Pseudo-F8 CAGTCCATGGGAGCCGTCGCCAACCCCTGG 78.9 
Pseudo-F9  CAGTCCATGGGAAGCGGCAACTTCCAGTTCGTCTAC 72.2 
   
Lumin-F3 GTCAGTCCATGGGATATAAACATAAAGTGAAAGTG 75.5 
Lumin-F4 GTCAGTCCATGGGACATGGTTATATTGATAGCCCA 61.2 
Lumin-R2 GTCAGTAGATCTAGCAGGGCTAATTGTTGTGTC 63.8 
   
Asymb-F3 GTCAGTCCATGGGATACAAACATAAAGTGAGA 62.6 
Asymb-F4 P-CATGGTTATATTGATAGTCCAGGAAG 74.3 
Asymb-R2 GTCAGTAGATCTGGCTGGGTTAATGGTTGT 64.8 
   
Marces-F1 GTCAGTGGATCCATGAACAAAACTTCCCGTACC 67.5 
Marces-R1 GTCAGTAAGCTTTTATTTGCTCAGGTTGACGTCGATCGCCTG 69.1 
Marces-F3 GTCAGTCCATGGGAAACAAAACTTCCCGTACC 76.8 
Marces-R2 GTCAGTAGATCTTTTGCTCAGGTTGACGTC 81.7 
Marces-F4 P-CACGGTTATGTCGAATCGCCGG 76.8 
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Table 2.3 contd.... 
Marces-R3 P-TCCCATGGTTAATTTCTCCTCT 70.9 
30-R1 P-CATGGATCCGTGATGGTGATGGTG 64.5 
Marces-F5 GTCAGTGCGGCCGCCCACGGTTATGTCGAAT 69.7 
Marces-R4 P-TTTGCTCAGGTTGACGTCGATCGCCTG 67.9 
55-60A_R P-GCTGCCGCACTGCGTGTTGAGTTGCAG 70.2 
Y54A_F P-GTGCAGGCGGGACCGCAGAGCGTCGAA  75.5 
E55A_F P-GTGCAGTACGCACCGCAGAGCGTCGAA 70.4 
P56A_F P-GTGCAGTACGAAGCGCAGAGCGTCGAA 68.3 
Q57A_F P-GTGCAGTACGAACCGGCGAGCGTCGAA 70.7 
S58A_F P-GTGCAGTACGAACCGCAGGCGGTCGAA 71.2 
E60A_F P-GTGCAGTACGAACCGCAGAGCGTCGCAGGCCTG 75.3 
E55_R_F P-GTGCAGTACNNNCCGCAGAGCGTCGAA 66.3-73.8 
T111A_F P-TTTACCTGGAAGCTGGCCGCCCGTCAC 72.6 
T111A_R P-GGAGTTCGGGCCGGTTTTCAGGTTGAGCTT 71.6 
H114A F  
 
P-TTTACCTGGAAGCTGACCGCCCGTGCCAGCACAACCAGCT 
GGCGC 
80.5 
H114_R_F P-TTTACCTGGAAGCTGACCGCCCGTNNNAGCACAACC 71.1-76.7 
T111A_R P-GGAGTTCGGGCCGGTTTTCAGGTTGAGCTT 71.6 
D182A_F  P-GTGTGGGACATAGCCGCCACCGCCAACGCCTTCTAT 75.6 
D182A_R  P-GGCAAGGATCACGTGCGAACCGCTGCGATC 72.6 
Sequencing Primers  
QE-F CCCGAAAAGTGCCACCTG 61.6 
QE-R GTTCTGAGGTCATTACTGG 53.5 
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Figure 2.1: The pQE30 vector (Qiagen). The 3461bp pQE30 expression vector 
contains the following features; the MSC is located before the (His)6 amino acid 
sequence (blue) which allows for the expression of C-terminally (His)6 tagged 
proteins. This is under control of the T5 promotor/lac operon (yellow). The bla 
gene encodes beta-lactamase which confers ampicillin resistance to the bacteria 
(red). This image was generated using pDRAW32. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: The pQE60 vector. The 3431bp pQE60 vector from Qiagen 
contains the following features. The MSC is located before the (His)6 amino acid 
sequence (blue) which allows for the expression of C-terminally (His)6 tagged 
proteins. This is under control of the T5 promotor/lac operon (yellow). The bla 
gene encodes beta-lactamase which confers ampicillin resistance to the bacteria 
(red). This image was generated using pDRAW32. 
T5 promotor/lac operon 
(His)6 
 
amp
R
 
Could you use the same 
program that Amy used to 
construct the vector map on 
her ISSC poster? It looked a bit 
nicer than pDRAW 
T5 promotor/lac operon 
(His)6 
 
amp
R
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Figure 2.3: pQE_PelB vector. pQE60-PelB derived vector contains the 
following features. The MSC is located downstream from the PelB leader 
sequence (orange). The (His)6 amino acid sequence (blue) allows for the 
expression of C-terminally (His)6 tagged proteins. This is under control of the T5 
promotor/lac operon (yellow). The bla gene encodes beta-lactamase which 
confers ampicillin resistance to the bacteria (red). This image was produced using 
pDRAW32. 
  
 
 
 
 
 
 
 
 
 
Figure 2.4: The pQE_DsbA vector. pQE60-DsbA derived vector contains the 
following features. The MSC is located downstream from the DsbA leader 
sequence (orange). The (His)6 amino acid sequence (blue) allows for the 
expression of C-terminally (His)6 tagged proteins. This is under control of the T5 
promotor/lac operon (yellow). The bla gene encodes beta-lactamase which 
confers ampicillin resistance to the bacteria (red). This image was generated 
using pDRAW32. 
(His)6 
 
T5 promotor/lac operon 
amp
R
 
DsbA 
T5 promotor/lac operon 
(His)6 
amp
R
 
PelB 
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2.2 Microbiological Media 
 
Microbiological media was obtained from LAB M. Sterilisation was achieved by 
autoclaving at 121°C for 20min, unless otherwise stated. 
 
Luria Bertani Broth (LB)  
Tryptone   10 g/L  
NaCl   10 g/L 
 Yeast Extract     10 g/L 
 pH               7.0  
  
NaOH was used to adjust to pH 7.0 and the volume brought to 1 L using dH2O. 
The solution was then sterilized by autoclaving. For the production of solid agar 
plates agar (15 g/L) was added prior to sterilization. 
 
Super Optimal Broth (SOB) 
 Tryptone  20 g/L 
 NaCl   500 mg/L 
 Yeast Extract  5 g/L 
 KCl   2.5 mM 
 pH    7.0 
  
The solution was autoclaved and allowed to cool to 55ºC before MgCl2 and 
MgSO4 were added to a final concentration of 10 mM from sterile 1 M stock 
solutions. 
 
 
2.3 Solutions and Buffers 
 
All chemicals and solutions were obtained from Sigma Aldrich unless otherwise 
stated. All chemicals were ACS grade. 
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TB Buffer 
PIPES 10 mM 
    CaCl2 15 mM 
KCl  250 mM 
pH  6.7  
 
Following pH adjusted with KOH MnCl2 was added to a final concentration of 
50 mM. The solution was filter sterilised through a 0.22µm filter membrane and 
stored at 4ºC. 
 
RF1 
 RbCl   100 mM 
 CaCl2   10 mM 
 Potassium Acetate 30 mM 
 Glycerol  15% (v/v) 
 pH   5.8 
 
When the pH had been adjusted with HCl MnCl2 was added to a final 
concentration of 50 mM. The solution was filter sterilised through a 0.22 µm 
filter membrane and stored at 4ºC. 
 
RF2 
 RbCl   10 mM 
 CaCl2   75 mM 
 MOPS   10 mM 
 Glycerol  15% (v/v) 
 pH   6.8 
  
The solution was filter sterilised through a 0.22µm filter membrane and stored at 
4ºC. 
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Solution 1 of the 1-2-3 method 
 Glucose  0.5 M 
 Na2-EDTA  0.1 M 
 Tris-HCl  1 M 
 
Solution 2 of the 1-2-3 method 
 NaOH    1 M 
 SDS   1% 
 
Solution 3 of the 1-2-3 method 
 KOAc   3 M 
 pH   4.8 
 
To 60mL of 5M potassium acetate, 11.5mL of glacial acetic acid and 28.5mL of 
dH
2
O was added. The resulting solution was 3M with respect to potassium and 
5M with respect to acetate. 
 
TE Buffer 
 Tris   10 mM 
 Na2-EDTA  1 mM 
 pH   8.0 
 
TAE Buffer (50X) 
 Tris   242 g/L 
 Glacial Acetic Acid 57.1 mL/L 
 EDTA   100 mL/L (of 0.5M stock) 
 pH    8.0 
 
Western Blot Transfer Buffer 
 Tris   25 mM 
 Glycine  150 mM 
 Methanol  10% (v/v) 
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TBS Buffer 
 Tris   20 mM 
 NaCl   150 mM 
 CaCl2   1 mM 
 MgCl2   1 mM 
 pH   7.6 
 
When the pH had been adjusted with HCl MnCl2 was added to a final 
concentration of 1mM. For TBST, the detergent Triton X-100 was added to a 
final concentration of 0.1% (v/v) 
 
PBS (10x) 
 Na2HPO4  10.9 g/L 
 NaH2PO4  3.2 g/L 
 NaCl   90 g/L 
 
A 1X has a pH of 7.2.  For PBST, the detergent Triton X-100 was added to a 
final concentration of 0.1% (v/v) 
 
Agarose Gel loading Dye  
 Bromophenol Blue 0.25% (w/v) 
 Xylene Cyanol 0.25% (w/v) 
 Ficoll (Type 400) 15% (w/v) 
 
Bromophenol Blue and/or Xylene Cyanol were used as appropriate. On a 1% 
agarose gel bromophenol blue and Xylene Cyanol migrate approximately with 
the 300bp and 4,000bp fragments respectively. 
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Ethidium Bromide Stain 
 
A 10mg/mL stock solution in dH2O was stored at 4ºC in the dark. For the 
staining of agarose gels, 100 µL of stock solution was mixed into 1 L of dH2O. 
The staining solution was kept in a plastic tray and covered to protect against 
light. Used ethidium bromide was collected and the ethidium bromide was 
extracted by mixing with de-staining bag (GeneChoice) overnight. The clear 
liquid was disposed of routinely, and the ethidium was incinerated. 
 
SDS-PAGE Buffer (5X) 
 Tris   15 g/L 
 Glycine  72 g/L 
 SDS   5 g/L 
 pH   8.3 
 
SDS-PAGE Sample Buffer (10X) 8mL 
 SDS   3.2 mL 10% Stock 
 2-Mercaptoethanol 0.8 mL 
 Tris   2.0 mL mM Stock, pH 6.8 
 Glycerol  1.6 mL 
 Bromophenol Blue 0.5% (w/v) 
 H2O   0.4 mL 
 
Coomassie blue stain solution 
 dH2O   50% (v/v)  
 Methanol  40% (v/v)  
 Acetic Acid  10% (v/v) 
 Coomassie Blue 0.25% (w/v) 
 
Coomassie blue de-stain solution 
 dH2O   50% (v/v) 
 Methanol  40% (v/v)  
 Acetic Acid  10% (v/v) 
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SDS solution 
 SDS   10% (w/v) 
 
Denaturing Solution 
 NaOH   0.5 M 
 NaCl   1.5 M 
 
Neutralisation solution 
 NaCl   1.5 M 
 Tris   0.5 M 
 pH   7.4 
 
20x Saline Sodium Citrate (SSC) 
 NaCl   3 M 
 Sodium Citrate 300 mM 
 
Lysis Buffer 
 NaH2PO4  20 mM  
 NaCl   0.5 M 
 Imidazole  20 mM 
 pH   7.4 
 
Resuspension Buffer 
 Tris   20 mM 
 pH   8.0 
 
Isolation Buffer 
 Urea   2 mM 
 Tris   20 mM 
 NaCl   0.5 M 
 TritonX-100  2% (v/v) 
 pH   8.0 
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Binding Buffer 
 Guanidine Hydrochloride 6 M 
 Tris    20 mM 
 NaCl    0.5 M 
 Imidazole   10 mM 
 2-mercaptoethanol  1 mM 
 pH    8.0 
 
Wash Buffer 
 Urea   6 M 
 Tris   20 mM 
 NaCl   0.5 M 
 Imidazole  20 mM 
 2-mercaptoethanol 1 mM 
 
Refolding Buffer 
 Tris   20 mM 
 NaCl   0.5 M 
 Imidazole   20 mM 
 2-mercaptoethanol 1 mM 
 
Elution Buffer 
 Tris   20 mM 
 NaCl   0.5 M 
 Imidazole  0.5 M 
 2-mercaptoethanol 1 mM 
 
Column Stripping Buffer 
 NaH2PO4  20 mM 
 NaCl   0.5 M 
 EDTA   50 mM 
 pH   7.4 
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TMB Solution (10mL) 
 Citric Acid  1.37 mL 0.1M Stock 
 Sodium Citrate 3.63 mL 0.1M Stock 
 dH2O   5 mL 
  
2 mg of TBM powder was dissolved in 200 µL DMSO and added to 9.8 mL 
TMB solution. 2 µL of H2O2 was added directly before use. 
 
DNS reagent 
 
 Solution A 
 Sodium potassium tartrate 300 g 
 
The sodium potassium tartrate was dissolve in 500 mL dH2O and heated to 40ºC. 
 
 Solution B 
 NaOH  16 g 
 DNS  10 g 
 
The NaOH was dissolved in 200 mL dH2O and heated to 90ºC before adding 10 
g DNS. 
 
Solution A and B were mixed together and allowed to cool. Phenol was added to 
a final concentration of 0.2% The solution was made up to 1 L with dH2O. The 
solution was stored in the dark at room temperature. 
  
 
2.4 Antibiotics 
Ampicillin was prepared in dH2O at a concentration of 100 mg/mL and stored at 
-20ºC. The working concentration in E.coli cultures was 100 µg/mL. 
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2.5 Storing and culturing of bacteria 
 
Bacterial strains were stored as 33% glycerol stocks. 1000 µL of an overnight 
culture was mixed with 500 µL sterile 80% glycerol in a microfuge tube. If the 
bacterial strains contained plasmids, the selective antibiotic was included in the 
culture. Duplicate stocks were stored at –20°C and –80°C. Working stocks 
streaked on LB agar plates, containing antibiotics where appropriate, were stored 
at 4ºC. 
 
2.6 Isolation and purification of DNA 
 
2.6.1 Isolation of Genomic DNA 
 
Genomic DNA was isolated using the Promega Wizard genomic DNA 
purification kit. This kit was used according to the manufacturer‟s instructions: 
1mL of a bacterial culture in a microfuge tube was centrifuged at 13,000 rpm for 
2 min (using a LabNet Spectrafuge, fixed rotar). The supernatant was discarded 
and the cells were re-suspended in 600 µL of nuclei lysis solution. Samples were 
incubated at 80°C for 5 min to lyse the cells. Cell lysate was cooled to room 
temperature. Next, 3 µL of RNase solution was added to the cell lysate and 
mixed by inversion. Samples were incubated at 37°C for 15-60 min and then 
cooled to room temperature. Subsequently 200 µL of protein precipitation 
solution was added to the RNase treated cell lysate. Samples were vortexed 
vigorously for 20 s to mix the protein precipitation solution with the cell lysate. 
Samples were incubated on ice for 5 min, followed by centrifugation at 13,000 
rpm for 3 min. The supernatant was removed and transferred to a fresh tube. 500 
µL of phenol chloroform isoamylalcohol (25:24:1) was added and the sample 
was centrifuged at 13,000 rpm for 5 min. Supernatant was removed a second time 
and again transferred to a fresh microfuge tube containing 500 µL of phenol 
chloroform isoamylalcohol (25:24:1) and centrifuged at 13,000 rpm for 5 min. 
The supernatant was transferred to a fresh microfuge tube containing 600 µL of 
room temperature isopropanol, and mixed by inversion. The sample was 
centrifuged at 13,000 rpm for 2 min to pellet the genomic DNA. The supernatant 
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was removed and the pellet was washed by the addition of 600 µL of 70% 
ethanol, and spun at 13,000 rpm for 2 min. The ethanol was removed carefully so 
as not to disturb the pellet and the pellet was allowed to air dry for 10-15 min. 
Finally, 100 µL of DNA rehydration solution was added to the tube. Samples 
were left to rehydrate overnight at 4°C. Genomic DNA was stored at -20°C. 
 
2.6.2 Isolation of Plasmid DNA 
 
Two procedures for the isolation of plasmid DNA were variably employed. The 
1-2-3 method was used for convenient plasmid isolation from large numbers of 
samples, mostly for the purposes of screening. The Sigma Plasmid Mini Prep Kit 
was used to prepare consistently pure and supercoiled DNA mostly for the 
purpose of DNA sequencing.  
  
2.6.2.1 1-2-3 Method 
 
Bacterial growth was taken off an agar culture plate with a sterile loop and re-
suspended in 200 µL of Solution 1. Alternatively, 1.5 mL of a bacterial culture in 
a microfuge tube was centrifuged at 13,000 rpm for 2 min to collect the cells. The 
supernatant was discarded and the cell pellet re-suspended in 200 µL of Solution 
1 (Section 2.3). The re-suspension was left for 5 min at room temperature. 
Subsequently 200 µL of Solution 2 (Section 2.3) was added and the tube was 
mixed by inversion and left for 5 min at room temperature. Finally 200 µL of 
Solution 3 (Section 2.3) was added, the tube was mixed by inversion and left at 
room temperature for 10 min. Cell debris was collected by centrifugation at 
13,000 rpm for 10 min. The supernatant was transferred to a fresh microfuge tube 
with 500 µL of phenol chloroform isoamylalcohol (25:24:1) and mixed by brief 
vortexing. Upon centrifugation at 13,000 rpm for 5 min the mixture is divided 
into an upper aqueous and lower organic layer. The aqueous (top) layer was 
removed to a new microfuge tube with an equal volume of isopropanol and 
mixed by inversion. The tube was then centrifuged at 13,000 rpm for 5 min to 
pellet the plasmid DNA. The pellet was washed with 70% ethanol and then dried 
briefly in a SpeedVac (Savant) vacuum centrifuge. The plasmid DNA was 
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resuspended in 30 µL of TE buffer (Section 2.3) and 1 µL of Ribonuclease A was 
added to digest co-purified RNA. Plasmid DNA was stored at –20ºC. 
 
2.6.2.2 Sigma GenElute Plasmid Mini Prep Kit 
 
This kit was used according to the manufacturer‟s instructions: 1.5 mL of 
bacterial culture in a microfuge tube was centrifuged at 13,000 rpm for 2 min to 
pellet the bacterial cells. The supernatant was discarded and the pellet was re-
suspended in 200 µL of re-suspension solution. To lyse the cells 200 µL of lysis 
solution was added and mixed by inversion, the mixture was incubated for 5min 
at room temperature. Following lysis 350 µL of neutralisation solution was added 
and mixed by inversion to precipitate the cell debris, lipids, proteins and 
chromosomal DNA. The mixture was incubated for 10 min at room temperature. 
The precipitate was collected by centrifugation at 13,000 rpm for 10 min. The 
supernatant was transferred to spin column in a microfuge tube and centrifuged 
for 30 s to bind the plasmid DNA. The flowthrough was discarded and 750 µL of 
wash solution was added and centrifuged at 13,000 rpm for 30 s, this step was 
repeated. The supernatant was discarded and the column was spun at 13,000 rpm 
for 2 min to dry the matrix. The spin column was transferred to a fresh microfuge 
tube, up to 100 µL of DNA elution/TE buffer was added. The DNA was eluted 
by centrifugation at 13,000 rpm for 30 s. 
 
2.7 Agarose gel electrophoresis 
 
DNA was analysed by electrophoresing through agarose gels in a BioRad 
horizontal gel apparatus. Agarose was prepared by adding the required amount 
(concentration typically 0.7-2%) to TAE buffer and was dissolved by boiling. 
Agrose was stored at 60°C. The agarose solution was poured into plastic trays 
and allowed to set with a plastic comb fitted to create sample wells. TAE buffer 
was used as the running buffer. Agarose gel loading dye (Section 2.3) was mixed 
with the DNA samples to facilitate loading and to give indication of migration 
distance during electrophoresis. Gels were run at 140 volts for 20-40 min 
depending on size of gel. Gels were stained for 20 min by immersion in an 
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ethidium bromide staining solution. Gels were visualised using a UV 
transilluminator coupled with an image analyser to capture the image to a PC. On 
every gel 0.5 μg of 1 Kb Plus DNA Ladder (Invitrogen) was run as a molecular 
size marker. 
     
Fig 2.5: 1kb Molecular Marker (Invitrogen). A representative image of the 1 
kb DNA molecular marker used in this study. 
 
2.8 Isolation of DNA from agrose gels 
 
The Hi Yield
TM
 Gel/PCR DNA extraction kit from RBC Bioscience was used to 
isolate DNA from agrose gels. The kit was used according to the manufacturer‟s 
instructions: The DNA band to be isolated from the agrose gel was excised using 
a scalpel. Up to 300 mg of gel slice was transferred to a microfuge tube. 500 µL 
of Detergent free (DF) buffer was added to the sample and mixed by vortexing. 
The sample was incubated at 55°C for 10-15 min until the gel slice was 
completely dissolved. During incubation the tube was inverted every 2-3 min. A 
DF column was placed in a collection tube. Up to 800 µL of the dissolved gel 
sample was transferred to the DF column. The DF column was centrifuged at 
13,000 rpm for 30 s. The flowthrough was discarded and 750 µL of wash 
solution was added to the DF column which was then centrifuged at 13,000 rpm 
for 30 s. The flowthrough was again discarded and the column was dried by 
centrifugation at 13,000 rpm for 2 min. 30 µL of DNA elution buffer was added 
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to the centre of DF column matrix. The column was left to stand for 2 min at 
room temperature and subsequently centrifuged at 13,000 rpm for 30 s to elute 
the isolated DNA. Isolated DNA was stored at -20°C.  
 
 
2.9 Preparation of high efficiency competent cells 
 
Two methods were used to prepare competent cells, the TB method and the RF 
method. The RF method was preferred as it is the easier of the two methods and 
was found to give the best efficiencies.  
 
2.9.1 The RF method  
 
5 mL of LB broth containing the relevant antibiotics was inoculated with a single 
colony of the desired bacterial strain from a plate stock and cultured overnight at 
37°C. A 1 L flask with 200 mL of SOB broth was inoculated with 2 mL of the 
overnight culture and incubated at 37ºC shaking at 180-220 rpm. When the 
culture had reached an OD
600 
of ~0.5 (early-mid exponential phase) the flask was 
cooled in ice water. All subsequent transactions took place at 4ºC. The culture 
was transferred to a sterile centrifuge bottle. The cells were collected by 
centrifugation at 3,000 rpm for 5 min (using a Beckman JA-14 rotor). The 
supernatant was decanted and the cells gently re-suspended in 60 mL of chilled 
RF1 buffer (Section 2.3). The suspension was left on ice for 90 min. The cells 
were again collected by centrifugation at 3,000 rpm for 5 min. The supernatant 
was decanted and the cells gently re-suspended in 8 mL of chilled RF2 buffer 
(Section 2.3). Aliquots of 400 µL were prepared in sterile 1.5 mL microfuge tubes 
and flash frozen using –80°C ethanol. The competent cells were stored at –80°C. 
 
 
2.9.2 The TB Method 
 
5 mL of LB broth containing the relevant antibiotics was inoculated with a single 
colony of the desired bacterial strain from a plate stock and cultured overnight at 
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37ºC. A 1 L flask with 200 mL of SOB broth was inoculated with 2 mL of the 
overnight culture and incubated at 37ºC shaking at 180-220 rpm. When the 
culture had reached an OD
600 
of ~0.4 (early-mid exponential phase) the flask was 
cooled in ice water. All subsequent transactions took place at 4°C. The culture 
was transferred to a sterile centrifuge bottle. The cells were collected by 
centrifugation at 4,500 rpm for 5 min.The supernatant was decanted and the cells 
gently re-suspended in 80 mL of chilled TB buffer (Section 2.3). The suspension 
was left on ice for 10 min. The cells were again collected by centrifugation at 
5,500 rpm for 5 min. The supernatant was decanted and the cells gently re-
suspended in 15 mL of chilled TB buffer. 7% (v/v) DMSO was slowly added to 
the suspension.  The suspension was incubated on ice for 10 min. Aliquots of 800 
µL were prepared in sterile 1.5 mL microfuge tubes and flash frozen using –80°C 
ethanol. The competent cells were stored at –80°C. 
 
2.9.3 Transformation of competent cells 
 
An aliquot of competent cells was thawed on ice, with 200 µL of the cell 
suspension gently mixed with 2 µL of plasmid DNA in a sterile 1.5 mL 
microfuge tube. The mixture was incubated on ice for 30 min to allow the DNA 
to bind to the cells. The cells were heat-shocked at 42°C for 45 s and placed back 
on ice for 2 min. Subsequently 800 µL of LB broth was added to the cells and 
they were incubated for 1 hour at 37°C. 200µL of the suspension was plated on 
LB agar containing appropriate antibiotics and incubated at 37°C overnight. 
 
2.9.4 Determination of cell efficiency 
 
Competent cell efficiency is defined in terms of the number of colony forming 
units obtained per μg of transformed plasmid DNA. A 10 ng/µL stock of pUC18 
plasmid DNA was diluted to 1 ng/µL, 100 pg/µL and 10 pg/µL. 1 µL of each 
dilution was transformed as described above. The cell efficiency was calculated 
from the number of colonies obtained, taking into account the dilution factor and 
the fraction of culture transferred to the spread plate. 
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2.10 Enzymatic reactions 
 
All enzymes and relevant buffers were obtained from Invitrogen Life 
Technologies®, New England Biolabs® or Sigma Corporation and were used 
according to the manufacturer‟s instructions. 
 
2.10.1 Polymerase chain reaction 
 
PCR reactions (Mullis and Faloona 1987) were carried out using a Veriti 
Thermocycler (Applied Biosystems).  
 
2.10.1.1 Standard PCR reaction mixture 
 Template DNA 1 µL 
 dNTP‟s  1 µL 
 Primers (10 μM) 1 µL of each 
 Buffer (10X)  5 µL 
 dH2O   40 µL 
 Taq polymerase 1 µL 
 
2.10.1.2 Standard PCR programme cycle for Phusion Taq polymerase     
              reactions 
 
Stage 1:  Step 1: 95ºC for 10 min 
     Stage 2: Step 1: 95ºC for 30 s 
   Step 2: Annealing temperature for 30 s 
   Step 3: 72ºC for 30 s per kb to be synthesised 
Stage 3: Step 1: 72ºC for 10 min 
 
Stage 2 was typically carried out for 30 cycles as per manufacturer‟s guidelines. 
A 1:3 dilution of Phusion Taq polymerase was carried out before use in PCR. 
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2.10.2 Ligation reaction 
 PCR product  6 µL 
 Vector   10 µL 
 T4 DNA Ligase 1 µL 
 Ligase Buffer (10X) 2 µL 
 dH2O   1 µL 
 
Reactions were incubated for 3 hrs at room temperature or for 16 hrs at 4ºC. 
 
2.10.3 Glycosyl hydrolase reaction 
 Glycoprotein  10 µL (100 µg) 
 Buffer   2 µL 
 Enzyme  2 µL 
 dH2O   6 µL 
 
Reactions were incubated overnight at 37ºC. 
 
2.11 Site specific mutagenesis 
 
Mutations were introduced into open reading frames on plasmid constructs by 
PCR amplification using complementary phosphorylated primers carrying the 
desired mutation. A standard PCR reaction mixture as show in Section 2.10.1.1 
was set up. The PCR was carried out using the high fidelity Phusion Taq 
polymerase.  The standard program cycle for Phusion Taq polymerase (Section 
2.10.1.2) was used. Typically an extension time of 2 min was used to amplify 
plasmids of 3.5-4 kb. The template DNA was eliminated by digestion with DpnI 
restriction endonuclease. DpNI is biased towards a methylated recognition 
sequence. It selectively digests the template DNA from dam
+
 E.coli strains over 
the newly synthesized DNA. The amplified plasmid, with the incorporated 
mutation, is circularized by ligation which was facilitated by the use of 
phosphorylated primers. 
 
 
83 
 
2.12 DNA Sequencing 
 
Recombinant clones and potential mutants were verified by DNA sequencing. 
Commercial sequencing services were provided by MWG Biotech/Eurofins and 
Source BioScience gene service. Suitable sequencing primers for standard 
vectors were sent with samples to be analysed. Samples were sent as plasmid 
preparations (see section 2.6.2.2). 
 
2.13 In silico analysis of DNA sequences 
 
To identify homologous protein and DNA sequences deposited in GenBank, the 
BLAST programme (Altschul, et al. 1998) available at NCBI 
(www.ncbi.nlm.nih.gov) was used. DNA sequences for the strains used in this 
study were obtained from the following sequencing studies; Pseudomonas 
aeruginosa PAO1 (NC_002516), Photorhabdus luminescens (NC_005126), 
Photorhabdus asymbiotica (NC_012962) and Serratia marcescens BJL200 
(AY665558). DNA and protein sequences were aligned using the ClustalW 
(Thompson, et al., 1994) available at http://www.ebi.ac.uk/Tools/clustalw/ and 
Gendoc programme, available to download at http://www.nrbsc.org/. DNA 
sequences were analysed for restriction sites using Webcutter 2.0 programme 
(http://rna.lundberg.gu.se/cutter2/). Protein imaging software used was Deepview 
Swiss PdbViewer from http://www.expasy.org/spdbv/ and PyMol from Delano 
Scientific available from http://pymol.sourceforge.net/.  
 
2.14 Standard expression culture  
 
An LB plate with the appropriate antibiotic was streaked from a glycerol stock of 
the strain containing the expression plasmid. One colony was selected and used 
to inoculate 5 mL of LB broth containing the appropriate antibiotic, and grown 
over night at 37°C while shaking. A 1 L baffled conical flask containing 500 mL 
of LB broth was inoculated with 5 mL of the overnight culture and the 
appropriate antibiotic added. The culture was incubated at 37°C, shaking at 180-
220 rpm, until an optical absorbance (A
600
) of 0.4-0.6 was reached. IPTG was 
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added to a final concentration of 50 μM to induce expression. The culture was 
allowed to incubate at 30°C for a defined period. The culture was then 
centrifuged at 4,000 rpm for 10 min (using a Beckman JA-14 rotor) to pellet the 
cells. The supernatant was autoclaved and discarded, and the pellets were stored 
at -20°C. 
 
 
2.15 Preparation of cleared lysate for protein purification 
 
Cell lysis was carried out using sonication and/or lysozyme.  
 
2.15.1 Cell lysis by sonication 
 
A cell pellet from a 500 mL expression culture was re-suspended in 50 mL lysis 
buffer containing 20 mM Imidazole, pH 7.6. The cells were disrupted with a 3 
mm micro-tip sonicator (Sonics & Materials Inc.) using 2.5 s, 40 kHz pulses for 
60 s. The lysate was centrifuged at 4,000 rpm for 20 min at 4ºC (using a Rotanta 
460 R rotar) to pellet any insoluble material. The cleared lysate was transferred to 
a fresh universal container and passed through a 0.2 µM filter to remove any 
remaining cell debris and stored at 4°C.  
 
2.15.2 Cell lysis using lysozyme 
 
A cell pellet from a 500 mL expression culture was re-suspended in 50 mL lysis 
buffer containing 20 mM Imidazole, 10 mg/mL lyzozyme and 10 µg/mL DNase, 
pH 7.6. The cells were incubated at 37°C for 30 min. The lysate was centrifuged 
at 4,000 rpm for 20 min at 4°C to pellet any insoluble material. The cleared 
lysate was transferred to a fresh universal container and passed through a 0.2 µM 
filter to remove remaining cell debris and stored at 4°C. 
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2.15.3 Solubilisation of insoluble inclusion bodies  
 
A cell pellet from 100 mL expression culture was re-suspended in 4 mL 
resuspension buffer. The cells were disrupted with sonication on ice with a 3 mm 
micro-tip sonicator using 2.5 s, 40 kHz pulses for 60 s. The lysate was 
centrifuged at 8,000 rpm for 10 min at 4ºC. The supernatant was discarded and 
the cell pellet was re-suspended in 3 mL cold isolation buffer. The cells were 
again disrupted with sonication on ice as above and centrifuged at 8,000 rpm for 
10 min at 4ºC. The re-suspension, sonication and spin steps were repeated, as 
above. At this stage the pellet material was either re-suspended in 5 mL binding 
buffer or washed once in a buffer lacking urea and stored at -20ºC for later 
processing. 
 
2.16 Membrane isolation by water lysis method 
 
This method was performed as described by (Ward, et al. 2000) and the principle 
of the method involved lysis of the cells by osmotic pressure. A 50 mL 
expression culture was centrifuged at 4,000 rpm for 10 min at 10
o
C. The 
supernatant was discarded and the pellet re-suspended in 10 mL 0.2 M Tris 
pH8.0 and left stirring for 20 min at room temperature. At this point 9.6 mL of 
deionised H2O should be aliquoted in anticipation of the water lysis step. At time 
zero, 4.85 mL of 1 M sucrose/ 0.2 M Tris pH8.0/ 1 mM EDTA was added. At 
time 1.5 min, 65 µL of 10 mg/mL lysozyme solution prepared in 1 M sucrose/ 
0.2 M Tris pH8.0/ 1 mM EDTA buffer was added. At time 2 min, 9.6 mL of 
deionised H2O, which had been prepared earlier was added, and left to stir for 20 
min. The preparation was examined under oil immersion for spheroplasts. 
Spheroplasts were sedimented at 18,000 rpm for 20 min at 4
o
C. The supernatant 
was retained and stored at -20
o
C (periplasmic fraction) and the spheroplasts were 
re-suspended in 15 mL deionised water using a 15 mL homogeniser. The 
suspension was fully homogenised and was left stirring for 30 min at room 
temperature. The suspension was sedimented at 18,000 rpm for 20 min at 4
o
C. 
The supernatant was retained (cytoplasmic fraction) and stored at -20
o
C. The 
preparation was then washed twice with 30 mL 0.1 M NaPhosphate buffer/ 1 mM 
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Mercaptoethanol pH7.2. The homogeniser was used to re-suspend the pellet each 
time and sedimented at 18,000 rpm for 20 min at 4
o
C. The final pellet (mixed 
membrane fraction) was re-suspended in ice cold re-suspension buffer 0.1 M 
NaPhosphate/ 1 mM Mercaptoethanol pH7.2 using a 1 mL homogeniser.  
 
2.17 Colony blot procedure 
 
Using a multichannel pipette, 300 µL of LB containing the required antibiotic 
was aseptically aliquoted into an autoclaved deep well 96-well plate. Each well 
was inoculated with a single colony obtained from a transformation plate. The 96 
well plate was sealed with a Breathe-easy Sealing Membreane and incubated at 
37°C, shaking at 800-1000 rpm overnight. Using a multichannel pipette 10 µL of 
growth from each well was aseptically transferred to a fresh autoclaved deep well 
96-well plate. The second 96-well plate was sealed and grown up as described 
above to ensure that there was sufficient growth to proceed. An LB-amp agar 
plate containing 50 µg/mL IPTG was overlaid with a nitrocellulose membrane 
and an equal volume of each overnight culture was spotted from the 96-well plate 
on to the membrane. The plate was incubated at 37°C for eight hours. A set of 
dishes for colony lysis was prepared. Each dish contained a sheet of 3 mM paper 
soaked in one of the following; 
 10% SDS solution (w/v) 
 Neutralisation solution  
 Denaturing solution 
 2x SSC 
Excess fluid was discarded from the dish so that the filter was moist but not wet. 
The nitrocellulose membrane was removed from the LB-amp plate carefully and 
placed colony side up, on top of each filter, taking care to exclude air bubbles. 
The filters were incubated at room temp, as outlined in Table 2.4.  
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Table 2.4: Incubation of nitrocellulose membrane for in situ lysis. Steps 
carried out on the nitrocellulose membrane of a 96-well colony blot. For 
denaturing, neutralization and 2x SSC buffer preparation, see Section 2.3. 
 
Solution Time 
SDS 10 min 
Denaturing 5 min 
Neutralisation 5 min 
Neutralisation  5 min 
2x SSC 15 min 
 
 
2.18 Protein purification  
 
Immobilised Metal Affinity Chromatography (IMAC) was used to purify 
recombinant proteins with terminal (His)6 tag. 
 
2.18.1 Standard IMAC procedure 
 
A 1 mL Ni-Agarose (Qiagen) column was washed with 5-10 column volumes of 
dH2O. The column was equilibrated with 5-10 column volumes of lysis buffer 
containing 20 mM Imadizole. The cleared lysate was gently mixed with nickel-
nitrilotriacetic acid resin (Ni-NTA, Qiagen) in a column. The column was 
washed with 10 column volumes of lysis buffer containing 20 mM Imadizole. A 
gradient of imidazole in lysis buffer was used to elute contaminating proteins 
from the column. Target protein was eluted from the column using a high 
concentration of imidazole in lysis buffer (depending on protein – 120-500 mM 
Imidazole). The column was washed with 5-10 column volumes of water 
followed by 3-5 column volumes of 20% ethanol. Samples were taken at each 
step and analysed by SDS-PAGE electrophoresis. 
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2.18.2 IMAC using FPLC and GE nickel resin 
 
A HisTrap FF 1mL column was washed with 5 column volumes of dH2O, and 
equilibrated with 5 column volumes of lysis buffer. Prior to the attachment of the 
column to the AKTA purifier 100 the maximum back pressure was set to 0.5 
MPa and the flow set to 1 mL/min. The top of the affinity column was attached 
to the pump outlet no 1 and the bottom of the column attached directly to the 
FPLC unit. The sample injection loop was filled with cleared lysate (Section 
2.15). A reservoir of lysis buffer containing 20 mM imidazole was attached to 
pump A, with lysis buffer containing 200 mM imidazole attached to pump B. 
The purification strategy involved  
 Column equilibration with 5 mL lysis buffer 
 Sample application from the sample injection loop 
 A wash of 10 mL lysis buffer 
 Application of an imidazole gradient to remove non-specifically bound 
proteins, by applying 10 mL of a 70 mM imidazole wash  
 Purified protein was then eluted by applying 20 mL of a 200 mM 
imidazole wash 
 
Samples were collected in 1mL fractions in 96-well plates. The FPLC software was 
used to monitor column back pressure, OD280, OD540, conductivity, flow rate and 
fraction collection through-out the run. 
 
2.18.3 Purification and on-column refolding of insoluble (His)6 protein 
 
Resolubilised cell lysate (Section 2.15.3) was passed through a 0.45 µm filter and 
loaded into the sample injection loop. The purification strategy involved;  
 
  Column equilibration with 5 mL binding buffer 
  Sample application from the sample injection loop 
  A wash of 10 mL binding buffer 
  A wash of 10 mL wash buffer 
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 Refolding of the bound protein through the application of a linear 30 
mL 6 – 0 M urea gradient, starting with wash buffer and finishing with 
refolding buffer. 
 A wash of 10 mL refolding buffer 
 Elution through the application elution buffer 
 
Samples were buffer exchanged into PBS using Vivaspin 500 (mass cut off at 
10,000 Da) micro-concentrators (Sartorius) and analysed using SDS-PAGE 
(Section 2.23). 
 
2.18.4 Desalting of purified protein using HiPrep 26/10 desalting column 
 
The FPLC back pressure limit was set to 0.35 MPa and the flow rate to 1 mL/min 
before attachment of the HiPrep 26/10 desalting column. The top of the column 
was attached to pump outlet no 1 and the bottom of the column attached to the 
FPLC using green peek tubing (0.75 mm I.D.). Before the first sample 
application the column storage buffer (20%) ethanol was removed, and the 
column equilibrated with sample buffer. This was done by washing with 2 
column volumes of water (106 mL) followed by 5 column volumes (265 mL) of 
PBS. Equilibration was not necessary between runs using the same buffer. 
Washing was carried out at the flow rate intended for chromatography (5 
mL/min). Samples were collected in 0.5 mL fractions in 96-well plates. 
 
2.19 Recharging of IMAC resin 
 
This column was routinely recharged prior to re-use of the Ni-NTA resin. The 
used resin was poured into a column and washed with 5 column volumes of 
dH2O. The resin was then stripped by washing with 5 column volumes of 
stripping buffer (Section 2.3). Ionically bound proteins were removed by washing 
with 5 column volumes of 1.5M NaCl. Precipitated proteins, hydrophobically 
bound proteins, lipoproteins and lipids were removed by washing with 5 column 
volumes of 1M NaOH, contact time 1-2 hours, followed by 10 column volumes 
of dH2O. Remaining impurities were removed by washing with 10 column 
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volumes of 30% isoproponal for 30 min, followed by 10 column volumes of 
dH2O. The resin was charged by adding 2 column volumes of 100 mM NiSO4. 
The resin was washed again with 2 column volumes of dH2O before storage in 
20% ethanol. 
 
2.20 Protein quantification  
 
Two procedures for the quantification of protein were variably employed. The 
Bradford protein as described by Bradford M.M. ((Bradford 1976)) assay is a 
colorimetric method, when the coomasie dye binds protein in an acidic medium 
an immediate shift in absorption maximum occurs from 465 nm to 595 nm with a 
concomitant color change from brown to blue.  Quantification of the protein 
concentration by 280 nm reading is based on the proteins ability to absorb 
ultraviolet light in solution with the absorbance maxima at 280 nm. 
 
2.20.1 Quantitative determination of protein by Bradford assay 
 
The Bradford assay using BradfordUltra
TM
 reagent (Expedeon) was used to 
quantify total protein in the range of 1 μg/mL – 1.5 mg/mL. For low range 
protein samples (1-25 μg/mL) 150 µL of sample was mixed with 150 µL 
Bradford Ultra, for high protein range samples (0.1 -1.5 mg/mL) 20 µL of sample 
was mixed with 300 µL of BradfordUltra
TM 
reagent. All samples, standards and 
blanks were prepared in triplicate. The absorbance was read at 600 nm. Bovine 
serum albumin (BSA) was used as the reference protein. BSA standards were 
prepared in PBS and assayed in triplicate to yield a standard curve. Protein 
concentration of samples was determined from this standard curve. 
 
2.20.2 Quantitative determination of protein by 280 nm readings 
 
Prior to reading all samples were spun down at 13,000 rpm for 10 min to 
minimize any debris present in solution that may interfere in absorbance 
readings. The UV lamp was set to 280 nm and allowed to warm up for 15 min. 
The zero absorbance was calculated with buffer solution. The absorbance of the 
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protein solution was read in triplicate. The concentration of the protein was then 
calculated using the Beer-Lambert law, Equation 2.1; 
 
A = ɛcl 
 
Equation 2.1: Beer-Lambert equation for the quantitative determination of 
protein concentration from absorbance readings at 280 nm. A = absorbance 
at 280nm, ɛ = molar extinction coefficient, c = concentration (in the units 
corresponding to ɛ) and l = path length. 
 
 
2.21 Quantitative determination of reducing sugars by DNS assay  
 
Reducing sugars, under alkaline conditions reduce 3.5-dinitrosalicylic acid to 3-
amino-5-nitrosalicylic acid. A red colour is produced on boiling, which absorbs 
maximally at 540-550 nm (Miller 1959). The DNS assay was used to quantify 
reducing sugars in the range 0.2-1 mg/mL. The carbohydrate solution was mixed 
with DNS reagent in the ratio of 1:2 and the samples were boiled for 10 min. 
Samples were allowed to cool for 5 min before aliquoting 250 µL of each 
solution into a microtitre plate.  All samples, standards and blanks were prepared 
in triplicate. The absorbance was read at 570 nm. 
 
 
2.22 Lyophilisation  
 
Samples were aliquoted (0.1-0.5 mL) in a 96-well plate and sealed with adhesive 
film, before being snap frozen in -80ºC ethanol. A pin hole was made in the film 
adhesive over the top of each well prior to lyophilisation. Samples were 
lyophilized at -45ºC and at a vacuum of 25 bar. Once lyophilized, samples were 
stored at -20ºC. 
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2.23 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
 
2.23.1 Preparation of SDS gels 
 
Protein samples were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE), based on the method outlined by LaemmLi 
(Laemmli 1970). 
 
10%, 12.5% and 15% resolving gels were prepared as outlined in table 2.5 
 
 
Table 2.5: Preparation of SDS gels 
Resolving Gel 7.5% 10% 12.5% 15% 4%  
30% Acrylamide (mL) 1.875 2.501 3.123 3.750 0.325 
H2O (mL) 3.633 3.007 2.385 1.758 1.540 
1.5M Tris-HCl pH8.8 (mL) 1.875 1.875 1.875 1.875    - 
0.5M Tris-HCl pH 8.8 (µL)    -    -    -    - 625 
10% APS (µL) 37.5 37.5 37.5 37.5 12.5 
10% SDS (µL) 75 75 75 75 25 
Temed (µL) 3.75 3.75 3.75 3.75 2.5 
 
 
2.23.2 Sample Preparation 
 
To a microfuge tube 18 µL of sample was added to 2 µL of 10X SDS-PAGE 
sample buffer (Section 2.3). Samples were boiled for 5 min and applied to wells 
that were flushed of un-polymerized acrylamide. To the insoluble pellet obtained 
from a 1 mL sample, 20 µL of 10X gel loading dye was added, and boiled for 5 
min. The sample was then diluted with water up to 100 µL. 
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2.23.3 Sample application 
 
A total of 15 µL of the prepared sample was applied to each SDS-PAGE well. 
One lane on each gel was kept for the relative molecular weight protein marker 
(Broad range protein marker, NEB, Fig 2.5). A 20 µL aliquot of the marker was 
applied for coomassie staining (Section 2.13.3), a 10 µL aliquot for silver 
staining (Section 2.12.3). When western blot analysis was required, the NEB 
prestained and color plus prestained protein markers were used (see Fig 2.6) 
 
The Broad range protein marker consisted of Rabbit Muscle Myosin (212 kDa), 
MBP-β-galactosidase from E.coli (158 kDa), β-galactosidase from E.coli (116 
kDa), Rabbit muscle Phosphorylase B (97 kDa), Bovine Serum Albumin (66 
kDa), Bovine liver Glutamic dehydrogenase (55 kDa), MBP2 from E.coli (42 
kDa), Thioredoxin reductase from E.coli (34 kDa), Soybean Trypsin inhibitor (20 
kDa), Chicken egg white  lysozyme (14 kDa), Bovine lung Aproptinin (6.5 kDa), 
Bovine pancreas insulin (3.4 kDa) and Bovine pancreas B chain (2.34 kDa). The 
prestained protein marker consisted of MBP-β-galactosidase from E.coli (175 
kDa), MBP-paramyosin from E.coli (80kDa), MBP-CBD from E.coli (58 kDa), 
CBD-Mxe Intein-2CBD from E.coli (46 kDa), CBDBmFKBP13 from E.coli 
(25kDa), Chicken egg white lysozyme (17 kDa), Bovine lung aprotinin (7 kDa).  
 
 
The color plus protein marker consisted of MBP-β-galactosidase from E.coli 
(175 kDa), MBP-truncated-β-galactosidase E.coli (80 kDa), MBP-CBDE E.coli 
(58 kDa), CBD-Mxe Intein-2CBDE E.coli (46 kDa), CBD-Mxe Intein E.coli (30 
kDa),  CBD E.coli ParE (23 kDa), Chicken egg white lysozyme (17kDa), Bovine 
lung aprotinin (7 kDa).  
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Figure 2.6:  A; NEB broad range protein marker, B; Pre-stained protein 
marker and C; Color plus pre-stained protein marker. Representative images 
of the NEB broad range protein marker, pre-stained protein marker and color plus 
pre-stained protein marker used in this study. Images obtained from 
www.NEB.com.   
 
 
 
 
2.23.4 Gel analysis 
 
Polyacrylamide gels were removed from the electrophoresis chamber and washed 
with dH2O. Gels were routinely stained for one hour with Coomassie blue stain 
solution (Section 2.3). An overnight de-stain followed using Coomassie blue de-
stain solution (Section 2.3). Subsequent soaking in dH2O  enhanced the protein 
bands further. For gels which required a greater degree of sensitivity the silver 
staining method (Blum, Beier and Gross 1987) was used as outlined in Table 2.6. 
 
  
 
A 
B C 
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Table 2.6: Silver staining of SDS-PAGE Gels 
Step Reagent Time Per Gel (50 mL) 
Fix 30% Ethanol 
10% Acetic acid 
>1 hour 15 mL 
5 mL 
Wash 1 20% Ethanol 15 min 10 mL 
Wash2 Water 15 min  
Sensitisation 0.1% Sodium 
Thiosulphate 
1 min 111 µL 4.5% 
Stock 
Rinse Water 2 x 20 s  
Silver Nitrate 0.1% AgNO3 
0.026% Formaldehyde 
30 min 0.05 g 
35 µL 37% 
Stock 
Rinse Water 2 x 20 s  
Development 3% Sodium Carbonate 
0.019% Formaldehyde 
Sodium Thiosulphate 
Until 
bands 
appear 
1.5 g 
25 µL 37% 
Stock 
2.2 µL 4.5% 
Stock 
Stop 5% Tris 1 min 2.5 g 
1.25 mL 
 
 
2.24 Western blot 
 
An SDS-PAGE gel was run (Section 2.23.2) using NEB pre-stained molecular 
weight markers. Four pieces of blotting paper and a piece of nitrocellulose 
membrane were cut to the same dimensions as the SDS-PAGE gel. The blotting 
paper, nitrocellulose and gel were then soaked in transfer buffer (Section 2.3), 
and arranged on the semi-dry electroblotter as per Fig 2.7. Transfer then occurred 
at a constant 20 V for 15 min. 
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To detect recombinant (His)6 tagged proteins, the membrane was blocked with 
3% BSA-TBST (Section 2.3) for one hour. The membrane was washed four 
times for 5 min with TBST, and then incubated with 1:10,000 murine anti-His 
antibody in 3% BSA-TBST. The membrane was washed four times for 5 mins 
with TBST and incubated in 15 mL dH2O containing SIGMAFAST
TM
 3,3-
Diaminobenzidine tablets. Development was stopped by washing with dH2O. 
 
 
 
 
 
 
 
 
 
Fig 2.7: Schematic of Western blot. Sheets of Whatman paper and 
nitrocellulose are cut to the same dimensions as the SDS-PAGE gel, as any 
overlap over the gel surface can lead to inefficient protein transfer. The transfer 
stack is laid down from bottom to top as follows, two sheets blotting paper, 
nitrocellulose membrane, SDS-PAGE gel, two sheets blotting paper. 
 
2.25 Size exclusion Chromatography 
 
The native molecular mass of recombinant proteins under native conditions were 
determined by size exclusion chromatography (Whitaker 1963 and Andrews 
1964). Size exclusion chromatography was carried out using FPLC.  
 
Before attachment of the gel filtration column to the AKTA purifier the 
maximum back pressure was set according to the manufacturers instructions. The 
column storage valve was disconnected from the gel filtration column, and the 
top was attached to pump outlet no 1. The bottom of the column was attached 
directly to the FPLC. To remove the column storage buffer (20% ethanol) two 
column volumes of water were pumped through the column at a flowrate of 1 
2 Sheets Whatman Paper 
2 Sheets Whatman Paper 
Nitrocellulose membrane 
SDS-PAGE Gel 
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mL/min (unless otherwise stated). The column was then equilibrated with 5 
column volumes of sample buffer, at the same flowrate, before sample 
application.  
 
2.25.1 Superdex 75 
 
With pump A attached to a reservoir of degassed sample buffer 100 µL of a 1 
mg/mL protein sample was applied through the sample injection port. The run 
commenced, with a flow rate of 0.5 mL/min of buffer A. Following sample 
injection 2.5 column volumes of buffer was passed through the column. The 
proteins retention time was measure through eluent absorbance at 280 nm.  
 
2.25.2 Toyopearl HW-55S 
 
With pump A attached to a reservoir of degassed sample buffer 500 µL of a 5 
mg/mL protein sample was applied through the sample injection port. The run 
commenced, with a flow rate of 1 mL/min of buffer A and a maximum back 
pressure of 0.5 MPa. Following sample injection 2.5 column volumes of buffer 
was passed through the column. The proteins retention time was measured using 
the online Monitor U-900 (GE Healthcare), which read the eluent absorbance at 
280 nm. 
 
2.26 Insoluble substrate activity assay 
 
A 1 mL volume (30 µg/mL) of chitin binding protein in PBS was mixed with 
0.05g of insoluble substrate (crustacean shell chitin, avicel (crystalline cellulose), 
crustacean shell chitosan (>85% deacetylation), squid pen chitin (BioLog), 
chitosan powder from carapacea skin (88-96% deacetylation - BioLog) in a 
column. The mixture was incubated with end-over stirring for a defined period of 
time. Unbound protein was collected in the eluent and subsequent washes with 
0.9% NaCl (2 x 1 mL). Bound protein was eluted from the insoluble substrates 
by boiling for 10 min in 50 µL SDS-PAGE sample buffer. Bound and unbound 
protein samples were visualized by 12% SDS-PAGE analysis and silver staining. 
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2.27 Enzyme linked lectin assay 
 
A 50 µL volume of glycoprotein was immobilized in each well of a NUNC 
MaxiSorp ELISA plate at 4ºC overnight. Each sample was assayed in triplicate, 
at a concentration of 10 μg/mL. The unbound glycoprotein was removed by 
inverting the plate and the wells were blocked with 150 µL 2.5% BSA in TBS for 
one hour at 25°C. The solution was then removed by inverting the plate and 
washing with TBS supplemented with 0.1% Triton X-100 four times. A 50 µL 
aliquot of lectin in TBS supplemented with 10 mM CaCl2 was then added at a 
concentration of 5 μg/mL and let incubate at 25ºC for one hour. This was 
removed by inversion and washed with TBST as before. This was followed with 
50 µL of 1:10,000 murine anti-histidine or anti-biotin antibody, as appropriate. 
Antibody was created fresh, diluted in TBST, and was incubated for one hour at 
25ºC. Unbound antibody was removed by inversion and washed four times with 
TBST, before the addition of 100 µL TMB substrate (Section 2.3). The reaction 
was stopped after a specified time by the addition of 50 µL 10% H2SO4. The 
absorbance was read at 450 nm. 
 
2.28 ElectroSpray ionization mass spectrometry 
 
Protein samples were desalted using Vivaspin 500 (mass cut off at 10,000 Da) 
micro-concentrators (Sartorius) and diluted 1 mg/mL in mass spectrometry grade 
solvents (50% H2O, 50% Methanol, 0.2% Formic acid). 
 
Electrospray ionization mass spectrometry (Q-TOF Ultime Global
TM
, 
Micromass, Manchester, UK) coupled with a nanoflow Z-spray source. The 
nanoflow source interface was operated at room temperature and was equipped 
with PicoTip
TM
 emitter with distal coating (20 μm i.d with 10 μm Silica tipTM, 
New Objective, Woburn, MA, USA). Ions were focused by a radio frequency 
(RF) lens before transmission to the quadropole. The ions were then transmitted 
through the hexapole collision cell and were pulsed into the TOF analyzer. The 
TOF analyzer was set in the positive ion mode at 9.10 kV when the reflectron 
was used in V configuration at 35.6 V and pusher was in auto mode. Acquisition 
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was achieved by using a time-to-digital convertor operating at 4 GHz. Mass 
spectra were recorded using a micro channel plate (MCP) detector at the exit of 
the TOF analyzer, after calibration with NaI solution (2 mg/mL) in 
isopropanol/water (50/50). A mass range (m/z) of 500 – 5000 Th was scanned 
over 2.4 s with an inter scan delay time of 0.1 s. Samples were analysed in 
“denaturing” conditions. Samples were introduced into the source by direct 
infusion using a syringe pump (Cole-Parmer, Vernon Hills, Illinois, USA) at a 
rate of 200 nl/min for the nanoflow source. 
 
Calculations and data analyses were performed using MassLynx software version 
4.0 (Waters, Manchester, UK). Deconvolution of spectra was accomplished 
either manually or by using a transform algorithm. Mass spectra were 
background subtracted, smoothed using the Savitzky Golay method, and centered 
before final calculations of the molecular mass. Molecular species were 
represented by an envelope of a series of peaks corresponding to multiple 
charged ions that deconvoluted to a mean mass ± standard deviation. 
 
2.29 Immobilisation of protein onto cyanogen bromide activated sepharose 
 
The protein to be immobilized was suspended in 0.1 M NaHCO3 coupling buffer, 
pH 8.5, which contained 500 mM NaCl. The capacity for the gel was 5-10 mg 
per mL of gel. The resin was then washed in cold 1 mM HCl for 30 min, at 200 
mL/g of gel. The supernatant was removed and the resin was washed with 10 
column volumes of dH2O, followed by 1 column volume of coupling buffer. The 
protein solution was immediately added to the column, and the flow stopped. The 
solution was allowed to mix by inversion overnight at 4ºC, after it was washed 
with coupling buffer to remove unbound protein. The resin was then blocked by 
the addition of 2 column volumes of 0.2M glycine, pH 8.0, and was allowed to 
mix by inversion for 2 hours at room temperature. The unbound glycine was 
removed by washing with 2 column volumes of coupling buffer, followed by 
washing with 2 column volumes of 0.1 M Sodium acetate, pH 4.0, containing 
500 mM NaCl. Alternate washing steps using coupling buffer and acetate buffer 
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were repeated 5 times. The resin was then used immediately or stored at 4ºC in 1 
M NaCl with 0.05% NaN3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
3.0 Cloning, Expression and 
Characterisation of CBP21 
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3.1 Overview 
 
This chapter describes the cloning of the cbp21 gene from Serratia marcescens 
that encodes the chitin binding protein CBP21, and the subsequent development 
of a recombinant expression system, which was utilised to prepare active 
recombinant protein of a high level of purity. Functional analysis of CBP21 was 
carried out, which included gel filtration (see Section 3.6), mass spectrometry 
(see Section 3.7) solid substrate assays (see Section 3.8) and the development of 
a novel chitin activity assay (Chapter 4). Mutant derivatives of the CBP21 
protein were also constructed and analysed (Chapter 4). Additionally alternative 
sources of chitin binding proteins were investigated (Chapter 5). 
 
 
3.2 Cloning and small scale expression of cbp21 from Serratia marcescens 
 
The utilisation of prokaryotic systems for protein expression is generally 
considered to be the most effective in terms of simplicity and reproducibility. 
Over expression of specific proteins in the natural prokaryotic host cell however 
is difficult to achieve. The gram negative bacterium Escherichia coli is one of the 
most commonly used hosts for the expression of recombinant heterologous 
proteins. This is due in part to its simplicity, safety, rapid high density growth 
rate on inexpensive substrates and well defined genetics, allowing for large scale 
protein production.  
 
There are a number of variable E. coli host strains available as well as a broad 
range of compatible cloning and expression vectors. Depending on the system 
employed expression of recombinant proteins in E. coli can facilitate protein 
labelling, the addition of fusion tags, the incorporation of unnatural amino acids, 
in addition to the direction of proteins to particular cellular compartments. The 
biggest disadvantage associated with recombinant protein expression in E. coli is 
its inability to perform many of the post-translational modifications necessary for 
eukaryotic protein functionality, mainly glycosylation. Carbohydrate binding 
proteins from prokaryotic sources, such as the chitin binding proteins, do not 
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require post translational modifications; therefore an E. coli based expression 
system can be exploited 
 
The Qiagen pQE expression vectors, pQE30 (see Fig 2.1) and pQE60 (see Fig 
2.2) have been designed to produce high yields of recombinant protein. These 
vectors also contain various desired elements including an optimised promoter 
consisting of the phage T5 transcriptional promoter and a lac operator sequence, 
extensive multiple cloning sites, and (His)6 tag sites at either the N- or C-
terminus. They also express the β-lactamase gene which confers ampicillin 
resistance to cells harbouring this plasmid.  
 
To study the effect of the (His)6 position, plasmids that express N-terminally and 
C-terminally (His)6  tagged proteins were desired. In order to determine the 
optimal system for the expression and purification of CBP21 in E. coli a number 
of constructs were examined. 
 
 
3.2.1 Initial cloning of the S .marcescens gene cbp21 
 
The S. marcescens strain Koln was obtained from NCIMB (Accession no 2302). 
The sequence for the related organism Serratia marcescens BJL200 (see Fig 3.1) 
was obtained from the NCBI data bank (Accession no AY665558). On the basis 
of the BJL200 cbp21 gene sequence primers were designed to amplify the cbp21 
gene for cloning into both the pQE30 and pQE60 vectors. The primers used for 
the amplification of N-terminally (His)6 tagged cbp21 were Marces-F1 and 
Marces-R1, which contained BamHI and HindIII restriction sites, and those for 
the amplification of C-terminally (His)6 tagged CBP21 were Marces-F3 and 
Marces-R2, which contained NcoI and BglII sites.  
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ATGAACAAAA CTTCCCGTAC CCTGCTCTCT CTGGGCCTGC TGAGCGCGGC CATGTTCGGC 
GTTTCGCAAC AGGCGAATGC CCACGGTTAT GTCGAATCGC CGGCCAGCCG CGCCTATCAG 
TGCAAACTGC AGCTCAACCG CAGTGCGGCA GCGTGCAGTA CGAACCGCAG AGCGTCGAGG 
GCCTGAAAGG CTTCCCGCAG GCCGGCCCGG CTGACGGCCA TATCGCCAGC GCCGACAAGT 
CCACCTTCTT CGAACTGGAT CAGCAAACGC CGACGCGCTG GAACAAGCTC AACCTGAAAA 
CCGGTCCGAA CTCCTTTACC TGGAAGCTGA CCGCGCGTCA CAGCACCACC AGCTGGCGCT 
ATTTCATCAC CAAGCCGAAC TGGGACGCTT CGCAGCCGCT GACCCGCGCT TCCTTTGACC 
TGACGCCGTT CTGCCAGTTC AACGACGGCG GCGCCATCCC TGCCGCACAG GTCACCCACC 
AGTGCAACAT ACCGGCAGAT CGCAGCGGTT CGCACGTGAT CCTTGCCGTG TGGGACATAG 
CCGACACCGC TAACGCCTTC TATCAGGCGA TCGACGTCAA CCTGAGCAAA TAA 
 
Fig 3.1: S. marcescens BJL200 cbp21 coding sequence. Nucleotide sequence 
AY665558. Annealing sites of primers Marces-F1, Marces-F3 and Marces-R1 
and Marces-R2 are indicated with red. There are no BamHI, HindIII, NcoI or 
BglII restriction sites within this gene. 
  
 
The PCR products were analysed by agarose gel electrophoresis and bands 
corresponding to the expected size were present. The PCR products were then 
restricted using either BamH1-HindIII or NcoI-BglII, gel extracted and ligated to 
BamH1-HindIII digested pQE30 or NcoI-BglII digested pQE60 vector 
respectively (see Fig 3.2). Following transformation into E. coli XL10-Gold cells 
(see Section 2.9.3), plasmid DNA was isolated and screened for inserts using gel 
electrophoresis and restriction analysis. The presence of the correct insert was 
further confirmed by DNA sequencing (see Section 2.12).  
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Fig 3.2: Schematic of the cloning of cbp21 into commercial pQE expression 
vectors pQE30 and pQE60. Outline of the positions of the relevant restriction 
sites and (His)6 tags involved in the generation of p30-CBP21 and p60-CBP21. 
The primers Marces-F1 and Marces-R1 amplified the cbp21 gene with the 
restriction sites BamHI and HindIII. Marces-F3 and Marces-R2 amplified the 
cbp21 gene, with restriction sites NcoI and BglII at the 5‟ and 3‟ ends 
respectively.  
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The cbp21 gene was successfully cloned into the pQE30 and pQE60 vectors, 
creating pCBP21_30 and pCBP21_60 respectively. Following sequencing it was 
observed that sequence variations existed between the cbp21 gene as amplified 
from S. marcescens koln genomic DNA and the previously reported sequence for 
cbp21 from S. marcescens BJL200 (see Fig 3.3). The changes in the gene 
sequence did not correspond to any changes in amino acid sequence (see Fig 3.4) 
 
Fig 3.3: DNA sequence alignment of the cbp21 gene from S. marcescens 
BJL200 and S. marcescens koln. Alignment generated using Clustal W and 
GenDoc 2.6 (see Section 2.13) 
 
Fig 3.4: Amino acid sequence alignment of the cbp21 gene from S. 
marcescens BJL200 and S. marcescens koln. Alignment generated using 
ClustalW and Gendoc 2.6 (see Section 2.13). 
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3.2.2 Small scale expression of CBP21 
 
The cbp21 gene was subsequently expressed in E. coli from pCBP21_30 and 
pCBP21_60 in 100 mL cultures (see Section 2.14), and the cell lysate examined 
by SDS-PAGE (see Section 2.23) and western blot (see Section 2.24), to 
determine if CBP21 is expressed as a soluble protein by E. coli. An over-
expressed protein of the correct size was visible in the insoluble protein fraction 
of N-terminal (His)6 tagged CBP21 (see Fig 3.5), while CBP21 cloned with a C-
terminal (His)6 tagged expressed to the soluble fraction (see fig 3.6). 
 
   
          
 
Fig 3.5: Expression analysis of N-terminally (His)6 tagged CBP21 in E. coli 
XL10-Gold. Analysis by 12% SDS-PAGE and western blot of N-terminally 
(His)6 tagged CBP21, expressed from pCBP21_30 in E. coli XL10-Gold. Lane 1; 
Protein ladder (see Section 2.23.3), Lane 2; pCBP21_30 soluble cell extract, 
Lane 3; pQE30 empty vector soluble cell extract, Lane 4; pCBP21_30 insoluble 
cell extract, Lane 5; pQE30 empty vector insoluble cell extract, Lane 6; Protein 
Ladder (see Section 2.23.3). Over-expressed CBP21 bands  are indicated with an 
arrow. 
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Fig 3.6: Expression analysis of C-terminally (His)6 tagged CBP21 in E. coli 
XL10-Gold. Analysis by 12% SDS-PAGE and western blot of C-terminally 
(His)6 tagged CBP21 expression from pCBP21_60 in E. coli XL10-Gold. Lane 1; 
Broad range protein ladder (see Section 2.23.3), Lane 2; pCBP21_60 soluble cell 
extract, Lane 3; pQE60 empty vector soluble cell extract, Lane 4; pCBP21_60 
insoluble cell extract, Lane 5; pQE60 empty vector insoluble cell extract. Over-
expressed CBP21 bands are indicated with an arrow. 
 
 
In nature, in order to facilitate the recognition of CBPs within the cell and 
secretion to the extracellular environment these proteins have signal sequences at 
the N-terminus of the protein (~25aa) (see Fig 1.23) (Brurberg, et al. 2000). 
CBP21 was cloned into the pQE30 vector (pCBP21_30) with a (His)6 tag at the 
N-terminus, upstream of the native signal sequence. Expression of the protein 
from this plasmid in E. coli resulted in the localisation of CBP21 to the insoluble 
protein fraction (see Fig 3.5).  
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3.2.3 Sub-cloning and small scale expression of CBP21 
 
The addition of a (His)6 tag to the N-terminus of the protein, upstream of the 
signal sequence, may be interfering with the recognition of the native signal 
sequence by E. coli, thus preventing the protein from being transported to the 
correct cellular location for accurate protein folding to occur. It is also possible 
that the (His)6 tag is not interfering with the recognition of the signal sequence 
and is simply preventing correct protein folding due to is position at the N-
terminus. In order to assess these theories cbp21 was amplified both with and 
without its native signal sequence and re-cloned into the pQE30 and pQE60 
vectors. 
 
cbp21 was amplified through PCR, without its native N-terminal signal sequence 
using a Phusion
TM
 directed whole vector amplification strategy (see Fig 3.7). 
Primers Marces-F4 and 30-R1 were used to amplify N-terminally (His)6 tagged 
cbp21  without its native N-terminal signal sequence, with pCBP21_30 used as 
the template (see Fig 3.8). For the amplification of C-terminally (His)6 tagged 
cbp21 without its native N-terminal signal sequence primers Marces-F4 and 
Marces-R3 were used, the template plasmid was pCBP21_60  (see Fig 3.9).  
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7: Schematic of Phusion
TM
 whole vector amplification strategy. The 
undesired DNA is shown in green, with forward and reverse primers shown in 
blue and red respectively. The two phosphorylated primers are designed to 
amplify the entire expression plasmid, each with an annealing site at either side 
of the undesired DNA. Following PCR (see Section 2.10.1) a DpnI restriction 
digest can be carried out to restrict any of the methylated template DNA. The 
phosphorylated ends are then ligated (see Section 2.10.2). Subsequently the 
ligation is transformed directly into an E. coli cloning strain (see Section 2.9.3).  
5’   
  5’ 
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                        GTGGTAGT GGTAGTGCCT AGGTAC 
ATTAACTATG AGAGGATCGC ATCACCATCA CCATCACGGA TCCATGAACA AAACTTCCCG  
TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC GGCGTTTCGC AACAGGCGAA  
    CACGGT TATGTCGAAT CGCCGG 
TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT CAGTGCAAAC TGCAACTCAA 
CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC GAAGGCCTGA AAGGCTTCCC 
ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC AAGTCCACCT TCTTCGAACT 
GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG AAAACCGGCC CGAACTCCTT 
TACCTGGAAG CTGACCGCCG TCACAGCACA ACCAGCTGGC GCTATTTCAT CACCAAGCCA 
AACTGGGACG CTTCGCAGCC GCTGACCCGC GCTTCCTTTG ACCTGACGCC GTTCTGCCAG 
TTCAACGACG GCGGCGCCAT CCCTGCCGCA CAGGTCACCC ACCAGTGCAA CATACCGGCA 
GATCGCAGCG GTTCGCACGT GATCCTTGCC GTGTGGGACA TAGCCGACAC CGCCAACGCC 
TTCTATCAGG CGATCGACGT CAACCTGAGC AAATAA 
Fig 3.8: Whole vector amplification strategy for the generation of 
pCBP2130_N. cbp21 was amplified without its native N-terminal signal 
sequence from pCBP21_30 using the primers Marces-F4 and 30-R1. The cbp21 
coding sequence is highlighted in purple, with the native leader sequence 
underlined in red. Primer annealing sites are shown in blue.  
                                                TCTCCT CTTTAATTGG                                           
GATTCAATTG TGAGCGGATA ACAATTTCAC ACAGAATTCA TTAAAGAGGA GAAATTAACC  
TACCCT 
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
                          CACGGT TATGTCGAAT CGCCGG 
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC 
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG 
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCG TCACAGCACA ACCAGCTGGC 
GCTATTTCAT CACCAAGCCA AACTGGGACG CTTCGCAGCC GCTGACCCGC GCTTCCTTTG 
ACCTGACGCC GTTCTGCCAG TTCAACGACG GCGGCGCCAT CCCTGCCGCA CAGGTCACCC 
ACCAGTGCAA CATACCGGCA GATCGCAGCG GTTCGCACGT GATCCTTGCC GTGTGGGACA 
TAGCCGACAC CGCCAACGCC TTCTATCAGG CGATCGACGT CAACCTGAGC AAAAGATCTC 
ATCACCATCA CATCACTAA 
Fig 3.9: Whole vector amplification strategy for the generation of 
pCBP2160_N. cbp21 was amplified without its native N-terminal signal 
sequence from pCBP21_60 using the primers Marces-F4 and Marces-R3. The 
cbp21 coding sequence is highlighted in purple, with the native leader sequence 
underlined in red. Primer annealing sites are shown in blue. 
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The resulting PCR products were analysed by agarose gel electrophoresis and 
bands corresponding to the correct size were present. The bands were gel 
extracted, subjected to digestion by DpnI, ligated and transformed into E. coli 
XL10-Gold, generating the plasmids pCBP2130_N and pCBP2160_N.  These 
plasmids were subsequently expressed in 100 mL cultures (see Section 2.14) to 
assess the level of protein solubility in E. coli. No over expressed or (His)6 
positive bands were visible on SDS-PAGE or western blot analysis for N-
terminally (His)6 tagged CBP21, expressed from pCBP2130_N. An over-
expressed band of the correct size was visible in the insoluble protein fraction of 
C-terminally (His)6 tagged CBP21, expressed from pCBP2160_N (see Fig 3.10). 
 
 
 
     
Fig 3.10: Expression analysis of C-terminally (His)6 tagged CBP21 expressed 
without its native leader sequence in E. coli XL10-Gold. 12% SDS-PAGE and 
the corresponding western blot analysis of C-terminally (His)6 tagged CBP21 
over-expression in E. coli XL10-Gold. Lane 1; Protein ladder (see Section 
2.23.3), Lane 2; pCBP2160_N soluble cell extract, Lane 3; pQE60 empty vector 
soluble cell extract, Lane 4; pCBP2160_N insoluble cell extract, Lane 5; pQE60 
empty vector insoluble cell extract. Over-expressed CBP21 bands are indicated 
with an arrow. 
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3.2.4 Cellular compartment analysis of pCBP21_60 lysate 
 
Expression of CBP21 from pCBP2160_N to the insoluble protein fraction lends 
weight to the theory that the native N-terminal signal sequence is functioning in 
E. coli through recognition and transport of the protein from the reducing 
environment of the cytoplasm to the periplasm, resulting in a soluble protein 
form. Although no CBP21 expression from pCBP21_30 was detectable, one 
could still surmise that it is the position of the N-terminal (His)6 tag that resulted 
in whole protein expression from pCBP21_30 to the insoluble fraction. To 
determine if E. coli was able to recognise the native signal sequence, and 
transport the CBP21 protein to the periplasm, cell fractionation was undertaken 
using the water lysis method, as outlined in section 2.16. Periplasmic and 
cytoplasmic fractions were isolated and analysed by SDS-PAGE and western blot 
(see Fig 3.11).  
 
                 
Fig 3.11: Soluble cell fraction analysis of C-terminally (His)6 tagged CBP21 
expressed from pCBP21_60. 12% SDS-PAGE and the corresponding western 
blot analysis of the periplasmic and cytoplasmic fractions from C-terminally 
(His)6 tagged CBP21 over-expression, from p60_CBP21 in E. coli. Lane 1; 
Protein ladder (see Section 2.23.3), Lane 2; periplasmic fraction, Lane 3; 
cytoplasmic fraction, Lane 4; Broad Range protein ladder.  
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Analysis of the periplasmic and cytoplasmic fractions from soluble E. coli lysate 
expressed from pCBP21_60 (see Fig 3.11) illustrated that E. coli is capable of 
recognising the native CBP21 N-terminal signal sequence, and transporting the 
protein from the cytoplasm to the periplasm. Further size estimation techniques 
will have to be undertaken to determine if the protein is further processed through 
cleavage of this signal sequence (see Section 3.6 and 3.7). 
 
 
3.3 Expression of recombinant CBP21. 
 
Due to the high quantity and quality of purified protein required by analytical 
methods such as size exclusion chromatography and mass spectrometry, 
optimisation of expression conditions is an essential step for the production of 
large scale recombinant protein production. The ability to produce considerable 
amounts of protein is also advantageous when looking to exploit molecules for 
novel analytical purposes. 
 
 
3.3.1 Selection of an E. coli expression strain for recombinant CBP21 
expression. 
 
The optimal E. coli strain for the expression of CBP21 was investigated. The 
plasmid pCBP21_60 (see Section 3.2), which expressed soluble C-terminally 
(His)6 tagged CBP21 was transformed into four different E. coli strains to 
ascertain the optimal expression strain for recombinant CBP21. The E. coli 
strains used were XL10-Gold, JM109, KRX and BL21 (DE3) (Table 2.1). 
 
XL10-Gold and JM109 cells are endonuclease and recombination deficient which 
makes them ideal cloning strains. The XL10-Gold and KRX strains also contain 
the lacIq allele. This genotype results in a high expression level of the LacI 
repressor protein, which in turn strongly represses the activity of the Ptac 
promoter in the absence of IPTG, allowing for tight control over protein 
expression. BL21 and KRX are commonly used expression strains that are OmpT 
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protease deficient, which should allow for higher recovery of recombinant 
protein. Culturing conditions for the four strains were outlined in section 2.14. 
The optimal expression strain was determined using the Colony blot procedure as 
outlined in section 2.17 and SDS-PAGE analysis (see Fig 3.12 and 3.13).  
 
 
 
 
Fig 3.12: Effect of strain selection on CBP21 expression in E. coli. Colony 
blots of CBP21 constructs expressed in E. coli. Column 1 and 2 (A-H); BL21, 
column 3 B-D; BL21 negative controls, F-G; (His)6 positive controls, column 4 
and 5 (A-H); XL10-Gold, column 6 B-D; XL10-Gold negative controls, F-G; 
(His)6 positive controls, column 7 and 8 (A-H); KRX, column 9 B-D; KRX 
negative controls, F-G; (His)6 positive controls, column 10 and 11 (A-H); JM109, 
column 12 B-D; JM109 negative controls, F-G; (His)6 positive controls. Clones 
selectede for further analysis are indicated with an arrow. 
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Fig 3.13: SDS-PAGE analysis of CBP21 expression in E. coli strains BL21, 
JM109, KRX and XL-10 Gold. Analysis by 12% SDS-PAGE of soluble and 
insoluble protein fractions at T = 4 hrs, of CBP21 over expression in four 
different E. coli strains, BL21, JM109, KRX and XL-10 Gold. Lane 1; Protein 
ladder (see Section 2.23.3), Lane 2; BL21 soluble fraction, Lane 3; BL21 
insoluble fraction, Lane 4; JM109 soluble fraction, Lane 5; JM109 insoluble 
fraction, Lane 6; KRX soluble fraction, Lane 7; KRX insoluble fraction, Lane 8; 
XL-10 Gold soluble fraction, Lane 9; XL-10 Gold insoluble fraction. 
Overexpresssed CBP21 bands are indicated with an arrow. 
 
 
In this optimisation study the CBP21 protein was expressed in a number of 
different E. coli strains to determine which strain yielded the highest amount of 
soluble protein. The most efficient clone from each of four different strains was 
selected using colony blot analysis (see Fig 3.12). The amount or protein 
expressed from each clone was then determined using SDS-PAGE analysis (see 
Fig 3.13). Upon selection of the most affluent KRX clone (see Fig 3.12), a 
glycerol stock of the clone was created, which could then be referred to when the 
protein was desired. 
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3.3.2 Optimisation of expression conditions for recombinant CBP21 
 
Having determined in the previous section that E. coli KRX was the optimal 
strain for CBP21 protein expression, the most favourable conditions for induction 
and harvesting of the protein were subsequently examined (see Fig 3.14, 3.15, 
3.16 and 3.17). 
 
The CBP21 protein is derived from a pQE expression plasmid which is under the 
control of the PTAC promoter system. The tac promoter/operator (PTAC) is one of 
the most widely used expression systems, and is a strong hybrid promoter 
composed of the -35 region of the trp promoter and the -10 region of the lacUV5 
promoter/operator. Expression of PTAC is repressed by the LacI protein. The lacI
q
 
allele is a promoter mutation that increases the intracellular accumulation of LacI 
repressor, resulting in strong repression of PTAC. Addition of the inducer 
molecule IPTG inactivates the LacI repressor. Thus the amount of expression 
from PTAC is proportional to the amount of IPTG added: low levels of IPTG 
result in low expression from PTAC and high concentrations of IPTG result in 
high expression from PTAC. The IPTG concentration was varied in CBP21 
expression and the amount of protein expressed from PTAC in soluble form was 
examined by densitometry (see Fig 3.14), the effect of IPTG on growth rate was 
also examined (see Fig 3.15). Following optimisation of IPTG concentration the 
effect of incubation temperatures and harvest time were also examined (see Fig 
3.16 and 3.17). 
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Fig: 3.14: Effect of varying IPTG concentration on expression of CBP21 in 
KRX. Analysis of increasing IPTG concentration on the expression of CBP21 
from pCBP21_60 in E. coli KRX by 15% SDS-PAGE. A; 0 µM, B; 5 µM, C: 50 
µM, D: 100 µM, E; 500 µM and F; 1000 µM. Lane 1; Broad range protein ladder 
(see Section 2.23.3), Lane 2; Soluble fraction 3 hours, Lane 3; Insoluble fraction 
3 hours, Lane 4; Soluble fraction 5 hours, Lane 5; Insoluble fraction 5 hours, 
Lane 6; Soluble fraction 7 hours, Lane 7; Insoluble fraction 7 hours, Lane 8; 
Soluble fraction 9 hours, Lane 9; Insoluble fraction 9 hours, Lane 10; Broad 
range protein marker. Over-expressed CBP21 bands are indicated with an arrow. 
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Fig: 3.15: Effect of varying IPTG concentration on the growth rate of E. coli 
KRX. Absorbance readings taken during expression of CBP21 from pCBP21_60 
in E. coli KRX using varying IPTG concentrations. The point of induction for all 
cultures is indicated with a red arrow. The growth rate for the cultures (increase 
in OD600 per hour during exponential phase) is indicated in red. Cell growth was 
not affected by the increasing concentrations of IPTG. 
 
 
It was deduced from densitometry that there was no significant difference 
between the amount of soluble protein produced upon induction with 100 μm 
IPTG (30.89%), 500 µM IPTG (28.55%) and 1 mM IPTG (33.1%). Increasing 
the concentration of IPTG from 100 µM to 1 mM was not found to significantly 
reduce the growth rate of the cells (see Fig 3.15). To save on reagents 100 µM 
IPTG was determined to be the optimal induction concentration. The effect of 
incubation temperature on CBP21 expression was then examined by measuring 
the amount of CBP21 in the total cell lysate at set time points, post induction, of 
active cell growth (see Fig 3.16 and 3.17). The optimal harvest time was also 
analysed (see Fig 3.16).  
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Fig 3.16: Effect of variation of growth temperatures and harvest time on 
CBP21 expression from KRX. A: 37°C incubation, B: 37°C incubation prior 
to induction, 30°C incubation following induction. Lane 1; Broad range 
protein ladder (see Section 2.23.3), Lane 2; soluble fraction T = 0, Lane 3; 
soluble fraction T = 1, Lane 4; soluble fraction T = 2, Lane 5; soluble fraction T 
= 3, Lane 6; soluble fraction T = 4, Lane 7; soluble fraction T = 5, Lane 8; 
soluble fraction T = 6, Lane 9; soluble fraction T = O/N. 
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Densitometry and SDS-PAGE were used to deduce optimal incubation 
temperatures and harvest time for the expression of recombinant CBP21 in E. 
coli KRX. From SDS-PAGE analysis it was clear that variations existed in the 
amount of CBP21 visible in the total cell lysate (soluble and insoluble) under 
both conditions. At time point T = 6 22.065% for 37°C and 12.481% for 30°C, at 
time point T = O/N 10.671% for 37°C and 13.324% for 30°C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.17: Effect of temperature variation on CBP21 expression in E. coli 
KRX. The log of absorbance readings against time recorded during CBP21 
expression from pCBP21_60 in E. coli KRX, with two different incubation 
temperatures following induction. The induction time for both cultures is 
indicated with a red arrow. The growth rate for the cultures (increase in OD600 
per hour during exponential phase) is indicated in red. 
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3.4 Purification of recombinant CBP21 
 
3.4.1 Purification of recombinant CBP21 using IMAC 
 
Immobilized metal ion affinity chromatography (IMAC) exploits a molecule‟s 
affinity for chelated metal ions. In this case the purification of a histidine tagged 
protein involves the exploitation of the strong interaction between the six 
histidine residues in the introduced tag and the two ligand binding sites of the 
Ni
2+
 ion, which has been immobilised on a solid matrix, in this case 
nitrilotriacetic acid linked to sepharose (Ni-NTA).  
 
As many cellular proteins will display histidine residues on their surface, several 
wash steps are employed using imidazole, the active side chain of histidine, 
which displaces loosely bound proteins, and when used in high concentrations 
displaces the (His)6 tagged recombinant protein. Depending on the position of the 
(His)6 affinity tag, purification conditions will vary, as the strength of binding 
between the tag and the nickel matrix is largely dependent on the availability of 
the histidine residues. The strength of binding will affect the strength of wash 
tolerated by the interaction, and the point at which the target protein will be 
eluted. This section outlines the investigation into whether CBP21 can be 
purified using IMAC (see Section 2.18.2) and the wash stringencies tolerated by 
CBP21 (see Fig 3.18). 
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Fig 3.18: Purification of C-terminally tagged CBP21 soluble cell lysate using 
Amersham Ni-NTA resin. Analysis by 12% SDS-PAGE of fractions collected 
from the purification of CBP21 containing soluble cell lysate on an Ni-NTA 
column. Lane 1; Broad range protein ladder (see Section 2.23.3), Lane 2; Crude 
lysate, Lane 3; Column flowthrough, Lane 4; 20mM Imidazole wash, Lane 5; 
30mM Imidazole wash, Lane 6; 40mM Imidazole wash, Lane 7; 50mM 
Imidazole wash, Lane 8; 60mM Imidazole wash, Lane 9; 70mM Imidazole wash, 
Lane 10; 80mM Imidazole wash, Lane 11; 90mM Imidazole wash, Lane 12; 
100mM Imidazole wash. 
 
 
It was evident from SDS-PAGE analysis that C-terminally (His)6 tagged CBP21 
protein could be purified to a high level of homogeneity using IMAC. It was 
observed that CBP21 could tolerate imidazole washes of up to 70mM before 
leaching from the column.  
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3.4.2: Protein purification using fast protein liquid chromatography 
 
Fast protein liquid chromatography (FPLC) is a form of high-performance 
chromatography, commonly employed for the separation of proteins from 
complex mixtures. First developed by Pharmacia in 1982 it features high loading 
capacity, biocompatible aqueous buffer systems, fast flow rates and a wide 
availability of stationary phases. The self-contained system comprises a liquid 
mobile phase, with a solid stationary phase. The buffer mobile phase is controlled 
by pumps, with the buffers accessed through tubing from an external reservoir. 
The sample is introduced into the system through an injector and carried onto the 
column by the mobile buffer phase. Once in the column the sample mixture 
separates as a result of different components adhering to or diffusing into the 
stationary phase. 
 
Having determined the optimal IMAC purification strategy for CBP21 using 
Amersham Ni-NTA resin, large scale purification could be carried out using 
FPLC-compatible Fast Flow HisTrap columns (GE Healthcare). This automated 
approach is preferable for large scale purifications as it makes reproducible 
separation possible by incorporating a high level of automation, including a 
gradient control programme and peak collection, as well as offering high levels 
of control over variables such as flow-rate and pressure, while allowing for 
online monitoring of temperature, conductivity and absorbance.  
 
 
A sample FPLC purification profile of CBP21 purification is shown in Fig 3.19. 
The HisTrap column was washed with 10 column volumes of 20mM imidazole, 
followed by a second 10 column volume wash of 70mM imdazole. The protein 
was eluted using a 200mM imidazole wash. The elution profile can be visualised 
at OD280nm as shown in Fig 3.19 (blue line), with the corresponding SDS-PAGE 
analysis of each fraction shown in Fig 3.20 
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Fig 3.19: Purification of CBP21 over HisTrap Crude Column by FPLC. 
Purification profile of cleared cell lysate from a 500 mL expression culture for E. 
coli KRX expressing the protein CBP21 from the plasmid pCBP21_60, passed 
through the Amersham HisTrap FF crude 1 mL column, using FPLC (see Section 
2.18.2). The blue line indicates the absorbance at A280, the green line indicates 
the percentage of imidazole contained in the running buffer, while the red 
markers signify the fractionation of the eluent.  
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Fig 3.20: SDS-PAGE analysis of elution fractions resulting from the 
purification of CBP21 by FPLC-IMAC. Analysis by 12.5% SDS-PAGE and 
coomassie staining of fractions collected during CBP21 purification by IMAC 
using Ni
2+
 charged sepharose 1 mL FF column. Lane 1; Broad range protein 
ladder (see Section 2.23.3), Lane 2; Crude lysate, Lane 3; Column flowthrough, 
Lane 4, 20 mM Imidazole wash, Lane 5; 70 mM Imidazole wash, Lane 6; 200 
mM Imidazole elution, Lane 7; Broad range protein ladder. 
 
 
It was found that CBP21 could be purified successfully on the FPLC using the 
strategies found optimal in Section 3.4.1. The advantages of protein purification 
using FPLC include the ability to control parameters such as flow rate, whereas 
in manual purification one has to rely on gravity flow. It also allows for instant 
analysis of flow-through fractions using A280 readings, and for greater control of 
buffer concentrations and gradients.  In addition FPLC allows for the accurate 
quantitation of purified protein as well as the calculation of peak heights and 
peak areas. This saves time by eliminating the requirement for subsequent protein 
quantification assays. 
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 3.4.3 Buffer exchange of CBP21  
 
Desalting and buffer exchange are necessary steps following IMAC purification. 
Downstream processes, such as protein quantification assays and subsequent 
activity assays can be adversely affected by the presence of excess salts, 
specifically imidazole. There are a number of techniques available to achieve 
these goals, namely dialysis, ultra filtration membranes and size exclusion 
chromatography. Both desalting and buffer exchange can be achieved 
simultaneously using size exclusion chromatography (see Section 2.18.4).  
 
Desalting is accomplished by first equilibrating the chromatography column in 
dH2O, whereas buffer exchange is achieved by first equilibrating the buffer 
exchange column in the replacement buffer. When the protein sample to be 
desalted/buffer exchanged is loaded onto the column, the protein macromolecules 
will be too large to enter the pores of the resin and will quickly pass through the 
column. On the contrary the buffer salts will enter the pores of the resin, thus 
slowing their rate of migration through the column. As a result the protein sample 
will be buffer exchanged into the pre-equlibration buffer. Consequently the 
protein macromolecules can be recovered separately from the smaller salt 
molecules. 
 
Buffer exchange using a desalting column on an FPLC system saves time and 
labour when compared to the use of dialysis tubing or ultra filtration membranes. 
It allows for online analysis or OD280 readings and conductivity measurements, 
therefore giving a more accurate picture of complete buffer exchange as well as a 
brief insight into protein behaviour in alternative buffers (see Fig 3.21). 
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Fig 3.21: FPLC trace of CBP21 desalting and buffer exchange using the 
HiPrep 26/10 desalting column (GE Healthcare). A; CBP21 desalting into 
dH2O, B; CBP21 – desalting and buffer exchange into PBS (see Section 2.3). 
FPLC trace of CBP21 desalting and buffer exchange into dH2O and PBS 
respectively. The blue line indicates the absorbance at A280, conductivity readings 
are denoted by the brown line, while the red markers signify the fractionation of 
the flow-through. 
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Desalting and buffer exchange of CBP21 using the HiPrep 26/10 desalting 
column from GE Healthcare proved successful. Using this technique it was 
possible to separate CBP21 from the imidazole salts present in the IMAC buffers. 
Desalting of CBP21 into dH2O resulted in a sharp peak with a broad tail (see Fig 
3.21a). When desalting protein into a water-equilibrated column peak 
broadening, such as this, can occur, resulting in higher sample dilution and 
poorer separation than when a buffered solution is used. Buffer exchange of 
CBP21 into PBS was more favourable, CBP21 resolved in a sharp peak with no 
broadening tail (see Fig 3.21b). 
 
3.5 Total yield of recombinant CBP21 
 
The expression conditions for the production of recombinant C-terminally (His)6 
tagged CBP21 from pCBP21_60 were optimised. A purification strategy and 
buffer exchange strategy were also developed that allowed for the preparation of 
high yields of highly homologous recombinant CBP21. The average yield of cell 
paste following expression of CBP21 in 500 mL LB broth was 3.2 g. The average 
yield of CBP21 per g/cell paste, following IMAC purification and buffer 
exchange into PBS was 3.1 mg/g cell paste. 
 
3.6 Determination of protein size using size exclusion chromatography  
 
C-terminally (His)6 tagged CBP21 has been cloned into and expressed in E. coli. 
It is necessary to establish the protein size to determine if the N-terminal signal 
sequence is processed by E. coli. Previously, it has been shown that recombinant 
wild type CBP21 exists as a monomer, but crystallised as a dimer (Vaaje-
Kolstad, et al. 2005b). The effect of the affinity tag incorporation into the protein 
structures are less well understood and can have deleterious effects on protein 
activity as well as adverse effects on protein conformation (Fitzpatrick, et al. 
2004, Mohanty and Wiener 2004, Bucher, et al., 2002, Goel, et al. 2000). To 
validate further the tertiary structure of recombinant C-terminally (His)6 tagged 
CBP21 size exclusion chromatography (SEC) was employed. 
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3.6.1 Validation of CBP21 conformation using size exclusion 
chromatography 
 
Gel filtration separates proteins based on differences in size as they pass through 
a packed column. The larger proteins will pass through the matrix more hastily 
than smaller proteins, due to the retardation of lower relative molecular mass 
proteins within the porous beads of the gel filtration medium. This technique can 
be used to characterise proteins through comparison with a set of standards used 
to create a standard curve. Equation 3.1 was used to create the standard curves, 
the standards used included alcohol dehydrogenase (ADH), bovine serum 
albumin (BSA), bovine carbonic anhydrase, ovalbumin, myoglobin, soybean 
trypsin inhibitor and cytochrome C.  
 
 
Equation 3.1    
   
 
In equation 3.1 Vt represents the total fill volume, Vo the void volume and Ve the 
elution volume of the protein standard. The Kav values were plotted against the 
log of the molecular weight (MW) to create a standard curve (see Fig 3.25 and 
3.31). The elution of each protein from the column can be seen in Fig 3.24 and 
3.30. 
 
 
3.6.2 Size exclusion chromatography using Superdex 75 column 
 
The Superdex 75 gel filtration matrix (GE Healthcare) has a special composite 
matrix of dextran and agarose (see Fig 3.22), which links the excellent gel 
filtration properties of cross-linked dextran with the physical and chemical 
stability of highly cross-linked agarose. 
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Fig 3.22: Schematic view through a section of a bead of superdex. The 
average particle size is 13 µm. (Image taken from Amersham Ltd.) 
 
 
 
 
Fig 3.23: Determination of Superdex 75 total column and void volumes. The 
total column volume and void volumes for the Superdex 75 column were 
determined using the elution volumes of blue dextran and acetone. A void 
volume (Vo) of 7.73 mL was determined from the elution volume of blue dextran, 
and total volume (Vt) was 19.9 mL, determined with acetone. 
Dextran 
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Dextran Blue 
Acetone 
mL 
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Fig 3.24: Elution of protein standards from the Superdex 75 size exclusion chromatography column. The elution profile of protein 
standards using size exclusion chromatography with the Superdex 75 column. The optical densities at OD280 of the eluted standard proteins 
are plotted against the elution volumes. The elution volume of each protein was used in the construction of the standard curve (see Fig 3.25). 
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 Fig 3.25: Development of size exclusion chromatography standard curve 
using the Superdex 75 SEC column. The protein molecular weight standard 
curve was created using SEC with the Superdex 75 column (see Section 2.22). 
The elution volumes of protein standards were as follows; ADH; 9.13 mL, BSA; 
9.87 mL, Ovalbumin; 10.58 mL, Carbonic Anhydrase; 11.78 mL, Myoglobin; 
12.52 mL, Cytochrome C; 13.2 mL. These values were used to construct a plot of 
Kav versus log MW. This could be in turn used to calculate the relative MW of 
all protein samples that were eluted in this range. 
 
Table 3.1: Construction of a protein molecular weight standard curve for 
the Superdex 75 SEC column. 
 
 
 
 
Standard  
Elution 
Volume 
Expected 
MW (Da) 
log 
MW Kav 
Calculated 
Mw (Da) 
% 
Error 
ADH 9.13 80000 4.90 0.88 97240 21.55 
BSA 9.87 67000 4.82 0.82 66828 0.26 
Ovalbumin 10.58 45000 4.65 0.76 46631 3.63 
Carbonic 
Anhydrase 11.78 27000 4.43 0.66 25383 5.99 
Myoglobin 12.52 17000 4.23 0.60 17444 2.61 
Cytochrome C   13.20     12300    4.08 0.55 12359 0.48 
Cytochrome C 
Myoglobin 
Carbonic 
Anhydrase 
Ovalbumin 
BSA ADH 
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3.6.3 Investigation of protein compatibility with Superdex 75 SEC column 
 
CBP21 was passed over the Superdex 75 SEC column as outlined in section 
2.25.1. Initial runs suggested that the molecular weight of CBP21 as calculated 
from the elution volumes were too low (Table 3.2). The concentration of NaCl in 
the running buffer (PBS) was increased to 0.5 M, in an attempt to decrease the 
retention time. The expected size of CB21 without cleavage of the N-terminal 
signal sequence is 22709.3 Da, with the predicted mass with cleavage of the 
signal sequence 19860 Da. It was observed from table 3.2 that CBP21 had a 
similarly retarded elution volume in both 0.5 M NaCl replete and deplete PBS 
conditions in the Superdex 75 column (see Fig 3.26). 
 
Due to the high carbohydrate content of the matrix it is possible that passage 
through the packed medium may be further retarded through interaction with the 
sugar component. To investigate if any binding was occurring between CBP21 
and the column matrix CBP21 was applied to the column in the presence of 
competing sugars, as outlined in section 2.25.1. Any difference in elution 
volumes between sugar replete and deplete conditions could then be accounted 
for by matrix-protein interaction. It was found that the addition of competing 
sugars did not cause the protein to elute from the matrix any sooner (see Fig 
3.27), again resulting in lower than expected molecular weight calculations 
(Table 3.3). This could indicate either a non sugar-specific interaction with the 
column matrix or that the appropriate competing sugar was not used. This 
column is therefore not suitable for CBP21 characterisation. 
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Fig 3.26: The adsorption A280nm of CBP21 through the Superdex 75 column 
in the presence of PBS and PBS with 0.5 M NaCl.  The elution profile of 
CBP21 in PBS is indicated with a blue line, with the elution profile in PBS with 
0.5 M NaCl highlighted in red. Peak maxima are at 13.67 mL and 13.43 mL 
respectively. 
 
 
Table 3.2: Molecular mass calculation using the Superdex 75 SEC column. 
Running Buffer Elution 
Volume 
Kav Log 
MW 
Calculated 
MW 
PBS 13.67 0.51 3.99 9739 
PBS  (500 mM NaCl) 13.43 0.53 4.04 10999 
 
 
 
mL 
mAU 
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Fig 3.27: The adsorption A280nm of CBP21 through the Superdex 75 column 
in the presence of galactose, glucose and GlcNAc.  The elution profile of 
CBP21 in PBS is indicated in blue, galactose is indicated in red, glucose is 
indicated with a pink line, with the elution profile of CBP21 in GlcNAc indicated 
in brown. Peak maxima are at 13.43 mL, 13.57 mL, 14.65 mL and 13.53 mL 
respectively. 
 
 
Table 3.3: CBP21 molecular mass calculations under sugar replete 
conditions, using the Superdex 75 SEC column. 
Running Buffer Elution 
Volume 
Kav Log 
MW 
Calculated 
MW 
PBS + 0.2 M GlcNAc 13.53 0.52 4.01 10245 
PBS + 0.2 M Glucose 14.65 0.43 3.77   5927 
PBS + 0.2 M Galactose 13.57 0.52 4.02 10455 
 
 
 
mL 
mAU 
136 
 
3.6.4 Investigation of protein compatibility with Toyopearl HW-55S 
 
As CBP21 interacted with the matrix in the Superdex 75 gel filtration column, it 
was decided to use another gel filtration matrix to examine protein size and to 
investigate if any non-specific interactions were causing the unexplained protein 
size. The Toyopearl SuperButyl-550 (HW-55S base bead) (Tosoh Bioscences, 
Germany) column matrix is composed of methyl-methacrylate, the compounds 
structure is displayed in fig 3.28, and has no carbohydrate component. As a 
result, it could be said that this matrix would be more suitable for the 
examination of carbohydrate binding molecules.  
 
The HW-55S column had to be poured manually and as a result an extra column 
validation step had to be carried out. Column performance was checked at regular 
intervals, as manually poured columns can be susceptible to compaction over 
time. The number of theoretical plates (N), the figure used to validate column 
efficiency, was determined using the following equation.  
 
 
Equation 3.2    
  
 
In this equation, Ve corresponds to the retention volume; V1/2 is the peak width at 
half the peak height; and L the peak height (mm). Depending on the matrix type, 
typical values for column performance will vary. Values are calculated by 
running 0.5 mL of 1% (v/v) acetone over the column at the flowrate to be used 
for running samples. The retention time measured is at OD280nm. The resulting 
elution profile can be seen in fig 3.29. Values for L, Ve and V1/2 are measured 
from this profile and imputed into equation 3.2, to obtain N. This is then 
compared to manufacturers‟ operating parameters to determine if the column is 
operational. 
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Fig 3.28: Polymeric structure of methyl methracylate. The hydroxylated 
polymeric structure that forms the filtration matrix in the SEC column HW-55S. 
R is a hydroxylated aliphatic group. Image produced using Chemsketch. 
 
 
 
Fig 3.29: Determination of Toyopearl HW-55S column efficiency. The elution 
profile of blue dextran and acetone (1% v/v) using SEC with the Toyopearl HW-
55S column. The optical density at OD280nm of eluted blue dextran and acetone 
are plotted against the elution volumes. The void volume (elution volume for 
blue dextran was determined to be 39.67 mL. The total volume (elution volume 
for acetone) was determined to be 97.45 mL.  
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Prior to any investigation using the Toyopearl HW-55S column its efficiency was 
determined using equation 3.2 and the values obtained from Fig 3.29. The 
theoretical plate count for this column was calculated to be 8,284 which is within 
the operable range (3,500 – 10,000) for this matrix. Before the unknown relative 
molecular mass of a protein could be determined a molecular weight standard 
curve was constructed as before for the Superdex 75 column (see Section 3.6.2). 
The standards used were in the range of the expected size of CBP21, with the R
2
 
value of the standard curve 0.98 (see Fig 3.31). 
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Fig 3.30: Elution of protein standards from the Tyopearl HW-55S size exclusion chromatography column. The elution profile of 
protein standards using size exclusion chromatography with the Tyopearl HW-55S column. The optical density at OD280 of eluted standard 
proteins are plotted against the elution volume. The elution volume of each protein was used in the construction of the standard curve (see 
Fig 3.31). 
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Fig 3.31: Development of size exclusion chromatography standard curve 
using the Toyopearl HW-55S SEC column. The protein molecular weight 
standard curve was created using SEC with the Tyopearl HW-55S SEC column 
(see Section 2.25). Void volume (Vo) of 39.67 mL was determined from the 
elution volume of blue dextran, and total volume (Vt) was 97.45 mL, determined 
with acetone. The elution volumes of protein standards were as follows; BSA; 
55.66 mL, Ovalbumin; 57.80 mL, Carbonic Anhydrase; 61.70 mL, Soybean 
trypsin inhibitor; 65.89 mL, Cytochrome C; 71.40 mL. These values were used to 
construct a plot of Kav versus log MW. This could be in turn used to calculate 
the relative MW of all protein samples that were eluted in this range. 
 
Table 3.4: Construction of a protein molecular weight standard curve for 
the Tyopearl HW-55S SEC column. 
Standard  
Elution 
Volume 
Expected 
MW (Da) 
log 
MW Kav 
Calculated 
Mw (Da) 
% 
Error 
BSA 55.66 66000 4.82 0.72 59778 9.43 
Ovalbumin 57.80 45000 4.65 0.69 47769 6.15 
Carbonic 
Anhydrase 61.70 29000 4.46 0.62 31771 9.56 
Soybean 
trypsin 
inhibitor 65.89 20100 4.30 0.55 20500 1.99 
Cytochrome C    71.40 12300 4.09 0.45       11521 7.08 
Cytochrome  C 
Soybean 
Trypsin 
Inhibitor 
Carbonic 
Anhydrase 
Ovalbumin 
BSA 
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3.6.5 Investigation of CBP21 compatibility with Toyopearl HW-55S column 
 
Having successfully created a standard curve for the Toyopearl SEC column the 
relative molecular mass of CBP21 was estimated using this standard curve (see 
Fig 3.31). CBP21 was applied to the Toyopearl HW-55S column as outlined in 
section 2.25.2, and was run three times with a representative elution profile 
shown in Fig 3.32. The predicted mass of CBP21 without cleavage of the signal 
sequence is 22709.3 Da, with the predicted mass with cleavage of the signal 
sequence 19860 Da. The average elution volume for CBP21 was 66.46 mL (see 
Fig 3.32) which correlates to a molecular mass of 19314 Da, indicating that 
CBP21 is a monomer, which is processed within an E. coli cell with cleavage of 
the signal sequence.  
 
 
 
Fig 3.32: Elution profile of CBP21 in PBS pH 7.2 from the Toyopearl HW-
55S SEC matrix. The elution profile of CBP21 using SEC with the Toyopearl 
HW-55S column. The optical density at OD280nm was plotted against the 
elution volume. The peak maximum was at 66.46 mL.  
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3.7 Mass Spectrometry 
 
Mass spectrometry is an analytical technique used to determine the mass of 
particles, through measurement of the mass-to-charge ratio of charged particles. 
The molecule is first loaded into the MS instrument where it undergoes 
vaporisation, followed by ionization. The charged ions are subsequently 
separated according to their mass-to-charge ratio, with the ion signal processed 
into a mass spectrum (see Fig 3.33).  
 
In order to confirm the size of the CBP21 protein expressed from pCBP21_60 
electrospray ionization mass spectrometry coupled with a nanoflow Z-spray 
source was carried out (see Section 2.28). A mass spectrometry method named 
collision-induced dissociation (CID) was used to break up ions in the gas phase. 
It dissociates the ions, in this case charged proteins, by accelerating them under 
high electric potential in the vacuum of the mass spectrometer, before collision 
with a neutral gas. The transfer of kinetic energy to internal energy within the 
analyte results in bond breakage. Results obtained could then be compared with 
those obtained from the SEC as described in section 3.6. 
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Fig 3.33: Manually de-convoluted mass spectrum of CBP21 in 50% ACN, 50% H2O and 0.2% formic acid, using the nano flow Z-
spray source. CBP21 was analysed using the nano flow Z-spray source and 50% ACN, 50% H2O and 0.2% formic acid as a solvent. The 
calculated molecular mass of CBP21 was 19857.29 ± 0.33 Da. 
 
 
144 
 
Fig 3.33 shows that the molecular mass of CBP21 to be 19857.29 ± 0.33 Da. The 
predicted mass of CBP21 without cleavage of the signal sequence is 22709.3 Da, 
with the predicted mass with cleavage of the signal sequence 19860 Da. This 
indicates that E. coli is capable of recognising the N-terminal native CBP21 
signal sequence, transporting CBP21 to the periplasm where cleavage of the 
signal sequence occurs. 
 
 
3.8 Insoluble substrate assays 
 
It has been established that it is possible to express soluble CBP21 protein from 
pCBP21_60 (see Section 3.2), and purify this protein to homogeneity (see 
Section 3.4). In order to determine if the (His)6 tagged protein is active, solid 
substrate activity assays were undertaken. Wild type untagged CBP21 has 
previously been shown to bind to β-chitin, and to avicel (crystalline cellulose) to 
a lesser extent (Vaaje-Kolstad, et al. 2005b, Vaaje-Kolstad, et al. 2005a). These 
polymeric substrates are insoluble, unless dissolved in an acidic solution, 
conditions unfavourable for a protein activity assay. Many chitin binding proteins 
and chitin binding protein domains also appear to bind the chitinous polymers so 
tightly that conventional methods for eluting proteins from a matrix are 
ineffective (Howard, et al. 2003). However, SDS-PAGE loading dye can be used 
to elute bound proteins for gel analysis. Assessment of CBP21 interaction with 
the insoluble substrates chitin from crustacean shells (α-chitin), chitosan from 
crustacean shells (α-chitosan), chitin from squid bone (β-chitin), chitosan from 
carapacea skin and avicel was typically carried out as described in section 2.26, 
with mixing for 16 hrs (overnight). 
 
The specificity of CBP21 for various insoluble substrates is shown in Fig 3.34 
and 3.35. CBP21 appeared to bind equally well to α-chitin from crustacean shells 
and β-chitin from squid pen. Crystalline cellulose appeared to be the next best 
substrate in terms of CBP21 affinity. A little interaction between CBP21 and the 
chitosan from carapacea skin is observed in Fig 3.35b, with no interaction 
recorded with α-chitosan from crustacean shells. 
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Fig 3.34: Efficiency of binding of CBP21 to various insoluble substrates. A; Crustacean shell chitin, B; Avicel, C; Chitosan from 
crustacean shells. 12% SDS-PAGE analysis of CBP21 insoluble substrate assay. Lane 1; Broad range protein ladder (see Section 2.23.2), 
Lane 2; Crude CBP21 sample, Lane 3; column flowthrough, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21-substrate sample, Lane 
7; Boiled PBS - substrate sample, Lane 8; Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 3.35: Efficiency of binding of CBP21 to various insoluble substrates, A; squid pen chitin, B; chitosan from carapacea skin. 12% 
SDS-PAGE analysis of CBP21 insoluble substrate assay.  Lane 1; Broad range protein ladder (see Section 2.23.2), Lane 2; Crude CBP21 
sample, Lane 3; column flowthrough, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21-substrate sample, Lane 7; Boiled PBS-
substrate sample, Lane 8; Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
A B 
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3.9 Discussion 
 
The chitin binding protein CBP21 was successfully cloned, expressed and 
characterised, with regard to chitin binding. Extensive optimisation of its 
expression was essential due to the ample amount of homologous protein 
required for characterisation, such as size exclusion chromatography, mass 
spectrometry and activity assay development. The ability to produce large 
amounts of recombinant protein is also a pre-requisite if this molecule was to be 
incorporated onto an affinity matrix or into array format. 
 
The cbp21 gene was successfully cloned from S. marcescens koln genomic DNA 
(see Section 3.2). As outlined in sections 3.2.1 and 3.2.3 a number of constructs 
were examined, in order to study the effect of the position of the (His)6 tag, and 
N-terminal signal sequence. The position of the (His)6 tag and/or presence of the 
signal sequence were found to influence, greatly, the solubility of the target 
protein. The incorporation of a (His)6 tag at either end of the protein was 
necessary for downstream protein purification using IMAC. Expression of N-
tagged (His)6 whole protein expression from pCBP21_30 resulted in protein 
localization to the insoluble fraction, with expression of C-tagged (His)6 protein 
from pCBP21_60 resulting in soluble protein expression.  
 
There are a number of reasons for insoluble protein production; including, 
incorrect protein folding, incorrect formation of disulphide bonds and the 
presence of inherent hydrophobic regions. As soluble CBP21 has previously been 
produced recombinantly, using E. coli, it was known that it is not an inherently 
insoluble protein. What was known, however, was that in S. marcescens the 
CBP21 protein is known to be involved in the degradation of chitin substrates 
outside the cell (Vaaje-Kolstad, et al. 2005a, Suzuki, et al. 1998, Suzuki, et al. 
2002). In order for extracellular interactions to occur it is required that the protein 
is secreted from the cell, where it can gain access to the chitin polymers. 
Secretion of the protein from the cell requires that it must first be recognised by 
intracellular mechanisms. To facilitate this recognition and secretion CBPs have 
signal sequences at the N-terminus of the protein (~25aa). The signal peptide is 
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cleaved by a periplasmic signal peptidase when the exported protein reaches the 
periplasm.  
 
In the case of pCBP21_30 the signal sequence and (His)6 tag are both situated at 
the N-terminus, it was therefore possible that the position of the (His)6 was 
interfering with the recognition of the signal sequence by E. coli. The cells 
inability to recognise the signal may have been preventing the protein from being 
transported to the correct cellular location, where correct protein folding could 
occur. It was also possible that the (His)6 tag was not interfering with the 
recognition of the signal sequence and was simply preventing correct protein 
folding due to its position at the N-terminus. Although expression from 
pCBP21_60 gave rise to soluble CBP21 it was unclear at this point if E. coli was 
equipped to recognise the N-terminal signal sequence and perform the necessary 
cleavage. 
 
Through sub-cloning the expression plasmids pCBP2130_N and pCBP2160_N 
were generated from pCBP21_30 and pCBP21_60 respectively. These plasmids 
expressed N- or C-tagged (His)6 protein without the native leader sequence. 
While expression from pCBP2130_N resulted in no target protein over 
expression, CBP21 expressed from pCBP2160_N accumulated with the insoluble 
proteinaceous material, thus removal of the signal sequence had an adverse effect 
on protein solubility. This result suggested that the N-terminal signal sequence is 
recognised by E. coli, and is required for soluble protein expression. 
 
The position of the N-terminal sequence is such that it could lie over the 
theoretical protein active site (see Fig 3.36). To confirm that E. coli was capable 
of recognising the native N-terminal signal sequence and transporting CBP21 
across the inner cell membrane to the periplasmic space, cell compartmental 
analysis was undertaken (see Section 3.2.4). Having ascertained that E. coli was 
transporting CBP21 to the periplasm it was still unclear if cleavage of the signal 
sequence was occurring. 
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Fig 3.36: A 3-D structure of the theorized active site of CBP21. Image of the 
3-D structure of CBP21. The residues thought to the responsible for chitin 
binding are highlighted in blue. The first N-terminal residue following cleavage 
of the mature protein is highlighted in yellow. The final C-terminal residue is 
indicated with orange. 
 
Following the successful expression of soluble CBP21 from pCBP21_60, 
expression optimisation was carried out (see Section 3.3). Colony blot analysis 
was undertaken to determine the optimal genotype for expression of recombinant 
CBP21. Four E. coli strains, XL-10 Gold, KRX, JM109 and BL21, were 
transformed with pCBP21_60, to express C-terminally (His)6 tagged CBP21 (see 
Section 3.3.1). The most affluent clone from each of the four strains was 
submitted to expression analysis by SDS-PAGE, with KRX selected as the most 
efficient clone for recombinant CBP21 expression. IPTG induction levels, 
incubation temperatures and harvest times were subsequently examined (see 
Section 3.3.2).  
 
 
Asn 185 
Asp 182 
Thr 183 
Glu 60 Glu 55 
Tyr 54 
Pro 56 
Tyr 30 
Gln 57 
Ser 58 
His 114 
57 Ala 112 
57 
Thr  111 
57 
His 28 
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As IPTG concentrations and incubation temperature can influence cell growth 
rate, cultures may not be directly comparable, due to different cell densities. To 
combat this, all cultures were inoculated from the same starter culture and 
samples were also diluted to the same OD prior to cell harvest and analysis by 
SDS-PAGE. The effect of induction with varying levels of IPTG was 
investigated by looking at the percentage of soluble and insoluble product 
produced at certain stages of fermentation. It was concluded that increasing the 
IPTG concentration did result in increased levels of recombinant protein 
expression to the soluble protein fraction (see Fig 3.14), and that dramatically 
increasing the IPTG concentration did not lead to product accumulation in the 
insoluble fraction and did not adversely affect the cells growth rate (see Fig 
3.15). From whole cell lysate analysis it was also determined that the optimal 
incubation temperature was 37°C with a harvest time at 6 hours post induction 
(see Fig 3.16). A harvest time of 6 hours post induction would necessitate 
immediate processing or overnight protein storage of the cell lysate.  Although 
KRX is deficient in ompT and ompP proteases it has been observed (Creavin 
2010) that prolonged protein exposure to other intra/extracellular proteases can 
cause protein degradation. Incubation at 30°C with overnight incubation would 
lend itself to higher cell densities compared to T = 6 with an increased amount of 
protein per cell. A morning harvest time would also lend itself to immediate 
downstream processing, thus reducing any prolonged protein exposure to 
proteases. 
 
Having evaluated the conditions for optimal expression of CBP21 from E. coli a 
purification strategy was investigated. Due to the presence of the (His)6 tag on 
the proteins C-terminus an IMAC purification strategy could be employed. The 
imidazole elution profile (see Fig 3.18) was used to establish suitable strategy for 
IMAC purification of (His)6 tagged CBP21. The standard elution profile 
consisted of using a concentration of 20mM Imidazole in the binding buffer 
(wash buffer 1), followed by an intermediate wash step using 70 mM Imidazole 
(wash buffer 2), with a concentration of 200 mM Imidazole used for the elution 
of CBP21 from the matrix, free from any contaminants. These optimised 
conditions were transferred to the automated FPLC system, to aid in the large-
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scale purification of recombinant proteins. The high level of purity obtained 
using IMAC can be seen in Fig 3.20. PBS was determined to be the most 
appropriate buffer for buffer exchange (see Fig 3.21). Using these standard 
expression and purification procedures, (His)6 tagged CBP21 concentrations of 
up to 3.1 mg per g of cells were achieved. 
 
A general feature of lectin binding sites is that they consist of a primary binding 
site that is capable of binding an individual monosaccharide unit, usually with a 
low affinity. This weak affinity is most often compensated for by the presence of 
multiple subunits (Loris, 2002). Consequently, any disruption to the lectins 
quaternary structure may have a greater impact on the lectins ability to interact 
with its target molecule. The crystal structure of CBP21 was determined by 
Vaaje-Kolstad et al., (2005b), where it crystalised as a dimer. Their biochemical 
studies however suggested that CBP21 was a monomer in solution. In order to 
corroborate CBP21 conformation size exclusion chromatography was 
undertaken.  
 
Initial gel filtration studies were undertaken using the Superdex-75 column from 
GE Healthcare. It was observed that the carbohydrate matrix impeded protein 
migration through the column. This migration retardation was not reverse by the 
addition of increased concentrations of NaCl (0.5M) to the running buffer nor 
excess free sugars GlcNAc, glucose, galactose (table 3.2). As the matrix consists 
of cross-linked dextran (polymeric glucose) and agarose (polymeric galactose), it 
is conceivable that while CBP21 does not appear to bind to the free 
monosaccharide sugar units in this instance, it may potentially interact with their 
polymeric counterparts. An alternative carbohydrate-free matrix, Toyopearl HW-
55S, was subsequently employed for size exclusion studies. The relative 
molecular mass predicted for CBP21 using the Toyopearl-HW55S matrix was 
19213 Da.  The actual relative molecular mass for CBP21 without cleavage of 
the signal sequence is 22709, with the predicted mass with cleavage of the signal 
sequence 19860 Da. This result would indicate that the passage of CBP21 
through the Toyopearl-HW55S matrix is not impeded, and that CBP21 exists in 
solution as a monomer.  
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The molecular mass of CBP21 as calculated from gel filtration also suggests that 
it exists in the periplasmic space in its processed form. Differences in the 
theoretical size as compared with the size calculated from gel filtration may be 
explained by the fact that the majority of standards used for the creation of the 
standard curve are globular proteins, thus it serves only as a rough estimate as to 
the size of non-globular shaped molecules. The Toyopearl-HW55S column was 
also poured manually, as a result the matrix will not give the same resolution as 
commercial columns, such as the Superdex 75 column. Therefore mass 
spectrometry was employed to determine the molecular mass of CBP21. The 
results obtained from mass spectrometry largely agreed with those from the size 
exclusion chromatography studies. The molecular mass as calculated using the 
nano-spray Z-spray source was 19857.29 ± 0.33 Da. This result confirms 
previous results that CBP21 exists in solution as a monomer, and that the protein 
is processed in E. coli, with the removal of the N-terminal signal sequence, thus 
theoretically displaying an accessible active site. The slight difference between 
the actual and calculated molecular mass of CBP21 of 2.71 ± 0.33 Da can be 
explained by slightly inaccurate calibration of the instrument with mass spec 
standards. 
To confirm that the purified (His)6 tagged CBP21 was active insoluble substrate 
assays were undertaken using a number of insoluble chitin and polymer derived 
substrates (see Fig 3.34 and 3.35). These assays confirmed that the recombinant 
CBP21 was active, and capable of binding to a number of different polymeric 
substrates, chitin in the α and β formation, chitosan and crystalline cellulose. 
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4.0 CBP21 Characterisation 
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4.1 Investigation of recombinant CBP21 affinity for glycoproteins 
 
Following the preliminary characterisation of CBP21 with regards to its 
specificity for various insoluble chitin substrates (Section 3.8), a number of 
experiments were undertaken to examine the potential of CBP21 for use as a 
novel carbohydrate-binding molecule. This was carried out by investigating the 
specificity, if any of CBP21 for protein-linked glycans.  
 
4.1.1 ELLA analysis of CBP21 
 
The principle of the ELLA, similar to an ELISA has been outlined in section 
1.5.5. In this study the primary antibody present in an ELISA has been replaced 
by a carbohydrate-binding protein, with the protein target a glycoprotein. As 
stated previously a (His)6 affinity tag has been engineered into the recombinant 
protein, CBP21, which will allow for detection of CBP21–glycoprotein 
interaction, through the use of an anti-His murine antibody. The potential 
affinities of recombinant carbohydrate-binding proteins can be studied through 
the comparison of the binding profiles of biotinylated plant lectins. All lectin, 
glycoprotein and antibody concentrations are outlined in section 2.27. Calcium, 
magnesium and manganese are known to be required for the function of some 
plant lectins, due to the location of the ions in the sugar binding pocket. The 
dependence of CBP21 on metal ions is thus far unknown.  
 
The binding of CBP21 to an array of glycoproteins was investigated, with the 
molecule showing no preference for any of the glycoproteins tested (see Fig 4.1).  
The glycoproteins used in this study were; bovine fetuin, bovine asialo fetuin, 
ovalbumin from chicken egg white, glucose oxidase from Aspergillus niger, 
invertase from Saccharomyces cerevisiae, bovine hyaluronidase and porcine 
thyroglobulin.  
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Fig 4.1: Comparison of CBP21 and GSLII ELLA binding profiles. 
Quantititive detection of carbohydrate-binding proteins bound to various 
glycoproteins, assayed by the activity of a HRP-linked antibody (OD450nm). The 
binding profiles of CBP21 and GSLII, a comercially available plant lectin that 
has a binding preference for terminal GlcNAc, were compared.  CBP21 did not 
have a similar glycoprotein binding profile to that of GSLII, and did not appear 
to interact with any of the glycoproteins tested to any extent.  
 
 
As stated in section 1.17.2 the know binding characteristics of CBP21 suggest 
that it may be capable of interacting with the terminal GlcNAc or core chitobiose 
structures of N-linked glycans. As outlined in section 1.4.1 mammalian lectins 
often contain terminal sialic acid or galactose, with terminal mannose residues 
most common among glycoproteins from yeasts and other microorganisms. 
Naturally occuring glycans with exposed terminal GlcNAc are more difficult to 
come across, while due to the nature of glycan synthesis it would prove 
impossible to find a glycoprotein displaying a simple core chitobiose structure. 
Glycan „customisation‟ is therefore necessary to achieve the glycan structures 
required for CBP21 analysis.  
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Custom chemical synthesis of complex glycans, perhaps displaying terminal 
GlcNAc structures is a very expensive and time consuming process. The small 
quantities that could be produced in this manner would be inadequate for 
comprehensive carbohydrate-binding protein characterisation. A more 
straightforward way of creating a „customised‟ glycan is through glycosidase 
treatment of pre-existing structures.  
 
4.1.2 Glycoprotein treatments 
 
The use of well defined glycosyl-hydrolases for the sequential hydrolysis of 
oligosaccharides is a technique commonlly used for the sequencing of 
glycoproteins. A wide variety of exo- and endoglycosidases, mostly of bacterial 
origin (Wongmadden and Landry 1995), are available commercially. In this 
instance a neuriminidase enzyme from Clostridium perfringens, capable of the 
hydrolysis of α 2-3, α 2-6 and α 2-8 linkages was used to cleave terminal sialic 
acid sturctures, while a β-galactosidase from Bacteroides fragilis, with a 
specificity for β 1-4 linkages was used for the hydrolysis of terminal galactose. 
The parameters of deglycosylation can vary with each glycoprotein, therefore 
they must be determined empirically (Tarentino and Plummer Jr. 1994). Two 
glycoproteins were chosen for glycosidase treatment and ELLA analysis, namely 
human transferrin and porcine thyroglobulin. 
 
Transferrins are monomeric glycoproteins that function in iron binding. Human 
transferrin has two N-glycosylation sites at Asn
413
 and Asn
611
, occupied by either 
bi-, tri- or tetraantennary glycans (Spik, et al., 1975, Dorland, et al., 1977, Spik, 
et al., 1985). Due to the natural heterogeneity of the glycan  stuructures whole 
serum transferrin includes a pool of glycovarients, 9 different transferrins can be 
separated electrophoretically due to differences in sialic acid content, with the 
two most abundant structures displayed in Fig 4.2 (De Jong and Van Eijk, 1989). 
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4.2 Structures of the two most anundant bi-antennary N-linked glycans 
present in human transferrin. Schematic representation of the structure of the 
most abundant glycan structure present on human transferrin (De Jong and Van 
Eijk 1989). 
 
Thyroglobulin is a high molecular weight glycoprotein, which is the polypeptide 
precursor of the thyroid hormones. Analysis of thyroglobulin from several 
species has shown that two main carbohydrate species occur, unit-A type 
(oligomannose) and unit-B type (N-acetyllactossamine type). Porcine 
thyroglobulin is known to contain approximately 300 monosaccharides per 
molecule  (Spiro 1965), of which unit-B type (see Fig 4.3) is the most abundant 
(Kamerling, et al., 1988). 
 
 
 
 
 
 
 
  
  
 
Fig 4.3: Structure of unit-B type glycan structure present on porcine 
thyroglobulin. Cartoon structure of the most abundant glycan structure present 
on porcine thyroglobulin (Kamerling, et al., 1988). 
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Sequential treatment of these glycoproteins with neuriminidase and β 1-4 
galactosidase should result in structures presenting terminal GlcNAc. Fig 4.4 
displays a simplified version of the glycan structures expected following each 
glycosidase treatment.  
 
 
 
 
 
 
   
 
 
Fig 4.4: Glycoprotein terminal structures following glycosidase treatments, 
A; untreated glycoprotein, B; Asialo glycoprotein, C; Asialo Agalacto 
glycoprotein. Cartoon structure of the expected glycan patterns on human 
transferrin and porcine thyroglobuling following sugar release by glycosidases. 
Glycosidase treatment of glycans will results in the exposure of different terminal 
sugars. Neuriminidase enzymes will cleave all terminal sialic acid structures, 
while β 1-4 galactosidases will remove any terminally exposed β 1-4 linked 
galactose, exposing terminal GlcNAc. 
 
 
ELLA analysis was carried out using untreated, neuraminidase and β 1-4 
galactosidase treated transferrin and thyroglobulin. Glycoprotein samples were 
also probed with a number of biotinylated plant lectins, to compare binding 
profiles, and to gauge the efficiency of deglycosylation (see Fig 4.5). From these 
results it was evident that while the degylcosylation was successful, CBP21 was 
unable to bind to terminal GlcNAc or core chitobiose in this assay format. 
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Fig 4.5: Quantitative detection of carbohydrate-binding protein interaction 
with A: Transferrin and B: Thyroglobulin. ELLA analysis of CBP21 and 
glycosidase treated transferrin and thyroglobulin. SNA is a terminal sialic 
binding lectin, ECL has a binding preference for terminal galactose, GSL II is a 
terminal GlcNAc binding lectin, DSL has been characterised as a chitin binding 
lectin, that appears to bind to core chitobiose. 
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While a neuriminidase and a β-galactosidase can be used to cleave terminal sialic 
acid and galactose structures, exposing the underlying galactose and GlcNAc 
residues, on both transferrin and thyroglobulin glycans, it is a more ardous task to 
cleave the underlying core mannose residues in order to expose the chitobiose 
core.  
 
Invertase is an enzyme that has the ability to breakdown sucrose to fructose and 
glucose. Invertase also has a high carbohydrate component, which assists in 
correct protein folding, with all glycans of the high mannose type. Removal of 
the high mannose core structure was attempted using an N-acetylhexosaminidase 
and a α1-2,3 and α1-6 mannosidase from Xanthomonas manihotis. 100% 
cleavage of the core mannose structure to expose core chitobiose proved 
unachievable (see Fig 4.6). 
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Fig 4.6:  β-N-acetylglucosaminidase and mannosidase treatment of invertase. 
Quantatitive detection of lectin binding to untreated and β-N-
acetylglucosaminidase and mannosidase treated invertase from Saccharomyces 
cerevisiae. NPL, GNL, ConA, GSLII and DSL are biotinylated plant lectins that 
have binding preferences for α1-6 (poly) mannose, α1-3 mannose, α-linked 
mannose/core mannose, α- or β- linked terminal GlcNAc, and GlcNAc oligomers 
respectively. 
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CBP21 did not appear to interact with any of the sugar species, sialic acid, 
galactose, GlcNAc, mannose or chitobiose, terminal or otherwise, in ELLA 
analysis (see Fig 4.5). The format of the ELLA may not be suitable for the 
characterisation of CBP21 in terms of glycan binding. An alternative method to 
determine if CBP21 can interact with the glycans attached to proteins is 
glycoprotein affinity chromatography.  
 
4.1.3 Glycoprotein affinity chromatography 
 
While the use of lectin affinity chromatography for the isolation of glycan 
species is prevalent (Section 1.5.5), the use of glycoproteins for the profiling of 
lectins is less commonplace. The latter can be achieved quite easily using a 
variety of surface chemistries. Cyanogen bromide-activated resins are one such 
surface that is commercially available and user friendly (Kohn and Wilchek 
1982). The procedure for the coupling of proteins to cyanogen bromide activated 
surfaces is outlined in Fig 4.7.  
 
   
 
 
  
   
 
 
Fig 4.7: Reaction activation scheme of sepharose by cyanogen bromide and 
protein coupling through primary amines. Cyanogen bromide (CnBr) under 
basic conditions reacts with the –OH groups on agarose, forming reactive cyanate 
ester groups. These groups react with primary amines on the protein surface 
under very mild conditions, resulting in a covalent coupling of the ligand to the 
sepharose matrix  
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4.1.4 Invertase affinity chromatography 
 
While terminal GlcNAc residues can be exposed through hydrolase treatment of 
oligosaccharides the enzymes are expensive, limiting the amount of glycoprotein 
that can be treated. Milligram quantities of glycoprotein are required for coupling 
to cyanogen bromide activated sepharose, therefore coupling of glycosidase 
treated glycans is not an option in this case. The glycans displayed on the surface 
of invertase are of the high mannose type. If CBP21 is capable of binding to the 
core chitobiose structure, the absence of galactose, sialic acid and/or bisecting 
fucose structures means that invertase oligosaccharides are smaller structures 
when compared with the more complex glycans of transferrin or thyroglobulin, 
theoretically resulting in less steric hindrance, giving the greatest chance of 
observing any interaction by CBP21. Previously GSLII, a plant lectin with an 
affinity for terminal GlcNAc has the shown the highest affinity for invertase 
compared to other glycoproteins (see Fig 4.1). 
 
Invertase was coupled to the cyanogen bromide activated sepharose-4B, bound 
by the exposed primary amines on the molecules surface, as outlined in section 
2.29. Table 4.1 summarises the extent of invertase immobilisation.  The lectin 
capture ability of the invertase resin was validated using the mannose binding 
lectin NPL. The binding profile of NPL was then compared to that of CBP21 
using OD280nm readings (see Fig 4.8).  
 
Fig 4.8 shows the attempted capture of CBP21 using invertase resin. If CBP21 
was capable of binding invertase one would expect the unbound sample flow-
through to contain less CBP21 than was loaded onto the column. 50 µg of CBP21 
was loaded on to the resin, with an OD280nm reading of 0.072, CBP21 flow-
through (OD280nm 0.0426) and wash samples 1-3 (OD280nm 0.028, 0.008, 0.004) 
were estimated to contain the entire loaded sample, indicating that no CBP21 was 
captured on the affinity resin. 
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Table 4.1: Immobilisation of invertase to cyanogen bromide activated 
sepharose 4B. 
Starting 
Invertase 
Dry weight 
resin 
Unbound 
Invertase  
Bound 
Invertase 
mg Invertase/ 
mL resin 
20 mg 0.66 g 5 mg 15 mg 7.5  
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Fig 4.8: Application of carbohydrate-binding proteins to sepharose bound 
invertase. OD280nm readings of invertase affinity chromatography using NPL and 
C BP21. The resin was pre-equilibrated with binding buffer until OD280nm 
reached 0.000 (fraction 1). 1 ml of 50 µg/mL carbohydrate-binding proteins were 
then added to and mixed with 500 µL of invertase resin for 1 hr at room 
temperature. The column flow-through was collected (fraction 2), and the resin 
was washed with 5 x 1 mL of binding buffer (fractions 3-7), until the readings at 
OD280nm returned to 0.000. Bound protein was eluted by the addition of 0.2 M 
mannose (fractions 8-12). 
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4.2 Establishment of a CBP21 activity assay  
 
Although it has been show in section 3.8 that recombinant CBP21 is active and 
capable of binding to large chitin and chitin related polymers, it has not yet been 
established if CBP21 can bind to protein attached glycan structures. If a potential 
exists for CBP21 to interact with the chitobiose core of a glycan it is necessary to 
show that CBP21 can bind to smaller chitin units, such as chitobiose ((GlcNAc)2) 
or chitotriose ((GlcNAc)3). The most straightforward assaying technique would 
be in line with an ELLA, in 96-well MaxiSorp plate assay format. The MaxiSorp 
surface is a highly charged polystyrene surface with a high affinity to molecules 
with polar or hydrophilic groups. For direct immobilisation of a sugar molecule it 
would need to be attached to a support polymer, in the form of a glycoconjugate.  
 
The use of neo-glycoconjugates for carbohydrate-binding protein profiling has 
escalated over the past two decades, in diverse fields, from xenotransplantation 
(Buonomano et al., 1999) to affinity electrophoresis (Rye and Bovin, 1998). 
They have been exploited for use in the study of carbohydrate active enzymes 
(Bovin, 1998, Dupuy et al., 1999), in the development of binding assays for cell 
adhesion molecules, including selectins and siglecs (Weitz-Schmidt et al., 1996), 
as a tool for the study of lectins expressed on tumour cells  (Kurmyshkina et al., 
2010), and most recently in the development of an expression system that permits 
genome-wide screening of proteins for interactions with glycans and proteins 
(Otto et al., 2011). 
 
Both uni- and multivalent glycoconjugate polymers are available from several 
companies including Glycotech (http://www.glycotech.com/index.htm) and 
Lectinity (http://www.lectinity.com/index.php). Polymers may be purchased in 
multiple formats included unlabelled, biotinylated and fluorescent, as well as 
sepharose bound probes. Polyacrylamide (PAA) is used as a high molecular 
weight carrier for the sugar molecules. It has a low non-specific sorption and it is 
stable to chemical and proteolytic action. The affinity of the probes is normally 
estimated at 10
2
-10
5
 higher than that of the corresponding free sugars. The 
spacer-arm for saccharides is normally -(CH2)3-, while the spacer-arm for Biotin 
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is -(CH2)6 (see Fig 4.9)-. The flexible polymer chain behaves as an additional 
spacer, with an approximate molecular weight of 30 kDa. PAA-linked 
biotinylated chitobiose and chitotriose were purchased from Glycotech. 
 
 
 
Fig 4.9: The general structure of PAA-linked multivalent biotinylated 
polymers. PAA is poly[N-(2-hydroxyethyl)acrylamide]. Image produced using 
chemsketch. 
 
 
 
4.2.1 Determining the limit of detection for assay substrates  
 
The first step in assay development was to ensure that both the CBP21 protein 
and the PAA-linked chitobiose and chitotriose oligos could be immobilised on 
the surface of a maxiSorp 96-well plate. The limit of detection would also need to 
be determined. Gradient concentrations (50 µL total volume) of protein and 
PAA-linked oligos were diluted in PBS buffer and immobilised on a 96-well 
plate, by passive adsorption, with incubation overnight at 4°C. The plates were 
blocked with blocking solution at 25°C for one hour and probed with anti-His or 
anti-Biotin antibody as appropriate, for one hour at 25°C. The peroxidase 
labelled antibody was subsequently detected using TMB solution (Section 2.3) 
and the absorbance read at OD450nm.  
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It was determined that CBP21, chitobiose and chitotriose could be immobilised 
on the surface of a maxiSorp plate. It was observed that CBP21 could be detected 
at a concentration as low as 1 µg/mL, with no discernable difference between 
sample concentrations above 25 µg/mL (see Fig 4.10). Chitobiose was detectable 
at concentrations as low as 0.03 µg/mL (30 ng/mL), with an upper detection limit 
upwards of 20 µg/mL (see Fig 4.11). Chitotriose was detectable in the range of 
0.01 µg/mL (10 ng/mL) to 10 µg/mL, with loss of linear detection at 
concentrations greater than 10 µg/mL (see Fig 4.12).  
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Fig 4.10: Determination of the limit of detection for CBP21. Quantitative 
detection of CBP21 using a peroxidase linked anti-(His)6 antibody. 2.5% BSA 
was used as a blocking agent. 
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Fig 4.11: Calculating the limit of detection for chitobiose, A; chitobiose 
concentrations in the range 0.09 – 20 µg/mL, B; chitobiose concentrations in 
the range 0.01 – 0.09 µg/mL. Calculating the limit of detection of chitobiose 
using anti-Biotin antibody. 1% PVA (30,000-70,000 average mol wt, Sigma-
Aldrich) was used as the blocking agent. 
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Fig 4.12: Calculating the limit of detection for chitotriose, A; chitotriose 
concentrations in the range 0.09 – 20 µg/mL, B; chitotriose concentrations in 
the range 0.01 – 0.09 µg/mL. Calculating the limit of detection of biotinylated 
chitobiose, using a peroxidase linked anti-Biotin antibody. 1% PVA (30,000-
70,000 average mol wt, Sigma-Aldrich) was used as the blocking agent. 
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4.2.2 Assay format development 
  
Once it had been established that CBP21 and the PAA-linked GlcNAc oligos 
could be immobilised on a maxiSorp 96-well plate the most appropriate assay 
format was explored. There were two potential assay formats, as outlined in Fig 
4.13. Assay format A was carried out with immobilisation of 20 µg/mL of 
CBP21 in PBS on a 96-well maxiSorp plate overnight at 4°C. The plate was 
blocked for one hour at 25°C with 2.5% BSA in PBST. The blocked wells were 
subsequently probed with 50 µL of 10 µg/mL chitobiose in PBST for one hour at 
25°C. The wells were washed four times with 200 µL of PBST prior to the 
addition of 50 µL 1/10,000 anti-Biotin antibody in PBST, which was 
subsequently incubated for one hour at 25°C. The wash step was repeated four 
times with PBST, the peroxidase linked antibody was detected by the addition of 
100 µL TMB solution, the reaction stopped by the addition of 50 µL 10% H2SO4. 
The absorbance was read at 450nm (see Fig 4.14a). 
 
Assay format B was carried out with immobilisation of 10 µg/mL of chitobiose 
in PBS on a 96-well maxiSorp plate overnight at 4°C. The plate was blocked for 
one hour at 25°C with 2.5% BSA in PBST. The blocked wells were subsequently 
probed with 50 µL of 20 µg/mL CBP21 in PBST for one hour at 25°C. The wells 
were washed four times with 200 µL of PBST prior to the addition of 50 µL 
1/10,000 anti-His antibody in PBST, which was subsequently incubated for one 
hour at 25°C. The wash step was repeated with PBST. The peroxidase linked 
antibody was detected by the addition of 100 µL TMB solution. The reaction was 
stopped by the addition of 50 µL 10% H2SO4, with the absorbance read at 450nm 
(see Fig 4.14b). The results from assay format A indicated that the chitobiose 
PAA-linked oligo was interacting with the blocking agent (2.5% BSA), although 
some interaction between CBP21 and the GlcNAc polymer was detectable. This 
result highlighted the need for an alternative blocking agent. Non-specific 
binding of the PAA-linked oligos to BSA would result in high background 
signals that could lead to false positive results. The absorbance readings from 
assay format B seemed less promising. Although the results suggested that there 
was no interaction between CBP21 and the chitobiose polymer.  
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Fig 4.13: Potential assay formats for the detection of CBP21 interaction with 
PAA-linked (GlcNAc)N oligos. A; Assay format A, immobilisation of CBP21, 
blocking, probing with Biotin labelled (GlcNAc)N, with detection by peroxidase 
linked ant-Biotin antibody. B; Assay format B, immobilisation of PAA-linked 
GlcNAc)N, blocking, probing with (His)6 labelled CBP21, with detection by 
peroxidase linked anti-His antibody.  
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Fig 4.14: Development of CBP21 – (GlcNAc)N Binding assay. Two alternate 
assay formats were explored. (His)6 labelled CBP21 was immobilised in assay 
format A, with probing by biotin labelled PAA-linked chitobiose. Biotinylated 
PAA-linked chitobiose was immobilised in assay format B, with the subsequent 
addition of (His)6 labelled CBP21. The blocking agent used was 2.5% BSA. The 
absorbance was read at OD450nm. 
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4.2.3 Blocking agent optimisation 
 
Agents are used in ELISA type assays for blocking possible excess solid surface 
following protein immobilisation, avoiding non-specific immobilisation of 
succeeding reactants. Typical blocking reagents are neutral macromolecules, 
large enough to establish a stable attachment to the surface, yet small enough to 
find its way between reactants. While BSA (67,000 Da) is probably the most 
commonly used blocking agent the optimal blocking reagent for any particular 
assay should be determined empirically (Vogt Jr. et al., 1987). The results from 
section 4.2.3 suggested that assay format A was the most appropriate. To use this 
assay format however the use of an alternative blocking agent would be required. 
While BSA is perhaps the most common blocking agent used in ELISAs there 
are many different types of blocking buffers available commercially. These 
include protein blocking buffers, protein-free blocking buffers, detergent 
blockers and SuperBlock blocking buffers (Rosas et al., 2000).  
 
The protein-free blocking buffers explored here were polyvinyl alcohol (PVA) 
(Rodda and Yamazaki, 1994, Studentsov et al., 2002), polyvinylpyrrolidone 
(PVP) (Studentsov et al., 2002, Mallorqui et al., 2010, Bouchez-Mahiout et al., 
2010) and Synblock (AbD Serotec) (Afrough et al., 2007). Protein based 
blocking buffers Carbo-Free blocking solution (vector labs) and casein (Kaur et 
al., 2002) were also compared. The blocking buffers were evaluated using direct 
detection of CBP21 with peroxidase linked anti-His antibody. Varying 
concentrations of CBP21 were immobilised on the surface of maxiSorp plate, 
overnight at 4°C. The wells were subsequently blocked with 200 µL of blocking 
agent diluted in PBS, for one hour at 25°C. CBP21 was then probed with 
1/10,000 dilution of anti-His antibody diluted in PBST, for one hour at 25°C. The 
wells were washed four times with PBST before development with TMB 
solution, the reaction stopped with 10% H2SO4 and the absorbance read at 
OD450nm.  
 
The ensuing results suggested that while some of the blocking agents did not 
block as well as others, some seemed to block any signal from developing (see 
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Fig 4.15). The tryptone solution (casein digests) was the least successful blocking 
agent, the signal at OD450nm was the same across all CBP21 concentrations 
suggesting non-specific binding of the anti-His antibody to the plate surface. 
Wells blocked with Synblock yielded a higher than average signal on blank 
wells, with quenching of signal on CBP21 immobilised wells. Both PVA and 
PVP blocked wells displayed high degrees of signal quenching across all CBP21 
concentrations, with very little discernable increase in signal with increasing 
CBP21 concentration. Carbo-free blocking solution from Vector labs was the 
most impressive agent next to BSA. While some degree of signal quenching was 
obvious when compared with BSA, there was a steady increase in signal in 
accordance with immobilised CBP21 concentrations, with very little difference 
between triplicate values. While Synblock is a protein based blocking solution 
PVA and PVP are synthetic blockers. These synthetic blockers consist of large 
polymers, with an average molecular weight of 30-70 kDa for PVA and 360 kDa 
for PVP, much larger than CBP21. In order to determine if the size of the 
synthetic polymers was influencing this phenomenon the experiment was 
repeated using PVA with an average molecular weight of 9-10 kDa (see Fig 
4.16). The same result was observed using this lower molecular weight PVA 
polymer.  
 
To establish if this problem of signal quenching was unique to CBP21 and/or the 
anti-His antibody the same experiment was undertaken using NPL (see Fig 4.17). 
NPL is a biotinylated plant lectin that exists as a dimer in solution, each 
monomer approximately 13 kDa, giving an overall mass of 26 kDa. Upon signal 
development it because apparent that while PVP didn‟t act as a sufficient blocker 
in this experiment (see Fig 4.17a) signal quenching of PVA blocked wells was 
again evident when compared to carbo-free or BSA blocked wells (see Fig 
4.17b). This result suggested that the blocking agent was influencing the ability 
of the antibody to recognise the immobilised proteins. Although some signal 
quenching was observed when carbo-free blocking solution was used to block the 
plate wells it was determined that it was the best option going forward next to the 
unsuitable BSA.  
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Fig 4.15: Comparison of blocking reagents. Quantitative detection of CBP21 using a peroxidase linked anti-(His)6 antibody in differently 
blocked wells of a Nunc ELISA plate. The blocking agents investigated were Synblock (AbD Serotec), 1% PVA (30,000-70,000 average mol 
wt, Sigma-Aldrich), 0.5% PVA (30,000-70,000 average mol wt, Sigma-Aldrich), 1% PVP (360,000 average mol wt, Sigma-Aldrich), 0.5% 
PVP (360,000 average mol wt, Sigma-Aldrich), 2.5% Tryptone (LabM), Carbo-free blocking solution (Vector labs), 2.5% BSA (Sigma-
Aldrich). 
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Fig 4.16: Comparison of blocking reagents. Quantitative detection of immobilised 
CBP21 using a peroxidase linked mouse anti-His antibody in differently blocked wells 
of a Nunc maxiSorp plate. The blocking agents investigated were 0.5% PVA (9,000-
10,000 average mol wt, Sigma-Aldrich), 2.5% BSA (Sigma-Aldrich), and Carbo-free 
blocking buffer (Vector labs). 
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 Fig 4.17: Comparison of blocking reagents using an immobilised biotin labelled 
lectin. A; Comparison of blocking agents PVA, PVP, BSA, Carbo-free and PBS, 
B; Highlighted comparison of PVA, BSA and Carbo-free blocking solutions. 
Quantitative detection of NPL using a HRP linked mouse anti-Biotin antibody. The 
blocking agents investigated were 0.5% PVA (30,000-70,000 average mol wt, Sigma-
Aldrich), 1% PVA (30,000-70,000 average mol wt, Sigma-Aldrich), 0.5% PVP 
(360,000 average mol wt, Sigma-Aldrich), 1% PVP (360,000 average mol wt, Sigma-
Aldrich), Carbo-free blocking buffer (Vector labs), 2.5% BSA (Sigma-Aldrich) and 
PBS. 
 
 
 
A 
B 
 177 
 
4.2.4 CBP21 characterisation using the (GlcNAc)N-binding assay 
 
Following the selection of a blocking solution, assays of format A and B (see Fig 4.13) 
were repeated to determine if CBP21 could bind to chitotriose and chitobiose. Assay 
format A, as outlined in Fig 4.13a, was used to determine if immobilised CBP21 could 
bind chitotriose and chitobiose PAA-linked oligos (see Fig 4.18), while assay format B, 
(see Fig 4.13b) was used to determine if CBP21 could bind to immobilised chitotriose 
and chitobiose (see Fig 4.19). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.18: Quantitative detection of biotinylated PAA-linked (GlcNAc)N oligos 
bound to immobilised CBP21, using assay format A. Detection at OD450nm of 
chitobiose and chitotriose PAA-linked olgios bound to immobilised C-terminally (His)6 
tagged CBP21, assayed by the activity of a HRP linked antibody. A gradient 
concentration of CBP21 (1–20 µg/mL) was immobilised on a NUNC maxiSorp plate 
overnight at 4°C. The plate was blocked with carbo-free blocking solution for one hour 
at 25°C, and probed with 50 µL 10 µg/mL and 20 µg/L chitobiose and chitotriose for 
one hour at 25°C. The biotinylated polymers were detected by probing with a 1/10,000 
dilution of anti-Biotin antibody in PBST, with development using TMB solution. The 
absorbance was read at OD450nm. Assay development time was 20 minutes. 
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Fig 4.19: Detection of binding of (His)6 tagged CBP21 to immobilised PAA-linked 
(GlcNAc)N oligos, using assay format B. Quantitative detection of CBP21 bound to 
immobilised PAA-linked Biotinlyated chitobiose and chitotriose oligos, assayed by the 
activity of HRP linked anti-His antibody (OD450mn). A gradient concentration of PAA-
linked chitobiose and chitotriose (5–20 µg/mL) was immobilised on a NUNC maxiSorp 
plate overnight at 4°C. The plate was blocked with carbo-free blocking solution for one 
hour at 25°C, and probed with 50 µL 20 µg/mL CBP21 for one hour at 25°C. Bound 
CBP21 was detected by probing with anti-His antibody, with development using TMB 
solution. The absorbance was read at OD450nm. Assay development time was 30 
minutes. 
 
 
Repeat assays demonstrated that CBP21 could bind both chitobiose and chitotriose 
PAA-linked biotinylated polymers, in a concentration dependent manner, using assay 
format A. Optimum assay development time was 20 minutes, after which time high 
background signals developed. The biotinylated polymers did not appear to interact 
with the carbo-free blocking solution. It is unclear however if any signal quenching 
occurred. It does not appear that CBP21 is able to bind to the (GlcNAc)N oligos in 
assay format B. While assay development times of up to 30 minutes are acceptable, 
after this time false positives may result. There exist unsubstantial differences in signal 
at OD450nm between different concentrations of PAA-linked oligos. 
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4.2.5 Validation of the chitin assay using wheat germ agglutinin  
 
Wheat germ agglutinin (WGA) is a well characterised plant lectin. Like most lectins it 
is a multivalent molecule consisting of two identical subunits, with an overall 
molecular weight of 36 kDa, the crystal structure of which is shown in Fig 1.17. The 
receptor sugar for WGA is GlcNAc, with preferential binding to dimers and trimers of 
this sugar. WGA is commercially available in both biotinylated and un-conjugated 
forms, making it an ideal molecule for assay validation.  
 
Un-conjugated WGA was used to validate format A of the CBP21 – (GlcNAc)N 
binding assay (see Fig 4.20). The assay was carried out as described in Fig 4.13a. It 
was observed that WGA bound the PAA-linked chitobiose and chitotriose polymers 
with greater affinity than CBP21. The development time for this assay was 3 minutes, 
compared to 20 minutes for CBP21, and had higher OD450nm readings. It is evident 
from the results that WGA had a slightly higher affinity for chitobiose over chitotriose, 
this was also observed in the CBP21 assays. In terms of assay validation, the use of 
WGA has proven that this assay format is sufficient to profile chitin-binding proteins. 
 
In order to validate format B an un-conjugated PAA-linked chitobiose was purchased 
from lectinity. The assay was carried out as described in Fig 4.13b, with immobilisation 
of the unlabelled chitobiose, and probing with biotinylated WGA. Although CBP21 
was unable to bind to the PAA-linked chitobiose in this format, it was observed that 
WGA had a high affinity for the polymer (see Fig 4.21). The time required for adequate 
development of a detection signal in this assay was the same as in assay format A (3 
minutes). 
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Fig 4.20: Binding of immobilised unlabelled wheat germ agglutinin to PAA-linked 
Biotin labelled chitobiose and chitotriose PAA-linked oligos. Quantitative detection 
of chitobiose and chitotriose bound to immobilised wheat germ agglutinin (WGA), 
assayed by the activity of an anti-Biotin HRP linked antibody (OD450nm). Assay 
development time was 3 minutes. 
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Fig 4.21: Binding of biotinylated wheat germ agglutinin to immobilised PAA-
linked un-conjugated chitobiose. Quantitative detection of biotinylated WGA bound 
to immobilised un-conjugated PAA-linked chitobiose, assayed by the activity of an 
anti-Biotin HRP linked antibody (OD450nm). Assay development time was 3 minutes. 
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Table 4.2: Final procedure for PAA-linked (GlcNAc)N assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3 CBP21 affinity chromatography 
  
It has been shown, through ELLA and glycoprotein affinity chromatography that 
CBP21 is incapable of binding to terminal GlcNAc and core chitobiose of glycans 
attached to glycoproteins. Through the development of a (GlcNAc)N assay it is known 
that CBP21 can bind the GlcNAc polymers chitobiose and chitotriose. It therefore may 
be possible that the secondary and tertiary structures of the glycoproteins may have 
prevented CBP21 from reaching the chitobiose core. CBP21 would be an extremely 
advantageous tool in the field of glycobiology if it could bind to the chitobiose core 
structure of protein released glycans.  
 
 
Step Procedure 
1 Immobilise 50 µL CBP21 in PBS on a maxiSorp plate, 
incubate overnight at 4°C 
2 Block wells with 200 µL of Carbo-free blocker diluted in PBS, 
incubate for 1 hour at 25°C. 
3 Probe wells with 50 µL (GlcNAc)N in PBS for one hour at 
25°C 
4 Wash wells with 4 x 200 µL of PBST 
5 Probe with 1/10,000 HRP linked anti-Biotin antibody diluted 
in PBST, for one hour at 25°C 
6 Wash wells with 4 x 200 µL of PBST 
7 Develop wells by the addition of 100 µL of TMB solution 
8 Stop reaction after 20 minutes by the addition of 50 µL 10% 
H2SO4 
9 Read absorbance at 450nm 
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A pool of released glycans could be generated using PNGase F. PNGase F is an 
endoglycosidase that cleaves N-linked glycans between the innermost GlcNAc and 
asparagines residue of high mannose, hybrid and complex oligosaccharides. It 
deaminates the asparagines to aspartic acid, but leaves the oligosaccharide intact. 
Released oligosaccharides could be separated from the protein mixture through use of 
C-18 reverse phase chromatography (see Fig 4.22). 
 
 
  
 
 
  
  
   
  
 
 
 
 
 
 
 
Fig 4.22: Release and isolation of PNGnase F liberated glycans using a C-18 
column. PNGnase F acts to release N-linked oligosaccharide chains between the inner 
most GlcNAc and asparagine residue. Released glycans can be separated from the 
protein mix through using C-18 reverse phase column chromatography. The polar 
residues elute first and the non-polar residues eluting last.  
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As the protein released glycans could not be immobilised on a maxiSorp plate, and 
would not be conjugated to a His or Biotin label, an assay of the ELISA format, 
outlined in Fig 4.13, would be unsuitable. The most appropriate format would follow 
that of the glycoprotein affinity chromatography as discussed previously (Section 
4.1.3). CBP21 could be immobilised on to cyanogen bromide activated sepharose, with 
addition of the protein released glycans. An assay for reducing sugars could be used to 
evaluate the success of the capture process. 
 
CBP21 was immobilised onto cyanogen bromide activated sepharose 4B as outlined in 
section 2.29 (Table 4.3). The potential of the assay was evaluated through the use of 
non PAA-linked, un-conjugated chitobiose (Megazyme). The limit of detection of 
chitobiose was determined using the DNS assay (see Fig 4.24) as outlined in section 
2.21. It was observed that chitobiose concentrations as low as 0.01 mg/mL could be 
detected using this assay, with linear detection between concentrations of 0.2-1 mg/mL.  
 
300 µL chiotobiose (0.25 mg/mL) was passed over the CBP21 affinity resin with 
collection of 1 mL fractions. The resin was pre-equilibrated with PBS. 100 µL of 0.25 
mg/mL chitobiose was mixed with the resin overnight at room temperature. Unbound 
sample was collected, and the resin was washed four times with 1 mL of PBS (fractions 
3-7). The column was subsequently washed 5 times with 1 mL of sodium acetate, pH 
4.0 (fractions 8-12). Elution fractions were assayed using the DNS assay as outlined in 
section 2.21 (see Fig 4.25).  
 
The total amount of unbound chitobiose from the CBP21 affinity column was estimated 
as a percentage of the total unbound chitobiose from the blank column. It was estimated 
that an average of 87.2% of the chitobiose eluted from the CBP21 affinity column in 
the elution samples. Subtracting this value from 100% gave an average of 12.8% of 
chitobiose bound to the column. As 0.075 mg of chiotobiose was applied to the column 
this 12.8% equates to a total of 0.01 mg of bound chitobiose. Sodium acetate buffer, pH 
4.0, was used to wash the resin in an attempt to elute any bound chitobiose. No 
chitobiose was detected in the eluted fractions. A sample of each resin was also mixed 
with DNS reagent and boiled in an attempt to discern further difference between 
CBP21-affinity and control resins (see Fig 4.26).  
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Subsequently PNGase F from Flavobacterium meningosepticum was used to digest 
bovine asialo fetuin. The released glycans were separated from the protein mix using a 
C-18 column (Alltech). The amount of released glycan in the purified sample was 
below the limit of detection of the DNS assay. A modified ELLA was also used in an 
attempt to detect any of the protein released glycans. CBP21 and un-conjugated WGA 
were immobilised on a maxiSorp plate, the plate was blocked and probed with the 
protein released glycans. The glycans were then probed with biotinylated ECL. No 
differences were distinguishable between glycan deplete and replete samples (see Fig 
4.27). 
  
Fig 4.23: Location of surface exposed lysine residues on the CBP21 molecule. 
Representation of the location of the amino acid lysine on the surface of CBP21 
molecule. Proteins are immobilised onto cyanogen bromide active sepharose through 
free amine groups. Lysine residues are highlighted in green. Image generated using 
PyMol. 
 
Table 4.3: Immobilisation of CBP21 onto cyanogen bromide activated sepharose 
4B. 
Starting 
CBP21 
Resin 
volume 
Unbound 
CBP21 
Bound 
CBP21 
mg 
CBP21/ 
mL resin 
8.9 mg 1 mL 0.1 mg 8.8 mg 8.8 
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Fig 4.24: Determining the limit of detection of un-conjugated chitobiose using the 
DNS assay for reducing sugars, A; Detection of chitobiose between 0.01 – 1 
mg/mL, B; Linear regression analysis of chitobiose between 0.2 – 1 mg/mL. The 
DNS assay was used to determine the limit of detection for un-conjugated chitobiose 
(Megazyme). The absorbance readings at OD570nm were plotted against the chitobiose 
concentration (mg/mL).  
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Fig 4.25: Analysis of chitobiose bound to sepharose immobilised CBP21. 
Quantitative analysis, by DNS assay of un-conjugated chitobiose (megazyme) bound to 
sepharose 4B immobilised CBP21. The resin was pre-equilibrated with PBS (fraction 
1). 100 µL of 0.25 mg/mL chitobiose was mixed with the resin overnight at room 
temperature. Unbound sample was collected (fraction 2), and the resin was washed four 
times with 1 mL PBS (fractions 3-6). The column was subsequently washed four times 
with 1 mL sodium acetate, pH 4.0 (fractions 7-10). Eluted fractions were assayed using 
the DNS assay as outlined in section 2.21. 
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Fig 4.26: Analysis of CBP21 affinity column bound chitobiose by boiling and DNS 
assay. 300 µL of sample resin was added to 300 µL of PBS and mixed with 600 µL of 
DNS reagent. Samples were boiled for 10 mins, allowed to cool for 5 min, and the 
absorbance was read at OD570nm.  
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Fig 4.27: Analysis of PNGase F released glycans by modified ELLA. Quantitative 
detection of PNGase F released glycans bound to carbohydrate-binding molecules 
CBP21 and WGA by biotinylated ECL. ECL is a plant lectin known to have an affinity 
for terminal galactose. 
 
 
4.4 Sugar Inhibition studies 
 
Although CBP21 has not shown an affinity for any of the glycans tested (Section 4.1), 
it has shown an ability to bind to both un-conjugated chitobiose and PAA-linked 
chitobiose and chitotriose (Sections 4.2 and 4.3). In its natural environment CBP21 
binds to long chain chitin polymers, and has been shown to bind to both chitosan and 
cellulose linked polymers (Section 3.8). CBP21 therefore while not able to bind single 
sugar units may have the ability to bind to other polysaccharides.  
 
Sugar inhibition studies were carried out using the labelled (GlcNAc)N assay as 
developed in section 4.2 (see Fig 4.28), and the data validated using insoluble substrate 
assays coupled with a Bradford assay (see Fig 4.29). Sugar concentrations used were 
glucose – 3.4%, galactose – 3.4%, galactan – 6%, mannose – 3.4%, mannan from 
Saccharomyces cerevisiae – 6%, GlcNAc – 4.4%, sucrose – 6.8%, lactose – 6.8%, 
fucose – 3.2% and chitobiose – 2%, unless otherwise stated. 
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Sugar inhibition studies using the labelled chitobiose assay (see Fig 4.28) suggested 
that interaction between CBP21 and chitobiose was not affected by the presence of 
glucose, galactose, GlcNAc, lactose or the un-conjugated chitobiose, while galactan, 
mannose, sucrose and fucose appeared to slightly alter the affinity of CBP21 for the 
PAA-linked chitobiose. Mannan showed the highest level of disruption to chitobiose 
binding compared to the control sample. Both α- and β-chitin sugar inhibition studies 
(see Fig 4.29) revealed conflicting results. These assays indicated that CBP21 was least 
likely to bind to chitin in the presence of galactan, and that mannan had the next highest 
inhibitory effect on α–chitin binding (see Fig 4.29a), but showed little effect in the 
study using β–chitin from squid pen (see Fig 4.29b). 
 
A saline solution of sepharose linked mannan, from Saccharomyces cerevisiae, was 
purchased from Sigma and used as an affinity matrix in an attempt to capture CBP21 
(see Fig 4.30). Three 200 µL volumes of mannan agarose was aliquoted into three 
separate columns and equilibrated with binding buffer. A 200 µL sample of blank 
cyanogen bromide activated sepharose was added to a fourth column. The mannan 
agarose was mixed with A; 1 mL NPL (50 µg/mL), B; 1 mL CBP21 (50 µg/mL) and C; 
1 mL PBS. The blank agarose was also mixed with 1 mL CBP21 (50 µg/mL), 
overnight at room temperature. Eluted sample was collected and the column was 
washed with 5 x 1 mL of binding buffer, prior to washing with 5 x 1 mL of 0.2 M 
mannose. The absorbance of each eluted sample was read at OD280nm and was plotted 
against each fraction number. It was evident from the mannan affinity chromatography 
that CBP21 did not bind to the mannan agarose. 
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Fig 4.28: Sugar inhibition study of CBP21 using biotin labelled PAA-linked 
chitobiose. Quantatitive detection of biotin labelled PAA-linked chitobiose bound to 
sugar inhibited CBP21. Immobilised CBP21 was incubated with 50 µL of each sugar 
prior to incubation with 50 µL 10 µg/mL PAA-linked chitobiose prepared in sugar 
solution. 
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Fig 4.29: Sugar inhibition study of CBP21 using A; α-chitin and B; β-chitin. 
Quantitative detection of unbound CBP21 following sugar inhibition with various 
sugars. 1 mL of CBP21 (30 µg/mL) was incubated with each sugar for one hour prior 
to incubation with 0.05 g of α-chitin from crustacean shells or β-chitin from squid pen, 
overnight at room temperature. Unbound protein was detected using the Bradford Ultra 
assay (Section 2.20.1). 
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Fig 4.30: Application of CBP21 to mannan affinity agarose. OD280nm readings taken 
during mannose affinity chromatography using CBP21. The resin was pre-equilibrated 
with binding buffer until OD280nm reached 0.000 (fraction 1). 1 ml of 50 µg/mL 
carbohydrate-binding proteins were added to and mixed with 200 µL of resin, 
overnight at room temperature. The column flow-through was collected (fraction 2), 
and the resin was washed with 5 x 1 mL of binding buffer (fractions 3-7), until the 
readings at OD280nm returned to 0.000. Bound protein was eluted by the addition of 0.2 
M mannose (fractions 8-12). NPL is plant lectin with a known affinity for mannose. 
 
 
4.5 CBP21 Mutagenesis 
 
Protein–protein interactions are central to most biological processes, and detection of 
specific amino acid residues that contribute to the specificity and strength of protein 
interactions is a problem of the utmost importance (Moreira, et al., 2007). 
Crystallographic studies of protein structures, especially those co-crystallised with 
various ligands can help to identify the specific residues in contact with a ligand. The 
crystal structure of CBP21 was eludicated by Vaaje-Kolstad et al in 2005. Although 
attempts were made to co-crystallise the protein with GlcNAc, they proved fruitless. 
Since the publication of the crystal structure Vaaje-Kolstad et al., have attempted to pin 
point the active site residues through mutagenesis (Vaaje-Kolstad et al., 2005a). While 
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they succeeded in decreasing the chitin-binding activity of a number of mutants (Table 
1.4), complete disruption of the active site has not been achieved. Identification of the 
most influential residues in the active site will highlight good targets for site direct 
random mutagenesis, which has the potential to alter the sugar specificity of this 
protein (McMahon, 2010). The CBP21 residues thought to be involved in chitin 
binding are shown in Fig 4.31.  
 
 
  
Fig 4.31: Structure of CBP21 with residues thought to be involved in chitin 
binding. The putative active site residues are highlighted in blue. Image generated 
using PyMol. 
 
 
 
 
 
 
 
 
Asn 185 
Asp 182 
Thr 183 Glu 60 
Glu 55 
Tyr 54 
Pro 56 
Tyr 30 
Gln 57 
Ser 58 
His 114 
57 
Ala 112 
57 Thr  111 
57 
His 28 
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4.5.1 Site directed mutagenesis of CBP21  
 
Alanine scanning is the most commonly used technique to map functional epitopes 
(Moreira et al., 2007, Cunningham and Wells, 1989, Morrison and Weiss, 2001, Wells, 
1990). Alanine substitution nullifies the amino acid side chain without altering the 
main-chain conformation, nor does it impost extreme electrostatic or steric effects 
(Cunningham and Wells, 1989). Amino acid replacement with proline or glycine would 
have similar effects, but could also introduce additional conformational freedom into 
the protein backbone. Alanine residues were introduced to CBP21 via site directed 
mutagenesis, using Phusion
TM
 directed whole vector amplification (see Fig 4.32). 
Residues Y54, E55, P56, Q57, S58, E60, T111, H114 and D182 were targeted for 
mutagenesis. The resulting genes were named cbp21Y54A, cbp21E55A, cbp21P56A, 
cbp21Q57A, cbp21S58A, cbp21E60A, cbp21T111A, cbp21H114A and cbp21D182A and the 
proteins named, CBP21Y54A, CBP21E55A, CBP21P56A, CBP21Q57A, CBP21S58A, 
CBP21E60A, CBP21T111A, CBP21H114A and CBP21D182A respectively. The construction of 
the CBP21 mutants is outlined in Fig 4.33 – 4.41. The predicted impact to the protein 
structure of the mutant proteins is show in Fig 4.42. 
 
 
 
               
 
 
Fig 4.32: Schematic of Phusion
TM
 site directed mutagenesis. Two primers are 
designed to amplify the entire expression plasmid, one of which contains the desired 
mutation. Following PCR (Section 2.10.1) a DpnI restriction digest can be carried out 
to restrict any of the methylated template DNA. The phosphorylated ends are then 
ligated. The ligation is subsequently transformed directly into an E. coli expression 
strain (Section 2.9.3). For the mutation of cbp21 the template plasmid was pCBP21_60.  
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGGCGGAAGC GCAGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.33:  Outline of the construction of CBP21Y54A. Representation of the position 
of the primers used for the mutation of cbp21Y54A, Y54A_F (blue), 55-60A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation Y54A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
      
 
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGCACC GCAGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.34:  Outline of the construction of CBP21E55A. Representation of the position 
of the primers used for the mutation of cbp21E55A, E55A_F (blue), 55-60A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation E55A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGAAGC GCAGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.35:  Outline of the construction of CBP21P56A. Representation of the position of 
the primers used for the mutation of cbp21P56A, P56A_F (blue), 55-60A_R (red) (Table 
2.3) within the cbp21 sequence which creates the mutation P56A. The nucleotides to be 
mutated are highlighted in yellow, with the nucleotides to be introduced on the forward 
primer in underlined bold. 
 
 
 
 
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGAACC GGCGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.36:  Outline of the construction of CBP21Q57A. Representation of the position 
of the primers used for the mutation of cbp21Q57A, Q57A_F (blue), 55-60A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation Q57A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGAACC GCAGGCGGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.37:  Outline of the construction of CBP21S58A. Representation of the position of 
the primers used for the mutation of cbp21S58A, S58A_F (blue), 55-60A_R (red) (Table 
2.3) within the cbp21 sequence which creates the mutation S58A. The nucleotides to be 
mutated are highlighted in yellow, with the nucleotides to be introduced on each primer 
underlined bold. 
 
 
 
 
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGAACC GGCGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GCAGGCCTG 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.38:  Outline of the construction of CBP21E60A. Representation of the position 
of the primers used for the mutation of cbp21E60A, E60A_F (blue), 55-60A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation E60A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC 
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
                                                    TT CGAGTTGGAC 
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
TTTTGGCCGG GCTTGAGGTT TACCTGGAAG CTGGCCGCCC GTCAC 
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.39:  Outline of the construction of CBP21T111A. Representation of the position 
of the primers used for the mutation of cbp21T111A, T111A_F (blue), T111A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation T111A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
 
                           
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC 
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
                                                    TT CGAGTTGGAC 
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
TTTTGGCCGG GCTTGAGGTT TACCTGGAAG CTGACCGCCC GTGCCAGCAC AACCAGCTGG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG  
CGC 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.40:  Outline of the construction of CBP21H114A. Representation of the position 
of the primers used for the mutation of cbp21H114A, H114A_F (blue), T111A_R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation H114A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC 
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC  
                       CTAGCGTCG CCAAGCGTGC ACTAGGAACG GGTGTGGGAC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC  
ATAGCCGCCA CCGCCAACGC CTTCTAT 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.41:  Outline of the construction of CBP21D182A. Representation of the position 
of the primers used for the mutation of cbp21D182A, D 182A_F (blue), D182A R (red) 
(Table 2.3) within the cbp21 sequence which creates the mutation D182A. The 
nucleotides to be mutated are highlighted in yellow, with the nucleotides to be 
introduced on each primer underlined bold. 
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Fig 4.42: Structure of CBP21, A; CBP21WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A, E; CBP21Q57A, F; CBP21S58A, G; CBP21E60A, H; 
CBP21T111A, I; CBP21H114A and J; CBP21D182A. Putative carbohydrate binding site residues are highlighted in blue, mutated residues are highlighted 
in purple. Image generated using PyMol. 
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B C D E 
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4.5.2 Expression and purification of CBP21 mutants 
 
Following successful construction of the CBP21 mutants, each plasmid was 
verified by sequencing and transformed into the E. coli KRX expression strain. 
Protein expression and purification was then undertaken. The optimised 
expression (Section 3.3.2) and purification (Section 3.4.2) strategies for 
pCBP21_60 were used for all derivatives of CBP21. It was observed that each 
mutant was successfully purified to a high degree of homogeneity using the 
FPLC and the purification strategy outlined in section 3.4.2 (see Fig 4.43 – 4.45). 
The average yield for each CBP21 variant per g/cell paste, following expression 
and purification, is given in table 4.4. The average yield is taken after 3 separate 
fermentations. The g/cell paste value is the weight of cells harvested from a 
500ml culture. It was found that not all mutants expressed to the same level as 
the wild type molecule. Some variants gave rise to overall lower cell densities 
following overnight incubation, with much lower protein yields as a result. 
 
 
Table 4.4: Average yield of recombinant CBP21 mutant variants from a 500 
mL expression in LB medium.  
 
 
Protein Mass of cells (g) mg protein/ g cell paste 
CBP21Y54A 5.96 3.13 
CBP21E55A  4.4 2.54 
CBP21P56A  2.72 0.79 
CBP21Q57A  5.18 1.68 
CBP21S58A  4.68 3.79 
CBP21E60A 3.21 2.15 
CBP21T111A 3.78 2.48 
CBP21H114A  3.92 2.37 
CBP21D182A 3.44 0.65 
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Fig 4.43: Purification of C-terminally tagged CBP21 mutants by IMAC, A; CBP21Y54A, B; CBP21E55A, C; CBP21P56A. Analysis by 
12.5% SDS-PAGE and silver staining of CBP21 purification by IMAC using Ni
2+
 charged sepharose. Lane 1; Broad range protein ladder 
(Section 2.23.3), Lane 2; Crude lysate, Lane 3; Column flow-through, Lane 4, 20mM Imidazole wash, Lane 5; 70mM Imidazole wash, Lane 
6; 200mM Imidazole elution, Lane 7; Broad range protein ladder. Purified protein bands are indicated with an arrow. 
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Fig 4.44: Purification of C-terminally tagged CBP21 mutants by IMAC, A; CBP21Q57A, B; CBP21S58A, C; CBP21E60A. Analysis by 
12.5% SDS-PAGE and silver staining of CBP21 purification by IMAC using Ni
2+
 charged sepharose. Lane 1; Broad range protein ladder 
(Section 2.23.3), Lane 2; Crude lysate, Lane 3; Column flow-through, Lane 4, 20mM Imidazole wash, Lane 5; 70mM Imidazole wash, Lane 
6; 200mM Imidazole elution, Lane 7; Broad range protein ladder. Purified protein bands are indicated with an arrow. 
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Fig 4.45: Purification of C-terminally tagged CBP21mutants by IMAC, A; CBP21T111A, B; CBP21H114A, C; CBP21D182AA. Analysis by 
12.5% SDS-PAGE and silver staining of CBP21 purification by IMAC using Ni
2+
 charged sepharose. Lane 1; Broad range protein ladder 
(Section 2.23.3),  Lane 2; Crude lysate, Lane 3; Column flow-through, Lane 4, 20mM Imidazole wash, Lane 5; 70mM Imidazole wash, Lane 
6; 200mM Imidazole elution, Lane 7; Broad range protein ladder. Purified protein bands are indicated with an arrow.
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4.5.3 CBP21 mutant characterisation 
 
Insoluble substrate assays were carried out to compare the strength of binding of 
the CBP21 mutants compared to the wild type protein (see Fig 4.46–4.50) Assays 
were carried out as outlined in Section 2.26, with definite differences observed in 
the affinity of the CBP21 mutants for the insoluble substrates compared to the 
wild type molecule (Table 4.5). The insoluble substrates used were β-chitin from 
squid pen, α-chitin from crustacean shells, crystalline cellulose, chitosan from 
carapacea skin and α-chitosan from crustacean shells.  
 
Studies of WT CBP21 using β-chitin established that all of the protein bound to 
the resin with none present in the elution fractions. The affinity of the mutants to 
β-chitin, compared with that of the WT, appeared to be diminished, with some 
displaying a very low binding capacity (see Fig 4.48). The most profound effect 
of the alanine scanning was observed with CBP21H114A, which appeared to have 
no affinity for β-chitin. CBP21T111A and CBP21Y54A also appeared to have a very 
low affinity for the insoluble substrate. While the WT protein appeared to bind to 
α- and β-chitin with similar affinities, the same was not true for all of the 
mutants. In the case of α-chitin all of the CBP21 mutants appeared to retain an 
ability to bind to the insoluble substrate (see Fig 4.49). Alanine scanning 
appeared to have little or no effect on CBP21E55A, CBP21P56A and CBP21Q57A, 
CBP21S58A, CBP21E60A, CBP21T111A and CBP21D182A. Interestingly similarly to 
the results of the β-chitin study the binding of CBP21Y54A and CBP21H114A to α-
chitin was diminished, with more protein present in elution fractions compared to 
the other mutants. 
 
The WT protein had a low affinity for the chitosan from carpacea skin, with the 
majority of the loaded protein eluting in the first elution fraction (see Fig 4.50b). 
None of the mutants appeared to have an increased capacity to bind to this 
substrate (see Fig 4.50), with CBP21S58A, CBP21T111A and CBP21H114A exhibiting 
extremely diminished capacities, with either notably faint or no protein bands 
visible in the boiled chitosan sample lane (Lane 6). The WT protein did not 
display a high affinity for chitosan from crustacean shells, and the same remained 
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true for the majority of the mutants (see Fig 4.51). CBP21Q57A however appeared 
to have an increased affinity for α-chitosan, while the CBP21E60A and 
CBP21T111A mutants displayed slight increases in band intensity. Significant 
differences between CBP21 mutants and the parent protein were again observed 
when crystalline cellulose was used as a substrate (see Fig 4.50). Mutants 
CBP21Y54A, CBP21E60A, CBP21H114A had little or no ability to bind to crystalline 
cellulose compared to the WT, while a marked increase was observed with 
CBP21T111A and CBP21D182A mutants. 
 
Differences in the CBP21 mutants ability to bind to glycoproteins was explored 
using an ELLA (Section 2.27). Each mutant was subjected to analysis using 
untreated, nuriminidase and β-galactosidase treated thyroglobulin as the substrate 
(see Fig 4.51). Unfortunately none of the mutants displayed an increased affinity 
for the oligos tested. 
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Fig 4.46: CBP21 solid substrate assay using β-chitin from squid pen. A; CBP21 WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A,  E; CBP21Q57A, F; 
CBP21S58A, G; CBP21E60A, H; CBP21T111A, I; CBP21H114A and J; CBP21D182A Lane 1; Broad range protein ladder (Section 2.23.2), Lane 2; Crude CBP21 
sample, Lane 3; Eluted sample, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21 β-chitin sample, Lane 7; Boiled PBS β-chitin sample, Lane 8; Broad 
range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 4.47: CBP21 solid substrate assay using α-chitin from crustacean shell. A; CBP21 WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A,  E; CBP21Q57A, 
F; CBP21S58A, G; CBP21E60A, H; CBP21T111A, I; CBP21H114A and J; CBP21D182A. Lane 1; Broad range protein ladder (Section 2.23.2), Lane 2; Crude CBP21 
sample, Lane 3; Eluted sample, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21 α-chitin sample, Lane 7; Boiled PBS α-chitin sample, Lane 8; Broad 
range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 4.48: CBP21 solid substrate assay using chitosan from carapacea skin, A; CBP21 WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A,  E; CBP21Q57A, 
F; CBP21S58A, G; CBP21E60A, H; CBP21T111A, I; CBP21H114A and J; CBP21D182A. Lane 1; Broad range protein ladder (Section 2.23.2), Lane 2; Crude CBP21 
sample, Lane 3; Eluted sample, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21 β-chitosan sample, Lane 7; Boiled PBS β-chitosan sample, Lane 8; 
Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 4.49: CBP21 solid substrate assay using α-chitosan from crustacean shell, A; CBP21 WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A,  E; 
CBP21Q57A, F; CBP21S58A, G; CBP21E60A, H; CBP21T111A, I; CBP21H114A and J; CBP21D182A. Lane 1; Broad range protein ladder (Section 2.23.2), Lane 2; 
Crude CBP21 sample, Lane 3; Eluted sample, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21 α-chitosan sample, Lane 7; Boiled PBS α-chitosan 
sample, Lane 8; Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 4.50: CBP21 solid substrate assay using crystalline cellulose, A; CBP21 WT, B; CBP21Y54A, C; CBP21E55A, D; CBP21P56A,  E; CBP21Q57A, F; 
CBP21S58A, G; CBP21E60A, H; CBP21T111A, I; CBP21H114A and J; CBP21D182A. Lane 1; Broad range protein ladder (Section 2.23.2), Lane 2; Crude CBP21 
sample, Lane 3; Eluted sample, Lane 4; Wash 1, Lane 5; Wash 2, Lane 6; Boiled CBP21 α-chitosan sample, Lane 7; Boiled PBS α-chitosan sample, Lane 8; 
Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
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Table 4.5: Overview of the marked changes observed between the CBP21 wild type protein and its mutants. 
 
Mutation β-chitin α-chitin Chitosan (carpacea skin) Chitosan (crustacean shell) Crystalline cellulose 
WT  √ √ √ √ √ 
Y54A - - - - √ √ X 
E55A - - √ √ √ √ 
P56A - - - √ √ 
Q57A - - - √ + + √ 
S58A - - - X √ √ 
E60A - - √ √ - - 
T111A - - √ X + + + 
H114A X - - X + - 
D182A - - √ √ √ + + 
√ Binding comparable to WT, slight increase in affinity compared to WT (+), larger increase in affinity compared to WT (+ +), slightly 
decrease in affinity compared to WT (-), larger decrease in affinity compared to WT (- -), no binding (X).
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Fig 4.51: ELLA analysis of CBP21 mutants using glycosidase treated thyroglobulin as a glycoprotein source. SNA, ECL, GSLII and 
DSL are commercially available plant lectins that show a binding preference for sialic acid, terminal galactose, terminal GlcNAc and 
chitobiose respectively.  
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4.5.4 Random mutagenesis of CBP21 
 
While it has been show in section 4.4.3 that alanine scanning of various CBP21 
residues impacted on the proteins affinity for various insoluble substrates, the 
replacement of amino acids with alanine is more likely to decrease a proteins 
affinity for a given substrate rather than alter it. Random mutagenesis is a 
technique better suited for inducing amino acid changes that may produce 
proteins with altered specificities. Alanine scanning of these sites had previously 
been shown to have the greatest impact in terms of βmax on the affinity for β-
chitin (Table 1.4) (Vaaje-Kolstad et al., 2005a). Site directed random 
mutagenesis was carried out on two positions within the CBP21 protein, E55 and 
H114, as outlined in Fig 4.32. The positions of the residues to be mutated and the 
locations of primer annealing sites are shown in Fig 4.52 and 4.53. 
 
Following PCR the reaction was cleaned up (Section 2.8) and subjected to DpnI 
digestion to remove any of the template DNA. The plasmids were then ligated 
(Section 2.10.2) and transformed (Section 2.9.3) directly into E. coli KRX. 
Following overnight incubation transformed colonies were subcultured in deep 
well 96-well plates, with transfer to fresh medium on Day 2. On Day 3 10 µl of 
cell culture was transferred to a fresh 96-well plate containing LB medium, with 
ampicillin and IPTG. The plate was incubated with shaking at 800-1000 rpm 
overnight, at 37°C. The plate was spun at 4,000 rpm to pellet the cells, and the 
medium removed. Cells were lysed as described in section 2.15.2. Asialo 
agalacto thyroglobulin was immobilised on a 96 well Maxisorp plate overnight at 
4°C. The plate was blocked with 200 µL carbo-free blocking solution for one 
hour at 25°C. 50 µL of cell lysate was transferred to this blocked maxiSorp plate 
for ELLA analysis (see Fig 4.54 and 4.56). Plates were developed over 30 
minutes, with lectin control samples stopped after 5 minutes. 
 
Once the OD450nm readings were normalised by the subtraction of background 
signal, few promising CBP21E55 random clones remained. The analysis was 
repeated using fresh cultures and lysate and the same clones surfaced as having 
potential for glycoprotein interaction. Clones B1, B2, G3 and G10 were then 
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selected for further analysis, they were grown up in 500 mL culture volumes 
(Section 2.14), purified using IMAC, buffer exchanged into PBS and re-
examined using ELLA analysis (see Fig 4.55). None of these selected clones 
showed an affinity for the glycoprotein derivatives tested in this assay format. 
Similarly for CBP21H114 random mutants, no clones stood out as having a 
potential affinity for the glycoprotein tested, following the initial ELLA analysis 
(see Fig 4.56). 
 
 
 
ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC  
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT                                                                             
         G ACGTTGAGTT GTGCGTCACG CCGTCGGTGC AGTACGAANN NCAGAGCGTC 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAA 
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG 
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.52:  Outline of the construction of CBP21E55 random mutants. 
Representation of the position of the primers used for the mutation of CBP21 at 
position E55. The position of the primer E55A_R_F is represented in blue, with 
55-60A_R represented in red (Table 2.3). The nucleotides to be mutated are 
highlighted in yellow, with the nucleotides to be introduced on each primer 
underlined bold. 
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ATGGGAAACA AAACTTCCCG TACCCTGCTC TCTCTGGGCC TGCTGAGCGC GGCCATGTTC 
GGCGTTTCGC AACAGGCGAA TGCTCACGGT TATGTCGAAT CGCCGGCCAG CCGCGCCTAT 
CAGTGCAAAC TGCAACTCAA CACGCAGTGC GGCAGCGTGC AGTACGAACC GCAGAGCGTC  
GAAGGCCTGA AAGGCTTCCC ACAGGCCGGC CCGGCTGACG GCCACATCGC CAGCGCCGAC  
                                                    TT CGAGTTGGAC 
AAGTCCACCT TCTTCGAACT GGATCAGCAA ACGCCGACGC GCTGGAACAA GCTCAACCTG  
TTTTGGCCGG GCTTGAGGTT TACCTGGAAG CTGACCGCCC GTNNNAGCAC AACC 
AAAACCGGCC CGAACTCCTT TACCTGGAAG CTGACCGCCC GTCACAGCAC AACCAGCTGG  
CGCTATTTCA TCACCAAGCC AAACTGGGAC GCTTCGCAGC CGCTGACCCG CGCTTCCTTT 
GACCTGACGC CGTTCTGCCA GTTCAACGAC GGCGGCGCCA TCCCTGCCGC ACAGGTCACC 
CACCAGTGCA ACATACCGGC AGATCGCAGC GGTTCGCACG TGATCCTTGC CGTGTGGGAC 
ATAGCCGACA CCGCCAACGC CTTCTATCAG GCGATCGACG TCAACCTGAG CAAAAGATCT 
CATCATCATC ACCATCACTA A 
 
Fig 4.53: Outline of the construction of CBP21H114 random mutants. 
Representation of the position of the primers used for the random mutation of 
CBP21 at position H114. The position of the primer H114_R_F is indicated with 
blue, with T111A R represented in red (Table 2.3). The nucleotides to be mutated 
are highlighted in yellow, with the nucleotides to be introduced on each primer 
underlined bold. 
 
 
 
 
 
 
 
 
 
 
 
  
 
Fig 4.54: ELLA analysis of CBP21E55 random mutants bound to asialo 
agalacto thyroglobulin. Quantitative detection of CBP21E55 random mutants 
bound to asialo agalacto thyroglobulin. Binding of the mutants to the 
glycoprotein was detected through the use of a peroxidase linked antibody at 
OD450nm. SNA is a terminal sialic binding lectin, ECL has a binding preference 
for terminal galactose, GSL II is a terminal GlcNAc binding lectin 
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Fig 4.55: ELLA analysis of CBP21E55 random mutants G3, G10, B1 and B2. 
Quantitative detection of CBP21E55 random mutants bound to untreated, 
neuraminidase and β-galactosidase treated thyroglobulin through the use of a 
peroxidase linked antibody at OD450nm. SNA is a terminal sialic binding lectin, 
ECL has a binding preference for terminal galactose, GSL II is a terminal 
GlcNAc binding lectin 
0
0.1
0.2
0.3
0.4
0.5
0.6
1 2 3 4 5 6 7 8 9 10 11 12
A
b
s 
at
 4
5
0
n
m
A
B
C
D
E
F
G
H
Fig 4.56: ELLA analysis of CBP21H114 random mutagenesis using asialo 
agalacto thyroglobulin. Quantitative detection of CBP21H114 random mutants 
bound to asialo agalacto thyroglobulin. Binding of the mutants to the 
glycoprotein was detected through the use of a peroxidase linked antibody at 
OD450nm. SNA is a terminal sialic binding lectin, ECL has a binding preference 
for terminal galactose, GSL II is a terminal GlcNAc binding lectin 
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4.6 Discussion 
 
Preliminary ELLA analysis of CBP21 revealed that it did not interact with the 
protein linked oligosaccharides tested. This result was perhaps unsurprising. As 
mentioned previously the purpose of this project was to evaluate if CBP21, a 
chitin-binding protein, has an affinity for GlcNAc sugars located within a protein 
linked glycan structure. It is known that all N-linked glycans share a common 
core structure, consisting of a chitobiose core, linked to 9 mannose residues (see 
Fig 1.2). Depending on the origin of the glycoprotein these structures are further 
processed, with trimming, reducing the mannose content, and further elongation 
with sugars such as GlcNAc, galactose, fucose and sialic acid (Section 1.2.1). 
GlcNAc is typically found in the chitobiose core, and as the first residue linked to 
the core mannose structure of N-linked glycans of glycoproteins.  
 
The binding profile of CBP21 was compared to that of GSLII, a commercial 
plant lectin, with a known affinity for terminal β-linked GlcNAc. While some of 
the glycans tested displayed sialic acid (fetuin and thyroglobulin) or galactose 
(asialo fetuin) as their terminal residues, others are high mannose structures, 
while for avian ovalbumin most of the terminal sites of the antennary structures 
of the N-glycans are GlcNAc (Kim et al., 2007). Although GSLII demonstrated 
an affinity for the glycoproteins ovalbumin, invertase and hyaluronidase, the 
apparent lack of affinity for these residues by CBP21 could be as a result of a 
number of reasons; CBP21 may not be able to bind to single GlcNAc residues, 
meaning it won‟t bind to terminal GlcNAc, or perhaps the format of this assay 
might not suit CBP21. The glycoprotein structure and nature of the glycosidic 
linkages might introduce some steric hindrance, or one may need a larger 
concentration of glycan structures on the protein to detect binding.  
 
Glycosidase treatment of the glycoproteins transferrin and thyroglobulin was 
used to expose terminal GlcNAc. Neuriminidase and β-galactosidase treatment of 
these glycoproteins was sufficient in removing the unwanted sialic acid and 
galactose residues. While both glycoproteins have similar glycan structures 
porcine thyroglobulin has a much higher concentration of monosaccharides per 
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molecule (approx 300) (Spiro, 1965).  Although the terminal moiety on display 
was GlcNAc, CBP21 did not show any affinity for the molecules. In 2005(b) 
Vaaje-Kolstad et al, succeeded in crystallising the CBP21 molecule. They also 
attempted to crystallise the protein in complex with GlcNAc, but did not succeed. 
This is probably because CBP21 cannot bind to a single GlcNAc sugar residue. 
From this experiment it was also evident that DSL, a plant lectin described as a 
chitin binding protein, showed affinity for all forms of transferrin and 
thyroglobulin, suggesting that it was interacting with the chitobiose core. It was 
observed that absorbance readings for DSL bound to thyroglobulin were 
significantly higher than those for transferrin bound DSL, this is probably as a 
result of the increased concentration of glycans displayed on the surface of 
thyroglobulin. As CBP21 did not display any binding pattern one could conclude 
that CBP21 is not capable of binding to the chitobiose core in a similar manner to 
DSL. An attempt was made to trim back a glycoprotein structure to completely 
expose the chitobiose core, but efforts to eliminate the core mannose structure 
using glycosidases proved fruitless. An alternative technique was then employed 
to test if the use of a different assay format would improve the understanding the 
situation. Glycoprotein affinity chromatography was carried out using invertase 
immobilised to cyanogen bromide activated sepharose. No interaction between 
CBP21 and the invertase resin was observed. From the cumulative results it was 
evident that CBP21 was unable to interact with terminal GlcNAc, nor the 
chitobiose core structure of undigested protein-linked glycans. 
 
Through the use of the chemically synthesised PAA-linked oligosaccharides a 
(GlcNAc)N assay was developed. The aim of this assay was to determine if 
CBP21 had an affinity for protein-free (GlcNAc)N oligosaccharides. Preliminary 
assay results revealed problems with the blocking agent BSA. There appeared to 
be some interaction between the PAA-linked oligos and the blocking solution, 
which gave rise to high background readings. This occurrence deemed BSA 
unsuitable as a blocking agent as its use could lead to false positive results.  An 
alternative blocking reagent was identified by the examination of a number of 
protein and non-protein based blockers. 
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There are numerous blocking agents on the market today, with a notable increase 
in the availability of non-protein based blocking solutions for sale over the last 
decade. Unlike BSA or other sera, casein, and other common protein-containing 
blocking agents, these products are free of glycoproteins, making them ideal for 
applications in which glycoprotein contamination could generate false positive 
results. The suitability of the blocking solutions was tested, with some interesting 
results (see Fig 4.15). The quenching of signal at OD450nm from the direct 
detection of CBP21 was observed with the use of PVA, PVP and synblock. 
These three blocking agents are non-protein based. While the exact content of 
synblock is proprietary, it is known that PVA and PVP are large water soluble 
synthetic polymers. The most likely explanation for this phenomenon is that 
these long chain polymers are inhibiting the anti-His antibody from reaching the 
antigen binding site on the protein surface. CBP21 is a small molecule (19.8 
kDa), with the antibody approximately 7.5 times larger (~150 kDa). Unlike 
protein blockers the synthetic agents won‟t necessarily immobilise in a horizontal 
position on the plate, but will be free to move into any number of positions, 
possibly branching over CBP21 blocking the antigen binding site (see Fig 4.57).  
 
 
     
 
 
 
Fig 4.57: Reduced detection of CBP21 by anti-His antibody caused by 
polymer based blocking agents PVA and PVP. Blocking with large polymeric 
blocking agents obstructs the detection of the (His)6 tagged protein by inhibiting 
the anti-His antibody from reaching the antigen binding site. 
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Wash with PBST 
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This theory was verified by repetition of the experiment using the biotinylated 
lectin NPL, with a reduced level of quenching observed (see Fig 4.17). This 
reduced level of signal loss is probably due to the steric availability of multiple 
biotins on each NPL monomer versus the single His tag present on CBP21 
 
Immobilisation of the same concentration of a larger molecule on a plate surface 
will reduce the amount of blocking agent used. The space between the polymer 
and the antigen binding site of a larger molecule will also be increased, 
theoretically leaving more room for the antibody-antigen interaction. Carbo-free 
blocker was determined to be the best alternative blocking agent and was selected 
for further experiments. Although this is a protein-based blocking solution this 
product is certified as being essentially free of glycoproteins.  
 
The optimal format for the (GlcNAc)N binding assay was then determined. Assay 
format A revealed that surface immobilised CBP21 could bind to PAA-linked 
chitobiose and chitotriose oligosaccharides (see Fig 4.18). This interaction was 
concentration dependent with slightly higher affinities for chitobiose over 
chitotriose. As CBP21 could bind to the oligos when free in solution its inability 
to do so in assay format B was unexpected. The inability of CBP21 to bind to the 
surface immobilised oligos may be due to the nature of immobilisation of the 
PAA-linked oligos. Although the sugar units are projected away from the PAA 
backbone by means of a spacer arm CBP21 may be unable to orientate itself for 
binding so close to the plate surface.  
  
The (GlcNAc)N-binding assay was validated using WGA, with WGA displaying 
an affinity for both free and immobilised PAA-linked chitobiose and chitotriose 
in assay formats A and B respectively. WGA also displayed higher affinity for 
the oligosaccharides than CBP21 in assay format A. Compared to the monomeric 
CBP21 WGA is known to exist as a dimer, made up of two identical polypeptide 
subunits (18 kDa each). When assembled as a dimer the molecule forms a 
horseshoe-shaped complex where the sub-unit interface contains eight putative 
independent carbohydrate-binding sites (Lienemann 2009, Wright 1992), 
whereas CBP21 is theorized to have just one carbohydrate-binding site. 
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Therefore WGA should theoretically have an increased affinity for the substrate 
compared to the same unit concentration of CBP21. 
 
With just one putative carbohydrate-binding site the immobilisation of CBP21 on 
the maxiSorp plate is an important experimental variable. The molecule adsorbs 
by passive adsorption, without the ability to control the orientation. Adsorption 
of CBP21 in multiple orientations will increase the variability of the assay, with 
the putative binding site displayed in multiple directions, meaning than not all 
CBP21 molecules will be functional i.e. capable of binding the oligosaccharides.  
 
This variability could be eliminated and the assay sensitivity improved by the use 
of Immobilizer
TM
 96-well plates from NUNC. This technology provides a simple 
one-step procedure for covalently coupling bio-molecules in an orientation 
specific way. This technology exploits the use of a binding module covalently 
bound to a linker arm, which is coupled to the plate surface. The linker distances 
the bound molecule away from the plate surface optimizing accessibility of the 
immobilised molecule. A number of configurations are available, including 
streptavidin module, glutathione and Ni-chelate plates.  
 
   
  
  
 
 
 
 
 
 
Fig 4.58: Immobilisation of a (His)6 tagged protein onto a NUNC 
Immobilizer
TM
 Ni-chelate plate. Specific orientation of a (His)6 tagged protein 
could be achieved by covalent coupling to the NUNC Immobilizer
TM
 Ni-chelate 
plate.  
Active site 
Protein 
(His)6 tag 
Ni-chelate 
 
Linker 
 
Plate surface 
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As discussed in section 1.5 the enrichment of protein released glycans for 
structural analysis is an important rate limiting step. Affinity chromatography 
using plant lectins is often used, but due to the cost of these affinity matrices can 
be quite expensive process. As CBP21 can bind to free chitobiose structures there 
existed the possibility that it may display an affinity for protein released glycans. 
The potential ability of CBP21 to bind to the core structure of protein release 
glycans would be exceptionally beneficial in the field of glycobiology. The 
ability of CBP21 to bind to the chitobiose core, a structure common to all N-
linked glycans would mean that the same molecule could be used for to capture 
all glycan species with the facility for recombinant production of the molecule 
reducing the overall cost.   
 
Through the use of affinity chromatography it was shown that CBP21 could be 
used to capture free chitobiose oligosaccharides from solution (see Fig 4.25). 
Similarly to the 96-well plate assays discussed above the sensitivity of this 
affinity chromatography could be improved by using alternative immobilisation 
matrices/chemistries. As proteins are immobilised on to the cyanogen bromide 
activated sepharose by the presence of free amine groups, specific orientation of 
the molecule cannot be achieved. The use of a matrix such as streptavidin 
agarose (Updyke, 1984) or a similar Ni-NTA agarose would allow projection of 
the molecule in an orientation specific manner which could increase the 
availability of the binding site, thus improving the capture of the target molecule. 
Alternatively a lysine tag could be incorporated into the protein recombinantly 
with the option of an additional spacer arm. 
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Fig 4.59: Comparison of A; Cyanogen bromide and B; Covalent coupling of 
protein molecules to an agarose support columns. Specific orientation of a 
biotin linked protein could be achieved by covalent coupling to streptavidin bio 
support matrix. 
 
 
Asialo fetuin was selected for N-glycan cleavage. The selection of a glycoprotein 
is important step as PNGase F will not remove oligosaccharide containing α1-3 
linked core fucose. The secondary and tertiary structure of proteins can also 
prevent endoglycosidases from reaching their substrate, thus making denaturation 
a crucial step in efficient cleavage. Unfortunately the molar concentration of 
CBP21 in the released glycan pool was too low to be quantified using a DNS 
assay. Significant improvements in assay sensitivity, to detect the released 
glycans could be introduced by using an online system such as LC-MS. 
 
Sugar inhibition studies (Section 4.4) revealed that the binding of CBP21 to 
chitobiose was inhibited by mannan and galactan polymers. Mannan affinity 
chromatography was undertaken, but CBP21 did not bind to the mannan agarose. 
Similar studies could be repeated using a range of sugar resins and/or PAA-
A B 
Linker bound streptavidin  Biotinylated protein 
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linked oligosaccharides with a range of repeating sugar units, but would be cost 
prohibitive.  
 
The structures of chitinases, chitin binding domains, cellulases and cellulose 
binding domains show that the common carbohydrate binding architecture 
consists of a surface groove, cleft, or tunnel lined with aromatic residues that are 
necessary for binding. The CBP21 monomer shows neither a groove/tunnel nor 
stretches of solvent-exposed aromatic residues (Vaaje-Kolstad et al., 2005b). The 
structural and sequence analysis of the CBP21 molecule by Vaaje-Kolstad et al., 
(2005a) suggested that the binding of CBP21 to chitin was primarily governed by 
polar interactions, involving residues in a polar surface patch. Alanine scanning 
of the residues proposed to be involved in chitin-binding was undertaken. 
Analysis of the mutants using the insoluble substrate assays, revealed a number 
of differences between mutant and WT proteins (Table 4.5).  
 
Interestingly the site directed mutagenesis appeared to have a greater impact on 
the interaction with β-chitin compared to α-chitin. The main difference between α 
β-chitin concerns the spatial ordering of groups that may engage in hydrogen 
bonds with a carbohydrate-binding protein (see Fig 1.13 and 1.14). It is 
conceivable that as different chitin-binding proteins have different affinities for 
the various forms of chitin, that mutations can have effects on affinity for certain 
types of chitin only (Vaaje-Kolstad et al., 2005b). Although the affinities of 
CBP21 mutants E55A and H114A for β-chitin were significantly impaired site 
directed random mutagenesis of these molecules revealed no increase in affinity 
for single GlcNAc residues attached to glycoproteins. Analysis of 90+ clones for 
a given mutant should cover all possible 20 amino acid combinations.  
 
  
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
5.0 Cloning, Expression, Purification and 
characterisation of CbpD, CbpA and 
CbpL 
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5.1 Overview 
 
This chapter describes the cloning of the CBP21 homologues, CbpD from 
Psuedomonas aeruginosa, CbpA from Photorhabdus asymbiotica and CbpL 
from Photorhabdus luminescens, the development of purification strategies and 
preliminary physiochemical characterisation.  
 
 
5.2 Initial cloning and small scale expression of the CBP21 chitin-binding 
protein homologues CbpD, CbpA and CbpL 
 
It has been demonstrated that the CBP21 was unable to bind to GlcNAc 
structures on protein linked glycans (Chapter 4). Although all chitin-binding 
proteins share a similar level of homology most show different characteristics in 
terms of their preference for the different forms of chitin (α, β or γ). The proteins 
CbpD, CbpA and CbpL were identified from BLAST analysis of CBP21 (Section 
2.13). CpbD has previously been reported in the literature (Section 1.16.3), while 
CbpL from P. luminescens has been identified in a BLAST alignment (Vaaje-
Kolstad et al., 2005a). CbpA has not yet been identified in the literature, and 
none of the proteins have been produced recombinantly. As stated in section 
1.16.3, unlike CbpA, CbpL and CBP21, CbpD appears to have a second C-
terminal binding domain (see Fig 5.1). It is unknown if this second domain is 
also a chitin-binding domain. BLAST analysis of this protein revealed that both 
domains clustered well with other putative GlcNAc-binding proteins and 
chitinases (see Fig 1.24). 
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Fig 5.1: Sequence alignment of CBP21 with homologues CbpD, CbpA and CbpL. Amino acid sequence alignment of CBP21, CbpD, 
CbpA and CbpL from S. marcescens, P. aeruginosa, P. asymbiotica and P. luminescens respectively. The N-terminal signal sequences are 
highlighted with red. The beginning of the putative C-terminal binding domain of CbpD is indicated with an arrow. Alignment was 
performed using ClustalW and the image generated using GeneDoc 2.6 (Section 2.13). 
 228 
 
5.2.1 Initial cloning of CbpD, CpbA and CbpL 
 
As discussed in section 3.2.3, the chitin-binding proteins have N-terminal signal 
sequences that promote extracellular localisation (see Fig 5.1). To accommodate 
downstream purification and detection an affinity tag, in the form of 6 histidine 
residues, can be engineered into the proteins termini. The tagging of CBP21 at 
the N-terminus resulted in the expression of insoluble CBP21, while engineering 
of the (His)6 tag at the C-terminus gave rise to a soluble form of CBP21, that 
could be isolated from the periplasmic space. The genes encoding CbpD, CbpA 
and CbpL were cloned into the pQE60 vector from Qiagen, facilitating the 
incorporation of the (His)6 tag at the C-terminus. 
 
The P. aeruginosa strain PAO1 was obtained from Prof. Keith Poole, and the 
sequence for the organism obtained from the NCBI data bank (Accession No. 
NC002516). The P. luminescens strain was provided by Dr David Clarke, 
University College Cork. Primers were designed using the TT01 sequence, 
available through the NCBI (Accession No. NC005126). P. asymbiotica genomic 
DNA was also provided by Dr David Clarke (UCC), and the sequence for the 
ATCC43949 strain was available from the NCBI data bank (Accession No. 
NC012962).  
 
Genomic DNA was prepared according to the method outlined in section 2.6.1.  
The genes were amplified using PCR (Section 2.10.1). The primers used for 
amplification of C-terminally tagged CBPD were Psuedo-F3 and Pseudo-R2, for 
CbpA, Asymb-F3 and Asymb-R2 and Lumin-F3 and Lumin R-2 were used for 
CbpL. The PCR products were analysed by agarose gel electrophoresis and a 
band corresponding to the expected sizes were present. The PCR products were 
subjected to restriction analysis with NcoI and BglII, then ligated (Section 2.10.2) 
into an NcoI BglII digested pQE60 vector (see Fig 5.5). E. coli XL10 Gold cells 
were transformed with the ligation mixture (Section 2.9.3). The plasmid DNA 
obtained from some of the resulting colonies was screened for inserts using gel 
electrophoresis and restriction analysis. The presence of the correct inserts was 
further confirmed by DNA sequencing (Section 2.12).  
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ATGAAACACT ACTCAGCCAC CCTGGCACTC CTGCCACTCA CCCTCGCCCT GTTCCTGCCC 
CAGGCAGCCC ATGCCCACGG CTCGATGGAA ACGCCGCCCA GTCGGGTCTA CGGCTGCTTC 
CTCGAAGGTC CGGAGAATCC CAAGTCGGCC GCCTGCAAGG CCGCCGTCGC CGCCGGCGGC 
ACCCAGGCAC TGTACGACTG GAATGGCGTC AACCAGGGCA ACGCCAACGG CAACCACCAG 
GCGGTGGTCC CCGACGGCCA GCTCTGCGGC GCCGGCAAGG CACTGTTCAA GGGCCTGAAC 
CTGGCTCGCA GCGACTGGCC CAGCACTGCC ATCGCGCCGG ACGCCAGCGG CAACTTCCAG 
TTCGTCTACA AGGCCAGCGC GCCGCACGCG ACCCGCTACT TCGACTTCTA CATCACCAAG 
GACGGCTATA ACCCCGAGAA GCCGCTGGCC TGGAGCGACC TGGAACCCGC GCCGTTCTGC 
TCGATCACCA GCGTCAAGCT GGAGAACGGC ACCTACCGGA TGAACTGCCC GCTGCCCCAG 
GGCAAGACCG GCAAGCATGT GATCTATAAC GTCTGGCAGC GCTCGGACAG CCCGGAAGCC 
TTCTACGCCT GCATCGACGT GAGCTTCAGC GGCGCCGTCG CCAACCCCTG GCAAGCGCTG 
GGCAACCTGC GCGCGCAGCA GGACCTGCCA GCCGGTGCTA CCGTCACCCT GCGTCTGTTC 
GATGCCCAGG GCCGCGACGC CCAGCGTCAC AGCCTGACCC TGGCCCAGGG CGCCAACGGT 
GCCAAGCAAT GGCCGCTGGC GCTGGCGCAG AAGGTCAACC AGGACTCCAC CCTGGTCAAC 
ATCGGCGTGC TGGATGCCTA CGGGGCGGTC AGCCCGGTGG CCAGCTCGCA GGACAACCAG 
GTCTACGTGC GCCAGGCCGG CTACCGCTTC CAGGTCGACA TCGAACTGCC GGTCGAGGGC 
GGCGGCGAGC AACCGGGCGG CGACGGCAAG GTCGACTTCG ACTATCCGCA AGGCCTGCAG 
CAATACGACG CCGGGACCGT AGTGCGCGGT GCCGATGGCA AGCGCTACCA GTGCAAGCCC 
TACCCGAACT CCGGCTGGTG CAAGGGCTGG GACCTCTACT ACGCCCCGGG CAAGGGCATG 
GCCTGGCAGG ACGCCTGGAC CCTGCTGTAA 
 
Fig 5.2: P. aeruginosa cbpd coding sequence. The nucleotide sequence of cbpD. 
The annealing sites of primers Asymb-F3 and Asymb -R2 are indicated with red. 
There are no NcoI or BglII restriction sites within the gene. 
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ATGTACAAAC ATAAAGTGAG AATGATGACT TTAGCCACCA CGGTAACCGC AGCTTTATTT 
AATGGTGTAT GGGCTCATGG TTATATTGAT AGTCCAGGAA GTCGAGCATT CCTTTGTTCT 
GCACAGGGAA ATAAACAAAA TACCGATTGC GGGTTGGTGG AATATGAGCC TCAATCTCTT 
GAAGCTAAGA AAGGCTTCCC GCAAGCTGGT CCAGAAGATG GTCATATTGC CAGTGCTGGT 
ATTGGTCACT TCGGCGCGTT GGATGTTCAA ACAGCAGAGC GCTGGAAGAA AATTCCCATT 
ACTACCGGTG ATATTGAGTT CAAATGGGAA ATTGTAATCC AACACAAGAC TTCAAGTTGG 
GAATATTTTA TTACTAAATT AGACTGGGAC CCCAATAAGC CTTTAACCAG AGAGCAATTT 
AATAGTACAC CTTTCTGTTT TGAGGATTAC CAGGAAAAAA TGCCGGGGAA TAAAGTTATT 
AATAAATGTA CTTTGCCAGA AGGTTATCAA GGCTACCACG TTATATTAGG TGTCTGGACA 
GTTGCAGATA CCCTGAATGC ATTTTACCAA GTGATTGATA CAACCATTAAC CCAGCCTGA 
 
Fig 5.3: P. asymbiotica cbpA coding sequence. The nucleotide sequence of 
cbpA. The annealing sites of primers Lumin-F3 and Lumin -R2 are indicated 
with red. There are no NcoI or BglII restriction sites within the gene. 
 
 
ATGTATAAAC ATAAAGTGAA AGTGATGGCT TTAGCCGCTA CGATAATTAC AGCTTTATCT 
AATGGTACAT GGGCTCATGG TTATATTGAT AGCCCAGGAA GTCGTGCATT CCTTTGTTCC 
GCACAAGGAA ATGAACAAAA TATGGATTGT GGGTTGGTTA AGTATGAGCC TCAATCTCTT 
GAAGCTAAGA AAGGCTTTCC ACAAGCTGGC CCGGAAGATG GTCATATTGC CAGCGCTGGC 
ATTGGTCATT TTGGCGCATT GGATGCTCAA ACCGAAGATC GTTGGAAAAA AATCCCTATT 
ACTGCCGGTG AGATTGAGTT CCAGTGGGAA ATTATGATTC AACACAAAAC CTCAAGTTGG 
GAATATTTTA TTACCAAACT TGGTTGGGAT CCCAATAAAC CTTTAACCAG AGAGCAATTT 
AATAGTACAC CTTTCTGCTT TGAGGATTAT CAGGAAAAAA TGCCGAGCAG CAGAGTTATT 
AATAAATGTA CCTTACCAGA GGGTTATCAA GGCTATCACG TTATACTGGG TGTTTGGACA 
ATCTCAGATA CCCTAAATGC ATTTTACCAA GTAATTGACA CAACAATTAG CCCTGCTTGA 
 
Fig 5.4: P. luminescens cbpL coding sequence. The nucleotide sequence of 
cbpL. The annealing sites of primers Psuedo-F3 and Pseudo-R3 are indicated 
with red. There are no NcoI or BglII restriction sites within the gene. 
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Fig 5.5: Outline of the cloning strategy for the genes encoding CbpD, CbpA and CbpL. Cbpd, cbpa and cbpL were cloned into the 
pQE60 vector from Qiagen as NcoI BglII fragments to yield the vector pCbpD_60, pCbpA_60 and pCbpL_60 respectively. 
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5.2.2 Small scale expression of CbpD, CbpA and CbpL 
 
The proteins were expressed from their respective vectors in 100 mL cultures 
(Section 2.14), to ensure the recombinant proteins were soluble in E. coli. It was 
observed that unlike CBP21 all three proteins associated with the insoluble 
protein fraction (see Fig 5.6 - 5.9). Optimisation of the expression conditions for 
CbpD was undertaken in an effort to improve protein solubility. CbpD was 
expressed in 100 mL E. coli cultures at either 37 or 30°C, with varying levels of 
IPTG (see Fig 5.10). Unfortunately, no improvement in protein solubility was 
observed.  
 
 
Table 5.1: Relative molecular masses of chitin-binding proteins CbpD, 
CbpA and CbpL 
Protein MW including signal sequence MW without signal sequence 
CbpD 42739 Da 40065 Da 
CbpA 23192 Da 19545.7 Da 
CbpL 23108 Da 20406.7 Da 
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Fig 5.6: Expression of C-terminally (His)6 tagged CbpD in E. coli XL10 
Gold. SDS-PAGE and corresponding western blot analysis of C-tagged CbpD 
expressed in E. coli. Lane 1; Broad range protein ladder (Section 2.23.3), Lane 2; 
pCbpD_60 soluble fraction, Lane 3; empty vector soluble fraction Lane 4; 
pCbpD_60 insoluble fraction, Lane 5; empty vector insoluble fraction, Lane 6; 
Broad Range protein ladder. The over-expressed band corresponding to CbpD is 
indicated with an arrow. 
 
 
 
 
Fig 5.7: Time course expression analysis of C-terminally (His)6 tagged CbpA 
in E. coli XL-10 Gold. Time course analysis by 12.5% SDS-PAGE of C-tagged 
CbpA expressed in E. coli. Broad range protein ladder (Section 2.23.3), Lane 2; 
Soluble fraction 0 hours, Lane 3; Insoluble fraction 0 hours, Lane 4; Soluble 1 
hour, Lane 5; Insoluble 1 hour, Lane 6; Soluble 2 hours, Lane 7; Insoluble 2 
hours, Lane 8; Soluble 3 hours, Lane 9; Insoluble 3 hours, Lane 10 Soluble 4 
hours, Lane 11; Insoluble 4 hours Lane 12; Broad range protein marker. 
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Fig 5.8: Time course expression analysis of C-terminally (His)6 tagged CbpL 
in E. coli XL10 Gold. 12.5% SDS-PAGE time course analysis of C-tagged 
CbpL expressed in E. coli. Broad range protein ladder (Section 2.23.3), Lane 2; 
Soluble fraction 0 hours, Lane 3; Insoluble fraction 0 hours, Lane 4; Soluble 1 
hour, Lane 5; Insoluble 1 hour, Lane 6; Soluble 2 hours, Lane 7; Insoluble 2 
hours, Lane 8; Soluble 3 hours, Lane 9; Insoluble 3 hours, Lane 10 Soluble 4 
hours, Lane 11; Insoluble 4 hours Lane 12; Broad range protein marker. 
 
              
Fig 5.9: Western blot analysis of C-terminally (His)6 tagged A; CbpA and B; 
CbpL. Analysis of the soluble and insoluble fractions from the expression of 
CbpA and CbpL from the pQE60 vector in E. coli XL10 Gold. Lane 1; Pre-
stained protein ladder (Section 2.23.3), Lane 2; pQE60 empty vector soluble 
fraction, Lane 3; pQE60 expression vector soluble fraction, Lane 4; pQE60 
empty vector insoluble fraction, Lane 5; pQE60 expression vector insoluble 
fraction. CbpA and CbpL are indicated with an arrow 
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Fig 5.10: Analysis of the expression of CbpD under varying temperature and 
induction conditions. 12.5% SDS-PAGE analysis of the expression of CbpD 
from pCbpD_60, A; 37°C incubation, 50 mM IPTG, B; 30°C incubation, 50mM 
IPTG, C; 37°C incubation, 25mM IPTG, D; 37°C incubation, 10 mM IPTG, E; 
30°C incubation, 25mM IPTG, F; 30°C incubation, 10 mM IPTG Lane 1; Broad 
range protein ladder (Section 2.23.3), Lane 2; soluble 0 hours, Lane 3; insoluble 
0 hours, Lane 4; soluble 2 hours, Lane 5; insoluble 2 hours, Lane 6; soluble 4 
hours, Lane 7; insoluble 4 hours, Lane 8, soluble 6 hours, Lane 9; insoluble 6 
hours, Lane 10; soluble o/n, Lane 11; insoluble o/n.  
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5.3 Sub-cloning of CbpD 
 
5.3.1 Cloning of untagged CbpD 
 
As the position of additional tags can effect protein solubility CbpD was sub-
cloned without the C-terminal (His)6 tag to observe the effect, if any of the 
affinity tag. To create untagged CBPD the cbpd gene was amplified using 
Phusion directed whole vector amplification (see Fig 3.7), pCbpD_60 was used 
as the template. The primers used for this amplification were pQE60_F1 and 
Pseudo-R6 (Table 2.3).  A stop codon was included in the reverse primer. Once 
incorporated into the gene this stop codon would stop transcription before the 
(His)6 tag located at the 3‟ end of the gene (see Fig 5.11). When expressed in E. 
coli untagged CbpD still associated with the insoluble protein fraction (see Fig 
5.12). 
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ATAAATAGAT TCAATTGTGA GCGGATAACA ATTTCACACA GAATTCATTA AAGAGGAGAA 
ATTAACCATG GGAAAACACT ACTCAGCCAC CCTGGCACTC CTGCCACTCA CCCTCGCCCT 
GTTCCTGCCC CAGGCAGCCC ATGCCCACGG CTCGATGGAA ACGCCGCCCA GTCGGGTCTA 
CGGCTGCTTC CTCGAAGGTC CGGAGAATCC CAAGTCGGCC GCCTGCAAGG CCGCCGTCGC 
CGCCGGCGGC ACCCAGGCAC TGTACGACTG GAATGGCGTC AACCAGGGCA ACGCCAACGG 
CAACCACCAG GCGGTGGTCC CCGACGGCCA GCTCTGCGGC GCCGGCAAGG CACTGTTCAA 
GGGCCTGAAC CTGGCTCGCA GCGACTGGCC CAGCACTGCC ATCGCGCCGG ACGCCAGCGG 
CAACTTCCAG TTCGTCTACA AGGCCAGCGC GCCGCACGCG ACCCGCTACT TCGACTTCTA 
CATCACCAAG GACGGCTATA ACCCCGAGAA GCCGCTGGCC TGGAGCGACC TGGAACCCGC 
GCCGTTCTGC TCGATCACCA GCGTCAAGCT GGAGAACGGC ACCTACCGGA TGAACTGCCC 
GCTGCCCCAG GGCAAGACCG GCAAGCATGT GATCTATAAC GTCTGGCAGC GCTCGGACAG 
CCCGGAAGCC TTCTACGCCT GCATCGACGT GAGCTTCAGC GGCGCCGTCG CCAACCCCTG 
GCAAGCGCTG GGCAACCTGC GCGCGCAGCA GGACCTGCCA GCCGGTGCTA CCGTCACCCT 
GCGTCTGTTC GATGCCCAGG GCCGCGACGC CCAGCGTCAC AGCCTGACCC TGGCCCAGGG 
CGCCAACGGT GCCAAGCAAT GGCCGCTGGC GCTGGCGCAG AAGGTCAACC AGGACTCCAC 
CCTGGTCAAC ATCGGCGTGC TGGATGCCTA CGGGGCGGTC AGCCCGGTGG CCAGCTCGCA 
GGACAACCAG GTCTACGTGC GCCAGGCCGG CTACCGCTTC CAGGTCGACA TCGAACTGCC 
GGTCGAGGGC GGCGGCGAGC AACCGGGCGG CGACGGCAAG GTCGACTTCG ACTATCCGCA 
AGGCCTGCAG CAATACGACG CCGGGACCGT AGTGCGCGGT GCCGATGGCA AGCGCTACCA 
GTGCAAGCCC TACCCGAACT CCGGCTGGTG CAAGGGCTGG GACCTCTACT ACGCCCCGGG  
              ACCGTCC TGCGGACCTG GGACGACTAA  AGATCTCAT CACCATCACC 
CAAGGGCATG GCCTGGCAGG ACGCCTGGAC CCTGCTG     AGATCTCAT CACCATCACC 
AT 
ATCACTAAGC TTAATTAGTG AGCTTGGACT CCTGTTGATA GATCCAGTAA TTAGTGAGCT  
 
Fig 5.11: Cloning of untagged CbpD. Amplification of untagged CbpD from 
pCBPD_60. The forward primer, pQE60_F1, is shown in red, and the reverse 
primer, Pseudo R6, is shown in blue. The nucleotides encoding the poly histidine 
tag are underlined in purple, with the nucleotides (stop codon) to be introduced 
on the forward primer underlined in red. 
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Fig 5.12: Analysis of the expression of untagged CbpD. 12.5% SDS-PAGE 
analysis of the expression of CbpD from pCbpD_UN in E. coli KRX. Lane 1; 
Broad range protein ladder (Section 2.23.3), Lane 2; pCbpD_UN soluble 
fraction, Lane 3; pQE60 empty soluble fraction, Lane 4; pCbpD_UN insoluble 
fraction, Lane 5; pQE60 empty insoluble fraction. 
 
 
5.3.2 Cloning of CbpD with alternative N-terminal signal sequences 
 
One of the overall goals in the production of recombinant proteins is to 
simultaneously reach a high specific recombinant protein production rate and a 
high product quality. Large scale protein recovery from insoluble inclusion 
bodies is not favourable. It is both costly and time consuming and the isolation 
and re-folding of insoluble proteins has been shown to impact on a proteins 
activity (Sun, et al., 2011). While reasons for the formation of protein inclusion 
bodies are plentiful it can sometimes be due to the malformation of disulfide 
bonds. Many cytoplasmic proteins have free cysteines that cannot form disulfide 
bonds in the reducing environment of the cytoplasm (Pugsley 1993). A strategy 
that can be employed to avoid inclusion body formation is to target a protein to 
an outer compartment of the host cell, where a less reducing environment exists 
(Shokri, et al., 2003).  
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There are three major pathways for the translocation of polypeptides across the 
cytoplasmic membrane in gram negative bacteria; the Sec pathway (Pugsley, 
1993, Fekkes and Driessen, 1999, Stephenson, 2005), the signal recognition 
particle (SRP) pathway (Steiner et al., 2006, Keenan, et al., 2001), and the Tat 
pathway (Berks et al., 2000). The Sec and SRP translocation systems are 
responsible for transmembrane transport of unfolded proteins whereas the Tat 
system is used by folded proteins. The transport of proteins through the inner 
membrane of E. coli can be either post-translational (Sec) or co-translational 
(SRP) (Fekkes and Driessen, 1999, Koch et al., 2003) (see Fig 5.13).  
 
Transport of polypeptides via these pathways is achieved by the use of N-
terminal signal sequences. Whether a signal targets its protein to SRP or to SecA 
depends on the degree of hydrophobicity of the core region of the signal 
sequence; the highly hydrophobic inner membrane protein signals associate with 
SRP, while the less hydrophobic signals utilize SecA (Lee and Bernstein, 2001). 
Two of the most commonly used signal sequences are the PelBss from the 
pectate lyase protein PelB from Erwinia carotovora (PelBss) (Lei et al., 1987, 
Khushoo et al., 2004, Johnson, et al., 1996, Shevchik et al., 1997) and DsbAss 
from DsbA, a periplasmic enzyme involved in protein disulfide bond formation 
(Zhang and Donnenberg, 1996, Bardwell et al., 1991, Jeong and Lee, 2000). 
PelBss directs proteins via the Sec based system while DsbAss directs proteins 
via the SRP system.  
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Fig 5.13: Schematic representation of single peptide interactions of the Sec 
system. Signal peptides of secretory proteins are bound by SecA (a) in the 
cytoplasm, delivered to, bound by, and translocated via SecY of the pore (b), and 
ultimately bind to signal peptidase for cleavage of the signal from the mature 
proteins (c). Inner membrane proteins signals are bound by SRP as they emerge 
from the ribosome (d) and targeted to the membrane. The signal anchor interacts 
with SecY (e) and translocation occurs via the membrane-embedded SecYEG 
channel followed by signal peptidase cleavage and folding of the mature protein 
(f). Image adapted from (Rusch and Kendall, 2007). 
 
CbpD was amplified from pCbpD_60 using primers Pseudo-F7 and Psuedo-R2. 
The PCR products were analysed by agarose gel electrophoresis and a band 
corresponding to the expected size was present. The PCR product was subjected 
to restriction analysis with NotI and BglII, then ligated (Section 2.10.2) into NotI 
BglII restricted pPelB and pDsbA to create pPelB_CbpD and pDsbA_CbpD 
respectively (see Fig 5.14). The ligated vectors were transformed (Section 2.9.2) 
into E. coli XL10 Gold cells and the plasmid DNA obtained from some of the 
resulting colonies was screened for inserts using gel electrophoresis and 
restriction analysis. The presence of the correct inserts was further confirmed by 
DNA sequencing (Section 2.12). Time course analysis was undertaken to 
establish the solubility of the recombinant proteins in E. coli (see Fig 5.16 and 
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5.17). It was observed that CbpD expressed with PelBss and DsbAss associated 
with the insoluble protein fraction.  
 
          
  
  
 
 
 
 
 
 
 
 
 
   
Fig 5.14: Schematic of the cloning of CbpD into pPelB and pDsbA. CbpD 
was cloned into the pDsbA and pPelB vectors as NotI BglII fragments to yield 
the vectors pDsbA_CbpD and pPelB_CbpD respectively. 
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Fig 5.15: Amino acid alignment of the N-terminal domains of CbpD with 
WT, PelB and DsbA signal sequences. The signal sequences begin with the first 
residue in the alignment, the arrow indicates the first residue of the mature 
protein. This alignment was generated using ClustalW and Gendoc 2.6. 
 
 
 
  
Fig 5.16: Time course expression analysis of CbpD expressed with PelBss. 
Analysis by 12.5% SDS-PAGE of the expression of CbpD expressed from 
pCbpD_PelB. Lane 1; Broad range protein ladder (Section 2.23.3), Lane 2; 
soluble 0 hours, Lane 3, insoluble 0 hours, Lane 4; soluble 1 hour, Lane 5; 
insoluble 1 hour, Lane 6; soluble 2 hours, Lane 7; insoluble 2 hours, Lane 8; 
soluble 3 hours, Lane 9; insoluble 3 hours, Lane 10, soluble 4 hours, Lane 11; 
insoluble 4 hours, Lane 12; Broad range protein ladder.  
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Fig 5.17: Time course expression analysis of CbpD expressed with DsbAss. 
Analysis by 12.5% SDS-PAGE of the expression of CbpD expressed from 
pCbpD_DsbA. Lane 1; Broad range protein ladder (Section 2.23.3), Lane 2; 
soluble 0 hours, Lane 3, insoluble 0 hours, Lane 4; soluble 1 hour, Lane 5; 
insoluble 1 hour, Lane 6; soluble 2 hours, Lane 7; insoluble 2 hours, Lane 8; 
soluble 3 hours, Lane 9; insoluble 3 hours, Lane 10, soluble 4 hours, Lane 11; 
insoluble 4 hours, Lane 12; Broad range protein ladder.  
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5.3.3 Cloning of CbpD sub-domains 
 
In an effort to improve protein solubility and to eludicate if both putative 
domains are chitin-binding domains a number of CbpD sub-clones were 
constructed. These sub-clones consisted of amino acid residues 1-212, 212-389 
and 117-389 and were named CbpDa, CbpDb and CbpDc respectively. The 
cloning of these gene fragments is outlined in Fig 5.18; CbpDa was cloned using 
the primers Pseudo-F3 and Pseudo-R5, CbpDb was amplified using primers 
Psuedo-F8 and Pseudo-R2 and CbpDc was amplified using the primers Pseudo-
F9 and Pseudo-R2. The PCR products were analysed by agarose gel 
electrophoresis and bands corresponding to the correct sizes were present. The 
PCR products were subjected to restriction with NcoI and BglII, then ligated 
(Section 2.10.2) into an NcoI BglII digested pQE60 vector to create pCbpDa_60, 
pCbpDb_60 and pCbpDc_60. E. coli XL10 Gold cells were transformed with the 
ligation mixture (Section 2.9.3). The plasmid DNA obtained from some of the 
resulting colonies was screened for inserts using gel electrophoresis and 
restriction analysis.  
 
Once confirmed by sequencing each plasmid was transformed into E. coli KRX 
and expressed in a 100 mL culture (Section 2.14) to assess protein solubility. 
Clones CbpDa and CbpDc were found to express to the insoluble protein 
fraction, but a band corresponding to the size of CbpDb was visible in the soluble 
protein fraction following expression and western blot analysis (see Fig 5.20). 
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   GTCAGTCCATGGGAAAACACTACTCAGCCACCC            
           ATGAAACACT ACTCAGCCAC CCTGGCACTC CTGCCACTCA CCCTCGCCCT 
GTTCCTGCCC CAGGCAGCCC ATGCCCACGG CTCGATGGAA ACGCCGCCCA GTCGGGTCTA 
CGGCTGCTTC CTCGAAGGTC CGGAGAATCC CAAGTCGGCC GCCTGCAAGG CCGCCGTCGC 
CGCCGGCGGC ACCCAGGCAC TGTACGACTG GAATGGCGTC AACCAGGGCA ACGCCAACGG 
CAACCACCAG GCGGTGGTCC CCGACGGCCA GCTCTGCGGC GCCGGCAAGG CACTGTTCAA  
                                                CAGTCCATGGGAAGCGG 
GGGCCTGAAC CTGGCTCGCA GCGACTGGCC CAGCACTGCC ATCGCGCCGG ACGCCAGCGG  
CAACTTCCAG TTCGTCTAC 
CAACTTCCAG TTCGTCTACA AGGCCAGCGC GCCGCACGCG ACCCGCTACT TCGACTTCTA 
CATCACCAAG GACGGCTATA ACCCCGAGAA GCCGCTGGCC TGGAGCGACC TGGAACCCGC  
GCCGTTCTGC TCGATCACCA GCGTCAAGCT GGAGAACGGC ACCTACCGGA TGAACTGCCC 
GCTGCCCCAG GGCAAGACCG GCAAGCATGT GATCTATAAC GTCTGGCAGC GCTCGGACAG  
                           CTGCA CTCGAAGTCG CCGCGGTCTAGATGACTG                         
                                    CAGTCCATGGGAGCCGTCGCCAACCCCTG 
CCCGGAAGCC TTCTACGCCT GCATCGACGT GAGCTTCAGC GGCGCCGTCG CCAACCCCTG   
G 
GCAAGCGCTG GGCAACCTGC GCGCGCAGCA GGACCTGCCA GCCGGTGCTA CCGTCACCCT 
GCGTCTGTTC GATGCCCAGG GCCGCGACGC CCAGCGTCAC AGCCTGACCC TGGCCCAGGG 
CGCCAACGGT GCCAAGCAAT GGCCGCTGGC GCTGGCGCAG AAGGTCAACC AGGACTCCAC 
CCTGGTCAAC ATCGGCGTGC TGGATGCCTA CGGGGCGGTC AGCCCGGTGG CCAGCTCGCA 
GGACAACCAG GTCTACGTGC GCCAGGCCGG CTACCGCTTC CAGGTCGACA TCGAACTGCC 
GGTCGAGGGC GGCGGCGAGC AACCGGGCGG CGACGGCAAG GTCGACTTCG ACTATCCGCA 
AGGCCTGCAG CAATACGACG CCGGGACCGT AGTGCGCGGT GCCGATGGCA AGCGCTACCA 
GTGCAAGCCC TACCCGAACT CCGGCTGGTG CAAGGGCTGG GACCTCTACT ACGCCCCGGG  
                   CC TGCGGACCTG GGACGACTCTAGATGACTG 
CAAGGGCATG GCCTGGCAGG ACGCCTGGAC CCTGCTGTAA 
 
Fig 5.18: The cloning of CbpD segments CbpDa, CbpDb and CbpDc. CbpDa 
was cloned using the primers Pseudo-F3 and Pseudo-R5, CbpDb was amplified 
using primers Psuedo-F8 and Pseudo-R2 and Cbpc was amplified using the 
primers Pseudo-F9 and Pseudo-R2. Forward primers are highlighted in red with 
reverse primers highlighted in blue. 
  
 
 
 246 
 
 
Fig 5.19: Amino acid alignment of CbpD and sub-clones CbpDa, CbpDb and 
CbpDc. This image was generated using ClustalW2 and Gendoc 2.7.  
 
 
 
Table 5.2: Properties of CbpD sub-clones CbpDa, CbpDb and CbpDc 
Protein CbpD residues Amino Acid residues Expected protein size (Da) 
CbpDa 1-212        221 23886 
CbpDb 212-389 188 20496 
CbpDc 117-389 283 31260 
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Fig 5.20: Western blot analysis of A; CbpDa, B; CbpDb and C; CbpDc expressed in E. coli XL-10 Gold. Lane 1; Pre-stained protein 
ladder (Section 2.23.3), Lane 2; expressed protein soluble fraction, Lane 3; empty vector soluble fraction, Lane 4; expressed protein insoluble 
fraction, Lane 5; empty vector insoluble fraction. (His)6 positive bands are indicated with arrows. 
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5.4 Purification of CBP21 homologues 
 
5.4.1 Solubilisation, refolding and purification of CbpD, CbpA and CbpL 
 
Recombinant protein in the form of inclusion bodies lacks any biological activity. 
While the expression of a protein to inclusion bodies is not ideal protein isolation 
and solubilisation is possible. The isolation of proteins from inclusion bodies 
does not usually give full recovery of biological activity, making the preparation 
of inclusion bodies of significant importance. Detergents such as tween or triton 
are often used to break down the inclusion bodies, while common denaturants 
such as urea and guanidine hydrochloride are used to solubilise the protein 
inclusion bodies prior to protein refolding. It is important that the denaturing 
agents are removed before refolding to allow for the formation of the correct 
intramolecular associations. There are a number of methods that can be used for 
protein refolding, including dialysis, dilution, gel filtration and on-column re-
folding.  
 
Dialysis is one of the most common techniques to aid protein refolding (Misawa 
and Kumagai, 1999), however it takes several days and uses large volumes of 
buffer. Dilution is another simple technique, but again it is quite slow and 
cumbersome. It also necessitates extensive dilution which is not beneficial to 
protein recovery. Gel filtration is another useful technique that allows for the 
separation of high concentrations of native protein from the aggregated material. 
The aggregated material can however be difficult to remove from the often 
expensive columns and this method can be quite slow despite the use of small 
volumes. On-column refolding has come to the forefront over the past decade as 
the foremost techniques for protein folding. It merits less time, high 
concentrations of product, high biological activity and easy scale up (Sun et al., 
2011, Middelberg 2002). In this instance solubilised protein was immobilised on 
an affinity matrix, a urea gradient was used to gently refold the protein on the 
column, thus helping it to refold into its natural structure.  
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CbpD, CbpA and CbpL were isolated from inclusion bodies as outlined in 
section 2.15.3 and subjected to on-column refolding using the FPLC procedure 
described in section 2.18.3.  Satisfactory solubilisation of the inclusion bodies 
was assessed by looking at the clarity of the pellet following the addition of 
denaturant (see Fig 5.21). On-line monitoring using the AKTA FPLC system 
revealed that the target protein was eluting from the column in the correct elution 
stage (see Fig 5.22, and 5.23), although the height of the elution peaks were quite 
low and subsequent quantification revealed low protein concentrations (Table 
5.3). SDS-PAGE analysis was used to gauge the size of the refolded proteins and 
the success of the purification (see Fig 5.24).  
 
Surprisingly analysis of the imidazole elution fractions following CbpD 
purification revealed that although there was a low but sharp protein elution peak 
upon initial application of the imidazole elution buffer the target protein 
continued to leach from the column beyond 74 mL of buffer application (see Fig 
5.25). It was theorized that the proteins could be associating with the column 
material. The purification was repeated using an elution buffer of pH 4.0 and an 
elution buffer containing GlcNAC to see if the elution of CbpD could be 
improved, but did not appear successful (see Fig 5.26). 
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Fig 5.21: Solubilisation of inclusion bodies from a pellet of E. coli cells 
expressing CbpD. A; CbpD insoluble cell pellet, B; solubilised CbpD pellet. The 
success of protein solubilisation can be measured by the clarity of the cell pellet.  
 
 
Fig 5.22: On-column refolding and purification of CbpD. Refolding and 
purification of resolubilised CbpD from a 400 mL E. coli expression culture on 
an Amersham HisTrap FF crude 1 mL column, using FPLC. The blue line 
indicates the absorbance at A280, the green line indicates the percentage of buffer 
B in the running buffer, while the red markers signify the fractionation of the 
eluent. 
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Fig 5.23: On-column refolding and purification of A; CbpA and B; CbpL. 
Refolding and purification of resolubilised CbpA and CbpL from a 400 mL E. 
coli expression culture on an Amersham HisTrap FF crude 1 mL column, using 
FPLC. The blue line indicates the absorbance at A280, the green line indicates the 
percentage of buffer B in the running buffer, while the red markers signify the 
fractionation of the eluent. 
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Fig 5.24: Analysis of fractions from the insoluble purification of A; CbpD, B; CbpA and C; CbpL. 12.5% SDS-PAGE analysis of the 
fractions resulting from the on column refolding and purification of CbpD, CbpA and CbpL using FPLC. Lane 1; Broad range protein ladder 
(Section 2.23.3), Lane 2; Spin 1 supernatant, Lane 3; Spin 2 supernatant, Lane 4; Spin 3 supernatant, Lane 5; Column flow-through, Lane 6; 
Binding buffer elution, Lane 7; Wash buffer elution , Lane 8; Refolding gradient elution, Lane 9; Refolding buffer elution, Lane 10; Pooled 
elutions  1A4 – 1A11 , Lane 11; 1B4 , Lane 12; Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
  
1   2    3   4    5    6   7    8   9   10  11  12 
97.2 kDa 
66.4 kDa 
55.6 kDa 
42.7 kDa 
34.6 kDa 
27 kDa 
20 kDa 
116 kDa 
158 kDa 
14.3 kDa 
1   2   3    4    5  6   7   8   9   10  11  12 1   2    3   4    5    6   7    8   9   10  11  12 
97.2 kDa 
66.4 kDa 
55.6 kDa 
42.7 kDa 
34.6 kDa 
27 kDa 
20 kDa 
116 kDa 
158 kDa 
14.3 kDa 
97.2 kDa 
66.4 kDa 
55.6 kDa 
42.7 kDa 
34.6 kDa 
27 kDa 
20 kDa 
116 kDa 
158 kDa 
14.3 kDa 
A B C 
 253 
 
 
 
Fig 5.25: Analysis of the elution fractions from purification of CbpD from 
insoluble cell pellet. 12.5% SDS-PAGE and silver stain analysis of the elution 
fractions of CbpD from a 1 mL HisTrap FF column following on column 
refolding and purification of solubilised CbpD. The ladder refers to the broad 
range protein ladder (Section 2.23.3). Imidazole wash concentrations and elution 
volumes are indicated. 
 
 
Fig 5.26: On-column refolding and purification of CbpD. Refolding and 
purification of resolubilised CbpD from a 400 mL E. coli expression culture on 
an Amersham HisTrap FF crude 1 mL column, using FPLC. The blue line 
indicates the absorbance at A280, the green line indicates the percentage of buffer 
B in the running buffer, while the red markers signify the fractionation of the 
eluent. 
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Table 5.3: Average yield of recombinant proteins CbpD, CbpA and CbpL 
following expression from a 400 mL E. coli culture and on-column refolding  
Protein Mass of 
cells (g) 
Total protein 
yield (mg) 
mg protein/ g cell 
paste 
CbpD 2.58 0.877 0. 34  
CbpA 1. 34 0.185 0.138 
CbpL 1 .42 0.372 0.262 
 
 
 
5.4.2 IMAC purification of CbpDb 
 
Previous western blot analysis of CbpDb containing lysate revealed that the 
protein was present in the soluble protein fraction. The protein was subsequently 
expressed as outlined in section 2.14, subjected to cell lysis (Section 2.15) and 
purified from the soluble cell lysate using IMAC as outlined in section 2.18.1. 
SDS-PAGE analysis of the elution fractions revealed that the protein began to 
elute from the column at an imidazole concentration of 200 mM and purified to 
homogeneity (see Fig 5.27). The average yield of CbpDd following expression 
and IMAC purification was 0.07 mg/g of cells. 
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Fig 5.27: IMAC purification optimisation of CbpDb from soluble E. coli cell 
lysate. Analysis by 12.5% SDS-PAGE and silver staining of the elution fractions 
resulting from the IMAC purification CbpDb. Lane 1; Broad range protein ladder 
(2.23.3), Lane 2; Crude lysate, Lane 3; column flow-through, Lane 4; 20 mM 
imidazole elution 1, Lane 5; 20 mM imidazole elution 2, Lane 6; 20 mM 
imidazole elution 3, Lane 7; 70 mM imidazole elution 1, Lane 8; 70 mM 
imidazole elution 2, Lane 9; 200 mM imidazole elution, Lane 10; 200 mM 
imidazole elution 2, Lane 11; 200 mM imidazole elution 3, Lane 12; Broad range 
protein ladder.  
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5.5 Protein Characterisation 
 
5.5.1 Insoluble substrate assays 
 
The specificities of CbpD, CbpDb, CbpA and CbpL for various insoluble 
substrates are shown in Figs 5.28-5.31. CbpD bound α-chitin from crustacean 
shells, with no protein visible in flow-through and wash elution fractions, while 
in contrast to CBP21 equal amounts appeared to have bound to both chitosan and 
crystalline cellulose.  CbpDb bound to α-chitin, with partial binding to crystalline 
cellulose, and no apparent binding to α-chitosan from crustacean shells. CbpA 
and CbpL had identical binding profiles. They bound to β- and α-chitin with 
similar affinities, both forms of chitosan, with faint protein bands visible in the 
unbound protein elution fraction, and to crystalline cellulose.  
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Fig 5.28: Analysis of CbpD bound to A; α-chitin, B; α-chitosan and C; Cellulose. 12.5% SDS-PAGE analysis of CbpD from P. 
aeruginosa bound to α-chitin and α-chitosin from crustacean shells and crystalline cellulose following incubation overnight, as outlined in 
section 2.26. Lane 1; Broad range protein ladder (Section 2.23.3), Lane 2; Crude CbpD sample, Lane 3; unbound CbpD, Lane 4; Wash 1 
elution, Lane 5; Wash 2 elution, Lane 6; Boiled protein-substrate sample, Lane 7; Boiled PBS-substrate sample, Lane 8; Broad range protein 
ladder. Substrate bound protein is indicated with an arrow. 
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Fig 5.29: Analysis of CbpDb bound to A; α-chitin, B; α-chitosan and C; Cellulose. 12.5% SDS-PAGE analysis of CbpDb from P. 
aeruginosa bound to α-chitin and β-chitin from crustacean shells and crystalline cellulose following incubation overnight, as outlined in 
section 2.26. Lane 1; Broad range protein ladder (Section 2.23.3), Lane 2; Crude CbpD sample, Lane 3; unbound CbpD, Lane 4; Wash 1 
elution, Lane 5; Wash 2 elution, Lane 6; Boiled protein-substrate sample, Lane 7; Boiled PBS-substrate sample, Lane 8; Broad range protein 
ladder. Substrate bound protein is indicated with an arrow. 
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Fig 5.30: Analysis of CbpA bound to A; β-
chitin, B; α-chitin, C; Chitosan from carpacea 
skin, D; α-chitosan and E; Cellulose. 12.5% 
SDS-PAGE analysis of CbpA β-chitin from squid 
pen, α-chitin from crustancean shells, β-chitosan 
from carpacea sking, chitosan from crustacean 
shells and crystalline cellulose. Lane 1; Broad 
range protein ladder (Section 2.23.3), Lane 2; 
Crude CbpD sample, Lane 3; unbound CbpD, 
Lane 4; Wash 1 elution, Lane 5; Wash 2 elution, Lane 6; Boiled protein-substrate sample, Lane 7; Boiled PBS-substrate sample, Lane 8; 
Broad range protein ladder. Substrate bound protein is indicated with an arrow. 
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Fig 5.31: Analysis of CbpL bound to A; β-chitin, 
B; α-chitin, C; Chitosan from carpacea skin, D; 
α-chitosan and E; Cellulose. 12.5% SDS-PAGE 
analysis of CbpL β-chitin from squid pen, α-chitin 
from crustancean shells, β-chitosan from carpacea 
sking, chitosan from crustacean shells and 
crystalline cellulose. Lane 1; Broad range protein 
ladder (Section 2.23.3), Lane 2; Crude CbpD 
sample, Lane 3; unbound CbpD, Lane 4; Wash 1 elution, Lane 5; Wash 2 elution, Lane 6; Boiled protein-substrate sample, Lane 7; 
Boiled PBS-substrate sample, Lane 8; Broad range protein ladder. Substrate bound protein is indicated with an arrow.  
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5.5.2 ELLA analysis 
 
ELLA analysis of CbpD, CbpA and CbpL using untreated, neuraminidase treated 
and β-galactosidase treated thyroglobulin revealed that none of the proteins were 
capable of binding to terminal or core GlcNAc in this format (see Fig 5.32). 
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Fig 5.32: Quantitative detection of A; CbpD, B; CbpA and CbpL interaction 
with thyroglobulin. ELLA analysis of CbpA and CbpL and glycosidase treated 
thyroglobulin. SNA is a terminal sialic binding lectin, ECL has a binding preference 
for terminal galactose, GSL II is a terminal GlcNAc binding lectin, DSL has been 
characterised as a chitin binding lectin that appears to bind to core chitobiose. 
 
 
A 
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5.6 Discussion 
 
The CBP21 chitin-binding proteins homologues CbpD, CbpA and CbpL were 
successfully cloned, expressed and characterised, with regard to chitin binding. 
Although the proteins showed high levels of homology to CBP21, unlike CBP21 
each protein associated with the insoluble protein fraction when expressed in E. coli. 
Solubilisation and refolding of the proteins was necessary for characterisation.  
 
The genes cbpd, cbpa and cbpl were successfully amplified from P. aeruginosa, P. 
asymbiotica and P. luminescens genomic DNA respectively, and cloned into the 
commercial pQE vector from Qiagen (Section 5.2.1).  The proteins were expressed 
from their respective constructs in E. coli with a C-terminal (His)6 tag and over-
expressed protein bands of the correct size were found to associate with the 
insoluble protein fraction. Examination of the CbpA and CbpL western blots 
revealed the presence of two (His)6 positive bands in the insoluble fraction, around 
21 kDa and 18 kDa in size, with the lower relative molecular mass band also visible 
in the soluble protein fraction. It is possible that both bands represent different forms 
of each protein. The size difference could potentially be due to proteolytic 
degradation but it is also possible that the lower molecular weight bands could 
represent CbpA and CbpL in which the N-terminal signal sequences have been 
proteolytically cleaved. Accumulation of over-expressed protein in this size range 
was not visible on SDS-PAGE analysis. Neither protein appeared to express 
particularly well in E. coli which suggested that the protein may have been slightly 
toxic, a commonly observed phenomenon in recombinant protein expression 
(Viaplana et al., 1997). Protein expression could be improved through the use of an 
enriched medium (Khushoo et al., 2004) or alternatively through the use of a strain 
with tight promoter control e.g. BL21 (DE3).  
 
As stated previously there are a number of reasons for insoluble protein production; 
including, incorrect protein folding, incorrect formation of disulphide bonds and the 
presence of inherent hydrophobic regions. It was shown in section 3.2 that the N-
terminal signal sequence of CBP21 was necessary for soluble protein expression. In 
the case of CbpD, CbpA and CbpL the most likely explanation for protein 
insolubility was that the presence of the native N-terminal leader sequences was not 
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promoting protein transport to the periplasmic space of the E. coli cell. From an 
evolutionary point of view it is plausible that E. coli is more closely related to 
Serratia spp. and therefore it is possible that E. coli incapable of recognising the N-
terminal signal sequences of CbpD, CbpA and CbpL.  
 
It was also indeterminate at this stage if the location of the poly-histidine tag, at the 
C-terminus, was affecting the ability of the proteins to fold properly. As CbpA and 
CbpL shared such high homology with CBP21 it was thought to be unlikely in their 
case. CbpD was cloned without the C-terminal (His)6 tag and expressed in E. coli. It 
was observed that the protein still expressed to the insoluble protein fraction. This 
result ruled out the presence of the affinity tag as the cause of protein insolubility.  
 
There are a number of strategies that can be employed to improve recombinant 
protein solubility, including reduction of the growth temperature, reduction of IPTG 
induction levels, secretion of the protein to the periplasm, the addition of fusion 
partners, use of alternative host strains (Zhang et al., 2011, Hatahet et al., 2010) and 
the expression of smaller soluble protein domains (Makrides, 1996). The expression 
of CbpD in E. coli was monitored at different growth temperatures at varying levels 
of IPTG induction. The effect of induction with varying levels of IPTG was 
investigated using SDS-PAGE, looking at the presence of soluble and insoluble 
product produced as certain stages of fermentation. It was observed that dramatically 
decreasing the IPTG concentration or lowering the growth temperature to 30°C did 
not result in increased levels of soluble recombinant protein production.  
 
The four cysteine residues of CBP21 appear as two disulfide bridges (Vaaje-Kolstad 
et al., 2005b). These cysteine residues are conserved in CbpA and CbpL whereas 
CbpD contains six cysteine residues. Cytoplasmic proteins do not generally contain 
structural disulfide bonds as they cannot form in the reducing environment causing 
the protein to misfold (Derman and Beckwith, 1991). This problem is often 
overcome through the addition of a signal sequence to the N-terminus of a protein, 
which directs the protein across the cytoplasmic membrane to an alternative cellular 
compartment. The oxidative periplasmic space is an ideal compartment for the 
formation of disulfide bonds. CbpD was cloned and amplified with two difference 
signal sequences, PelBss and DsbAss. The PelBss directs transcribed proteins to the 
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periplasm through use of the Sec system (post-translational process), while the 
DsbAss directs actively transcribing proteins through use of the SRP and Sec 
pathway components (co-translational process). Expression of CbpD with both 
signal sequences still resulted in insoluble protein expression. It is possible that 
replacement of the native signal sequences of CbpD, CbpA and CbpL with that from 
CBP21 might result in the transport of the proteins to the periplasm leading to 
soluble protein expression.  
 
CbpD contains two putative chitin-binding domains. These domains were cloned 
separately; CbpDa and CbpDb, along with a third construct CbpDc, both in an 
attempt to improve protein solubility but also to eludicate if both domains are chitin 
binding domains. The presence of multiple protein binding domains is common. 
Typically proteins that display multiple domains also have multiple activities, 
evolved through the recruitment of the different domains (Jaffe et al., 1996, 
Montanier et al., 2009), although some proteins display multiple domains with 
identical activities (Guillen et al., 2007, Guillen et al., 2010). While CbpDa and 
CbpDc both expressed to the insoluble protein fraction in E. coli it was clear that 
there were traces of CbpDb present in the soluble fraction.  
 
An insoluble protein purification protocol was adapted based on the method by 
Amersham. The protocol for the isolation and solubilisation of the inclusion bodies 
worked well, with complete solubilisation of the protein pellet apparent from the 
change in colour. Although final re-suspension of the cell lysate is in 5 mL per 100 
mL of culture the cell debris becomes very viscous following solubilisation and was 
difficult to sediment even using high-speed centrifugation, thus reducing the amount 
of protein that is passed through the FPLC system. Each protein was successfully 
purified using the refolding and purification protocol outlined in section 2.18.3 with 
few contaminants evident in subsequent silver stained SDS-PAGE gels. Intricacies 
were observed with protein elution, specifically with CbpD which leached very 
slowly from the column upon the application of imidazole. The efficiency of elution 
showed no improvement with pH adjustments or by the addition of GlcNAc. CbpDb 
was isolated from E. coli soluble cell lysate through IMAC purification. CbpDb 
withstood washes up to 100 mM imidazole and eluted homogeneously upon the 
application of 200 mM imidazole.  
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Protein characterisation was undertaken using both the insoluble substrate assays 
and ELLA analysis developed in section 4.1.2. From the insoluble substrate assay 
analysis it was evident that all four proteins were active and capable of binding to 
chitin, following solubilisation and re-folding from inclusion bodies. Unlike CBP21 
CbpD appeared to have similar affinities for α-chitin, α-chitosan from crustacean 
shells and crystalline cellulose, and very little protein, if any, was visible in the 
unbound protein elution fractions. CbpDb appeared to mirror the affinity of CBP21 
somewhat more closely with complete binding to α-chitin, partial binding to 
crystalline cellulose and no apparent binding to α-chitosan from crustacean shells. 
This suggests that the N-terminal chitin-binding domain of CbpD is responsible for 
chitosan binding. CbpA and CbpL differ in just 11 amino acids and as predicted had 
extremely similar binding profiles. Both bound to β and α-chitin with no protein 
visible in the first elution fraction. They displayed an almost equal affinity for α-
chitosan from crustacean shells, chitosan from carpacea skin, and crystalline 
cellulose with minute amounts of protein visible in the unbound protein elution 
fraction.  Although multiple protein bands were present in CbpA and CbpL His-Trap 
purified protein samples, each of the bands bound to the insoluble substrates, 
suggesting that they are all smaller, proteolytically cleaved, forms of CbpA and 
CbpL. Analogous to the ELLA analysis of CBP21 CbpD, CbpA nor CbpL appeared 
to bind to either the treated or untreated forms of thyroglobulin.  
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
6.0 Final Discussion and Recommendations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 267 
 
This research thesis described the cloning of the cbp21 gene that encodes the chitin-
binding protein CBP21 from S. marcescens, into a bacterial expression system, 
enabling recombinant expression and affinity purification. The physico-chemical 
characterisation of CBP21 protein was carried out (see Chapter 3) including the 
investigation of the affinity and specificity of the recombinant molecule using a 
series of both novel and pre-established assays (see Chapter 4). The ability of 
CBP21 to bind to both α- and β-chitin, chitosan and crystalline cellulose was 
established. Despite displaying an affinity for GlcNAc polymers, CBP21 was found 
to have no affinity for the GlcNAc sub-units of protein attached glycans.  
 
A novel GlcNAc binding assay was developed and described in section 4.2. Using 
this assay CBP21 was shown to have an affinity for polyacrylamide-linked 
chitobiose and chitotriose.  The possibility of incorporating the molecule onto an 
affinity chromatography platform was also investigated. It was observed that CBP21 
immobilised successfully on a sepharose matrix, with successful capture of 
chitobiose. The capture of PNGaseF released glycans was also explored. However 
an alternative technique, with increased sensitivity would need to be employed for 
the detection of the captured/released glycans as the quantities released were too 
small for the reducing sugar assay used.  
 
As discussed in section 1.5, glycan enrichment of protein released glycans, is an 
important step in the characterisation of novel glycoproteins. Currently lectin 
affinity chromatography is the most commonly used technique for this type of 
characterisation. However, the availability and cost of the affinity matrices is the 
most restrictive feature of this method. As the chitobiose core is a common 
structural feature of all N-linked glycans, if bound by CBP21 this molecule could be 
exploited as a broad range N-linked glycan binding protein, used to concentrate 
glycan mixes prior to glycan profiling.  The ability of CBP21 to bind to the 
chitobiose core of N-linked glycans could also lead to the creation of an alternative 
immobilisation strategy for carbohydrate arrays, with each glycan species bound 
directly to a matrix using CBP21, ensuring optimal orientation of the sugar species 
on the immobilisation matrix.  
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Novel CBP21 mutants were created to explore the role of specific residues in the 
putative carbohydrate binding site. It was theorised that through mutagenesis of the 
residues involved in chitin binding, novel molecules with alternative binding 
affinities or specificities could be generated. However, it was shown in section 4.5 
that although mutagenesis of these residues did impact on the molecules ability to 
bind to chitin, chitin sub-structures and cellulose, complete disruption of binding to 
all of the polymers tested was not achieved and the affect of binding to glycoprotein 
structures was negligible, suggesting that no one residue was responsible for 
recognition and binding. 
 
The availability of a crystal structure of CBP21 in complex with a GlcNAc polymer 
would allow for further site-directed mutagenesis studies, which may allow for the 
development of alanine mutants with more pronounced differences in specificities.  
The incorporation of alternative amino acids, through site-directed random 
mutagenesis, might even open the possibility of creating mutants with affinities for 
other glycan residues such as mannose or galactose. As crystallisation requires large 
amounts of pure soluble protein the optimisation of expression of CBP21 carried out 
in section 3.3.2 is of key importance. Further improvements to protein yields could 
be attained through the introduction of alternative growth media. Although LB was 
used throughout this study a number of alternative enriched media exist, including 
TB medium, SOB broth, YT broth, as well as several proprietary media components. 
Alternatively the introduction of more stable antibiotic resistance cassettes, such as 
carbenicillin, could improve plasmid retention within the cell, thus increasing 
protein production. The use of vectors with stronger promoters could also be 
introduced.  
 
The creation of a library of carbohydrate-binding proteins displaying a wide variety 
of specificities all with a common core molecule would be highly advantageous in 
the field of glycobiology and specifically in the manufacture protein/lectin 
microarrays. An array consisting of recombinant molecules of common origin would 
mean that each carbohydrate-binding protein would have the same requirements for 
activity, such as temperature, pH and buffer. The ability to produce these proteins 
recombinantly would not only ensure consistent production (not seen with plant 
lectins) but would also allow the incorporation of affinity tags into the protein, 
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allowing more direct immobilisation strategies, leading to a dramatic decrease in 
cost, and greater accessibility. 
 
Finally this thesis included an initial study of CBP21 related molecules. 
Bioinformatic analysis revealed the existence of a number of closely related CBP21 
homologues, which had not been the subject of any previous characterisation 
studies. CbpD from Pseduomonas aeruginosa, CbpA from Photorhabdus 
asymbiotica and CbpL from Photorhabdus luminescens were selected for further 
study and subsequently cloned into bacterial expression systems similar to that of 
CBP21, enabling recombinant protein expression. Significant difficulties were 
encountered with the production of these molecules as they were expressed to the 
insoluble protein fraction. Although a number of strategies were explored to 
improve protein solubility, none proved fully successful. Solubilisation of these 
recombinant molecules provided enough protein to be purified and isolated for basic 
characterisation. It was shown that all three molecules are in fact chitin-binding 
molecules, that can bind to both the α and β forms of chitin and that the second 
putative chitin-binding domain of CbpD is capable of binding to chitin.  As with 
CBP21 these molecules did not show any affinity for glycans attached proteins when 
tested using ELLA analysis.  
 
Chitinolytic microorganisms play an important role in the biosphere by recycling 
chitin, the second most abundant carbohydrate, next to cellulose. Like organisms 
that degrade cellulose chitinolytic organisms produce a battery of enzymes with 
different specificities that act together to break down chitin microfibrils. As with 
cellulases many chitinases also have simple binding domains, not involved in 
catalysis, thought to anchor the enzymes to the substrate surface (Beguin and Aubert 
1994). However, independent proteins such as CBP21, CbpD, CbpA and CbpL have 
been shown to increase the ability of chitinases to breakdown chitin.  
 
Although development of these molecules for glycan analysis was not successful 
there are many commercially viable fields where the availability of characterised 
molecules such as these would be of great advantage. As outlined in section 1.18 the 
extraction of chitin from source is invariably carried out using a chemical process, 
leading to a build up of waste chemicals which are expensive to dispose of 
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(Goycoolea et al., 2000). The use of prokaryotic chitinases with the synergistic 
effect of chitin-binding proteins would potentially lead to a more environmentally 
friendly, efficient process. Similarly in the field of bio-control chitinases have been 
engineered into plant expression systems to act as bio-pesticides in an effort to stave 
off attack by insects and pathogenic fungi. Enhanced resistance to chitin containing 
plant pathogens could be achieved through the introduction of chitin-binding 
proteins, to increase the effectiveness of chitinase action (Dehestani, et al., 2010).  
Chitinolytic enzymes also have wide ranging applications in the preparation of 
chitooligosaccharides, preparation of single cell protein, isolation of protoplasts 
from fungi and yeast, the treatment of chitinous waste and the control of malaria 
transmission, all of which could benefit from the collaborative effect of the small 
chitin-binding proteins.   
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